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Abstract: Protein ubiquitination is a key regulatory process in a plethora of physiological and pathological
pathways. During ubiquitination, the protein ubiquitin is covalently attached to a substrate protein form-
ing mono- or polyubiquitin chains. Ubiquitination can be reversed via deubiquitinases (DUBs). OTUB1
(ovarian tumor domain-containing ubiquitin aldehyde binding protein 1) is one of the most highly ex-
pressed deubiquitinases in cells with a unique enzymatic activity cleaving Lys48 ubiquitin chains and
preventing Lys48 and Lys63 ubiquitin chain formation non-enzymatically. OTUB1 regulates various
pathways and processes in vitro, like proinflammatory and profibrotic signaling, DNA damage response,
proliferation and apoptosis. The cellular oxygen sensor factor inhibiting HIF (FIH) is an asparagine
hydroxylase controlling the transactivation activity of the hypoxia inducible factor (HIF), key regulator
of the transcriptional response to hypoxia. Our group recently demonstrated that FIH hydroxylates
OTUB1 on Asn22, regulating cellular energy metabolism. This thesis aims to investigate the interaction
between FIH and OTUB1 in more detail and to assess if OTUB1 is a possible physiological target of
FIH. The molecular interaction between FIH and OTUB1 showed a denaturing-resistant, likely covalently
linked protein heterodimer, highly sensitive to hypoxia and depending on FIH enzymatic activity. Several
studies have investigated the role of OTUB1 in diseases in vivo. However, the physiological function of
OTUB1 is unknown. To understand the in vivo role of OTUB1 and to assess if it is a likely physiologi-
cally relevant FIH target, we characterized mice with constitutive (Otub1-/-) and conditional whole-body
Otub1 (wbOtub1-/-) deletion. Otub1-/-mice died perinatally due to asphyxiation and showed decreased
alveolar space, increased lung cell proliferation and cardiac hypertrophy. wbOtub1-/- mice showed pul-
monary hyperventilation and cardiac hypertrophy with left ventricular dysfunction. Additionally, adult
animals presented with decreased body weight, increased energy expenditure and glucose metabolism.
Furthermore, the AKT/mTOR signaling was increased in cells and tissues without Otub1. Overall, these
results demonstrate that OTUB1 is essential for development, respiration, cardiac function and energy
metabolic homeostasis in vivo. Interestingly, Hif1an (the gene encoding FIH) homozygous knockout
(KO) mice display a metabolic phenotype that is virtually identical to the metabolic alterations observed
in Otub1 KO mice. In summary, we found that FIH forms a stable complex with OTUB1 at a cellular
level. Interestingly, the metabolic and respiratory phenotypes of Otub1 KO mice support that the FIH-
dependent regulation of OTUB1 is physiologically relevant. Our studies of Otub1 KO mice will further
help evaluating the potential of OTUB1 as a therapeutic target and possible role in diseases.
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Protein ubiquitination is a key regulatory process in a plethora of physiological and 
pathological pathways. During ubiquitination, the protein ubiquitin is covalently attached to a 
substrate protein forming mono- or polyubiquitin chains. Ubiquitination can be reversed via 
deubiquitinases (DUBs). OTUB1 (ovarian tumor domain-containing ubiquitin aldehyde binding 
protein 1) is one of the most highly expressed deubiquitinases in cells with a unique enzymatic 
activity cleaving Lys48 ubiquitin chains and preventing Lys48 and Lys63 ubiquitin chain 
formation non-enzymatically. OTUB1 regulates various pathways and processes in vitro, like 
proinflammatory and profibrotic signaling, DNA damage response, proliferation and apoptosis. 
The cellular oxygen sensor factor inhibiting HIF (FIH) is an asparagine hydroxylase controlling 
the transactivation activity of the hypoxia inducible factor (HIF), key regulator of the 
transcriptional response to hypoxia. Our group recently demonstrated that FIH hydroxylates 
OTUB1 on Asn22, regulating cellular energy metabolism. This thesis aims to investigate the 
interaction between FIH and OTUB1 in more detail and to assess if OTUB1 is a possible 
physiological target of FIH. 
The molecular interaction between FIH and OTUB1 showed a denaturing-resistant, likely 
covalently linked protein heterodimer, highly sensitive to hypoxia and depending on FIH 
enzymatic activity. Several studies have investigated the role of OTUB1 in diseases in vivo. 
However, the physiological function of OTUB1 is unknown. To understand the in vivo role of 
OTUB1 and to assess if it is a likely physiologically relevant FIH target, we characterized mice 
with constitutive (Otub1-/-) and conditional whole-body Otub1 (wbOtub1-/-) deletion. Otub1-/-
mice died perinatally due to asphyxiation and showed decreased alveolar space, increased 
lung cell proliferation and cardiac hypertrophy. wbOtub1-/- mice showed pulmonary 
hyperventilation and cardiac hypertrophy with left ventricular dysfunction. Additionally, adult 
animals presented with decreased body weight, increased energy expenditure and glucose 
metabolism. Furthermore, the AKT/mTOR signaling was increased in cells and tissues without 
Otub1. Overall, these results demonstrate that OTUB1 is essential for development, 
respiration, cardiac function and energy metabolic homeostasis in vivo. Interestingly, Hif1an 
(the gene encoding FIH) homozygous knockout (KO) mice display a metabolic phenotype that 
is virtually identical to the metabolic alterations observed in Otub1 KO mice. 
In summary, we found that FIH forms a stable complex with OTUB1 at a cellular level. 
Interestingly, the metabolic and respiratory phenotypes of Otub1 KO mice support that the 
FIH-dependent regulation of OTUB1 is physiologically relevant. Our studies of Otub1 KO mice 
will further help evaluating the potential of OTUB1 as a therapeutic target and possible role in 
diseases.  
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1.1. Embryonic development 
For over the last 60 years, mice have been used to understand mammalian embryonic 
development [1]. The mouse is a suitable embryological model due to its early fertility (6 weeks 
in females and 8 weeks in males), the large number of animals per litter, the possibility to get 
pregnant again within 4 hours after giving birth, the brief  estrous cycle (4 to 6 days) and the 
short pregnancy period (between 18 and 21 days) [2], allowing for a manageable time frame 
of analyses. Moreover, mice and humans present a comparable embryonic development, a 
fertilized egg proliferates and is exposed to cell differentiation forming a primitive streak with 
anterior-posterior and left-right polarization. From the primitive streak with an epidermal and 
endodermal layer, the mesoderm is formed by the epidermal to mesodermal transition. The 
ectoderm, mesoderm and endoderm develop into the different organs and tissues [3]. 
According to the WHO, 947,000 deaths occurred during preterm birth and 637,000 deaths 
immediately after birth in humans due to asphyxia and trauma worldwide in 2015 [4]. Due to 
the previously described advantages and the similarities to the human developmental process, 
mice constitute a good model to study embryonic development, aiming to understand the 
causes and to reduce the numbers of pre- and peri-natal deaths in humans. 
1.1.1. Mouse lung development 
Gas exchange between the environment and organism is required to supply oxygen for the 
generation of energy by respiration in the mitochondria and to release the carbon dioxide 
formed by the cells in the body. Respiratory gas exchange occurs in diverse manners in nature 
ranging from simple diffusion in unicellular organisms to complex avascular air sacs in birds 
[5]. In mammals, the air enters the lungs from the environment through the mouth and nose 
and then the gases are exchanged with the body by gas diffusion from lung alveoli into 
surrounding capillaries. To obtain an efficient gas exchange, humans possess a total lung 
alveolar surface area of 70m2 [6] and mice of 80 cm2 [7]. At the initial phase of the respiratory 
development, human and mouse embryos present only a laryngo-tracheal tube with reduced 
surface area and no alveoli. To reach the necessary diffusible interface area at an adult stage, 
this laryngo-tracheal tube undergoes several complex branching processes [8]. 
The development of the mouse lung in utero includes five different stages (Figure 1) [8]: 
(1) Embryonic stage, E9-E12 [8]. From the simple layered blastula, three different layers 




forms a primitive tube surrounded by mesoderm to originate the laryngo-tracheal groove 
[8]. At E9 in mice or week 4 in humans, the laryngo-tracheal groove constitutes dorso-
ventrally the tracheal rudiment and laterally two bronchial buds. In mice, the first 
observation of a tracheal bifurcation occurs briefly after the laryngo-tracheal groove [10]. 
From the tracheal diverticulum, symmetric primitive pulmonary buds are formed inside the 
pleuroperitoneal canals. The reproducible branching is completed at E12 with unilobed left 
and quadrilobed right lungs in mice. In humans, two left lobes and three right lobes are 
present at 16 weeks [8]. This branching processing requires high proliferation of epithelial 
and mesenchymal cells [11]. During this phase, the pulmonary artery travels to the lungs 
as a branch of the branchial arch arteries [8]. 
(2) Pseudoglandular stage, E12-E16.5. The bronchial and respiratory tree is formed as an 
undifferentiated primordial system [8]. During the beginning of this phase neuroendocrine 
precursor cells are in proximal conducting airways and move towards distal airways [12]. 
These neuroendocrine cells form clusters and neuroepithelial bodies [12]. Functionally, 
neuroendocrine cells are key regulators of surrounding cell proliferation and the center of 
secretory cell differentiation [12]. Together with the neuroendocrine cell differentiation, 
ciliated, globular and Clara cells begin to differentiate [11]. 
(3) Canalicular stage, E16.5 to E17.5. The most relevant events are the formation of terminal 
sacs and vascularization [8]. The morphogenesis of the distal airway and the air-blood 
barrier occur together with the production of surfactant and epithelial differentiation [10]. 
Thinning of the alveolar walls is initiated mainly via apoptosis of the interstitial tissue [11].  
Furthermore, the pulmonary vascularization level increases in this stage [11].  
(4) Saccular stage, E17.5 to P5. Terminal sacs and vascularization increase, and the 
pneumocytes type I and II are differentiated [8]. The saccular phase is characterized by 
expansion of the airway spaces [10], transient increase of cell apoptosis during birth with 
continuous proliferation of epithelial cells and a final surge of apoptosis in order to remove 
cell excess [11]. 
(5) Alveolar stage, P5 to P30. Terminal sacs develop into mature alveolar ducts and final 
alveoli [8]. Mature alveoli are characterized by the thinning of their epithelial-endothelial 
layer which occurs mainly by apoptosis [11]. The alveolar surface is increased by epithelial 
cell proliferation [11]. After birth, important morphological and physiological changes occur 
to reach constant postnatal respiration: body temperature decrease, gaseous distention of 
the lungs, increase of oxygen partial pressure resulting in decreased carotid oxygen 
sensitivity, Hering-Breuer reflex activation and functional connectivity between oxygen 




Figure 1: Mouse lung developmental stages. Lung endoderm starts to develop at E9 on 
the ventral anterior foregut during the embryonic stage. Between E12 and E16.5, branching 
morphogenesis occurs during the pseudoglandular stage. In the canalicular (E16.5-E17.5) 
and saccular (E17.5-P5) stages, terminal sacs develop and the lung vascularization level is 
significantly increased. The last developmental stage of the lung is the alveolar stage between 
P5 and P30 with alveoli maturation. Figure was adapted from [15]. 
All changes in the lung during the five distinct development stages are mainly orchestrated by 
diffusible signals from the mesenchyme, instead of cell intrinsic [12]. During the last two stages 
of lung development, apoptosis and proliferation are key regulators of the crucial expansion 
of the alveolar airway space [10, 11, 16-18]. Once the lung development is completed, about 
5000 branches in mice and 54000 branches in humans are present. Within the distinct 
sections of the branches, we can observe a diverse cellular population [10]. The 
tracheobronchial epithelium contains serous, ciliated, goblet and basal cells. In the proximal 
bronchi, Clara, ciliated and neuroendocrine cells are present in mice [12]. Finally, bronchioles 
show ciliated, serous, alveolar type I and II cells [12]. Goblet cells consist of a compact nucleus 
in the basal area and contains granules with acidic mucin glycoproteins in the apical side of 
the cytoplasm that can be secreted to the airway lumen to protect the epithelial surface [19]. 
Serous cells present a similar morphology as the goblet cells but with a higher electron-density 
in the granules and secrete glandular fluid to hydrate the mucus released by goblet cells and 
enhance innate immunity [20-22]. Ciliated cells are constituted of up to 300 cilia on the luminal 
region of each cell and present a high mitochondrial content with the possibility to differentiate 
morphologically under stress conditions [23, 24]. Basal cells connect through 
hemodesmosomes to the basement membrane, constitute the attachment source to ciliated 
and goblet cells and regulates inflammatory response [25, 26]. Clara cells contains granules, 
can secrete surfactant proteins and proteinases protecting the epithelium and show a high 
proliferative capacity [27-29]. Neuroendocrine cells are elongated and pyramidal with microvilli 




alveolar surface where the gas exchange occur by this large flat cells [31]. On the other hand, 
alveolar type II cells are less frequent than type I, show a cuboidal shape with apical microvilli, 
contain lamellar bodies, secrete surfactant protein and can differentiate into alveolar type I 
cells [31, 32]. Considering the critical function of the lungs, mutations in genes specifically 
linked to lung development are typically associated with perinatal lethality [33].  
1.1.2. Mouse heart development 
In vertebrate embryos, the heart is the first functional organ to be developed (at E8 in mice 
and at week 3 in humans) [34]. Cardiac congenital malformations constitute 1% of the live 
births and 8% of the prenatal births in humans [34]. Currently, there are more than 150 gene 
mutations known in mice that are associated with cardiac development abnormalities which 
are investigated to increase our understanding of developmental heart formation [35]. 
Cardiac development can be divided into five different stages in mice (Figure 2): 
(1) Cardiac crescent stage, E7.5 [36]. Two different tubes are formed from the cardiogenic 
mesoderm, the first and second heart fields. The first heart field proliferates and 
differentiates during this stage whereas the second heart field remains undifferentiated as 
a myocardial progenitor [36]. Precursor cells in the primitive streak differentiate into 
cardiomyocytes and travel anterior-laterally to constitute the myocardial primordial with a 
cranial and caudal peak. In parallel, endothelial cells are differentiated and build two tubes 
below the myocardial primordial[37].  
(2) Linear heart stage, E8 [36, 38]. The heart starts to pump irregularly and the parallel tubes 
formed by endothelial cells in the previous phase fuse across the ventral midline forming 
the cardiovascular lumen [37]. During this phase, the myocardium begins to differentiate 
and is connected to the endocardium via finger-like protrusions [39]. 
(3) Looping heart stage, E8.5-E10 [36, 38]. The heart starts to pump regularly with the venous 
pole as a pacemaker. The linear heart turns anti-clockwise forming a premature heart 
structure with a rostral arterial or aortic sac together with a caudal venous pole (left and 
right sinus poles)[37, 40]. At a cellular level, the proliferation of cardiomyocytes is increased 
to a high rate, the highest of all cardiac developmental stages. Specifically, 700 
cardiomyocytes are present in 0.0014 mm3 of heart tissue at E8 and 68000 cardiomyocytes 
can be found in 0.150 mm3 of heart tissue at E11. Since the increase in cardiomyocyte 
numbers and cardiac size occur in parallel, the cardiomyocyte size stays constant at around 




(4) Chamber formation stage, E10-12 [36]. A bulboventricular canal connects the left and right 
ventricle. The right ventricle is connected via an outflow tract to the aortic sac. The four 
different chambers of the heart are originated from the expansion and bulging of the walls 
of the looped heart [37]. The cardiac trabeculae in the luminal side of the ventricles are 
formed from the myocardium [39]. They grow by basal apposition leading towards an 
outward expansion of the chambers [39].  
(5) Maturation/septation stage, overlaps with the previous phase starting after E10 and 
finishing at birth [36]. In this stage, the heart undergoes sarcomere alignment in their 
myofibrils, T-tubule formation, a decrease in glycolysis and an increase in mitochondrial 
number and activity [41]. At the end of the embryonic cardiac development (E17.5), the 
mouse heart contains approximately 1 million cardiomyocytes with a cellular volume of 
around 2150 m3 [39]. During birth, major changes occur in the heart. When the oxygen 
and nutrients supplied by the placenta and umbilical cord cease, the circulation to the lungs 
and of the rest of the newborn begins to be differentiated to allow the adult gas exchange 
in the alveoli [42]. Those changes in circulation together with the first breath provoke 
different pressure between the right and left atrium and lead to the closure of the connection 
between both atria via the foramen ovale [42]. 
Figure 2: Mouse heart developmental stages. The first stage of cardiac development is the 
cardiac crescent stage (E7.5) characterized by myocyte differentiation. This is followed by the 
linear heart stage (E8) with an irregularly beating heart. At stage 3, it follows the looping heart 
stage (E8.5-E10) with a regularly beating heart and the beginning of the left and right sinus 
pole differentiation. The different aortic and ventricular sacs are formed during the chamber 
formation stage (E10-E12). Finally, maturation and septation of the heart occur (E10-birth) 
together with adaptations of the energy metabolism of cardiomyocytes. Ot: outflow tract; v: 





1.2. Adult lung 
1.2.1. Mouse pulmonary structure and function 
The adult mouse lung is formed by four right lobes and one left lobe [43]. Overall, 18% of the 
total lung volume is filled by pulmonary parenchymal tissue [44]. Inhaled air travels through 
the trachea to the main bronchi subsequently to 13-17 bronchioles generations and finally to 
alveolar ducts with monopodial branching [2]. In the alveoli, diffusion of gases like oxygen and 
carbon dioxide occur within the bloodstream through a 0.32 m thick blood-gas barrier [45, 
46]. Other functions of the lung include a role in immune defense against inhaled pathogenic 
particles, conversion of angiotensin I to angiotensin II (a potent vasoconstrictor), and release 
of diverse substances as surfactant proteins that decrease the alveolar elastic recoil [44, 47-
49]. 
One of the main parameters to assess pulmonary function is the tidal volume (TV), which is 
the volume of inspired and expired air per breath under resting conditions. In adult mice the 
average TV is about 0.3 mL. the average respiratory frequency is 168 breaths per minute [50]. 
This rapid respiratory rate is necessary to dissipate body heat and to maintain the body 
temperature [51]. 
The lung includes a wide variety of cells as non-ciliated, dome-shaped, secretory bronchiolar 
Clara cells and ciliated cells. From the bronchi to the alveoli the cellular general morphology 
changes from columnar to cuboidal shape [52, 53]. Additionally, the number of Clara cells 
increases towards the alveoli [54, 55]. These Clara cells are key regulators in anti-
inflammatory and immune regulations in the lung epithelium by expressing the P-450 
monooxygenase enzymatic system that is involved in metabolism and detoxification of 
xenobiotics [56]. In the alveolar and acini region of the lung, pneumocytes type I and type II 
cells can be found. Type I pneumocytes constitute 93-95 %  of the alveolar surface of each 
alveolus, are not able to undergo mitosis and the flat cellular morphology aid gaseous diffusion 
to the underlying endothelium [57]. Type II pneumocytes represent 3-5 % of the alveolar 
surface, show a quick repairing capacity, produce surfactant protein to maintain homeostasis 
of the alveolus and regulates innate immune response [58, 59].  
The regulation of the respiration is driven by thoracic neural receptors, peripheral 
chemoreceptors and central chemoreceptors [60-62]. Thoracic neural receptors are 
mechanoreceptors located in trachea, airways and pulmonary vessels sending information 




brain [63, 64]. Peripheral chemoreceptors are divided between carotid bodies that send the 
information via the glossopharyngeal nerve and aortic bodies that informs via the vagus nerve 
[60]. Peripheral chemoreceptors are able to sense carbon dioxide and hydrogen ions, but 
mainly response to low arterial oxygen levels [65]. Central chemoreceptors mostly sense pH 
modifications in the central nervous system due to changes in arterial carbon dioxide [66]. 
Carbon dioxide forms hydron ions in the cerebrospinal fluid, producing an acidic pH that is 
sensed by the chemoreceptors which send the signal to the brain that in turn will stimulate 
hyperventilation [61]. 
Whole-body plethysmography is the most commonly used technique to assess the respiratory 
function in unrestrained and conscious mice in a non-invasive manner [67, 68]. 
1.2.2. Pulmonary diseases 
Lung hypoplasia constitutes the main cause of neonatal lethality and present around 18 % of 
all perinatal lethality in humans [69-71]. Lung hypoplasia is referred as pulmonary 
underdevelopment that leads to a decreased pulmonary weight and/or volume due to 
decreased bronchial branches, alveoli and/or alveolar size. Lung hypoplasia is sub-classified 
based on the symptoms and causes [72]. For example, primary pulmonary hypoplasia displays 
with a congenital malformation of the pulmonary parenchyma and a reduced lung volume. The 
lungs do not respond to treatment with surfactants and neonates do not survive [73, 74]. 
Current studies try to unravel the mechanisms underlying this disorder [75-78]. Opposite to 
lung hypoplasia, pulmonary hyperplasia is the enlargement of the lung by the increase on the 
pulmonary cell number and extremely uncommon in neonates [79, 80].  
In general, pulmonary diseases include five of the 30 leading death causes world-wide: chronic 
obstructive pulmonary disease (COPD) is ranked as third, lower respiratory tract infection is 
fourth, bronchial and lung cancer is sixth and asthma is ranked as twenty-eighth [81]. COPD 
is the pulmonary disease with the highest mortality and a wide number of symptoms [82]. 
COPD displays chronic airway inflammation, decreased numbers of small airways and 
destruction of parenchymal area, leading to emphysema and shortness of breath. The 
epithelium airway that functions as a first defense barrier against air pathogens is impaired 
presenting with squamous metaplasia, goblet cell hyperplasia and loss of epithelial 
morphology [82]. The epithelium metaplasia or change in the tissue nature may occur by the 
proliferation of airway epithelial cells. However, the molecular mechanisms underlying the 




pathogenesis develops in emphysema formation due to the imbalance between proliferation 
and apoptosis [83], resulting in an excess of mucus and higher infection susceptibility [84]. 
COPD is irreversible and leads to a decreased parenchymal elasticity due to the degradation 
of elastin by diverse proteases [85]. Furthermore, COPD affects blood flow and pressure 
leading to cardiac and renal dysfunction increasing in turn the pulmonary edema [86]. 
Pulmonary edema is an increase of fluids in the interstitial space and alveoli. At a molecular 
level, proteoglycans in the extracellular matrix break, leading to decreased intermolecular 
interactions with the extracellular matrix components facilitating the pulmonary edema [87]. 
To understand further the function and treatment of pulmonary diseases, different mouse 
models have been studied. Between the advantages of using the mice are the deeply studied 
immunologic system, the short reproducible cycle, the wide variety of available mouse 
reagents, the characterized genome and available transgenic technology applied to this 
specie [44].  
1.3. Adult heart 
1.3.1. Mouse cardiac structure and function 
The general human and mouse anatomy and function are comparable. The adult heart is a 
four-chamber organ divided into the right and left heart, each of them formed by one atrium 
and one ventricle. The main function of the heart is to ensure blood circulation and, thereby, 
the delivery of nutrients and oxygen in the blood throughout the organism. A cardiac cycle 
ranges from the contraction of the atria to the relaxation of the ventricles and is divided into 
two phases: (1) the diastole where the ventricles relax and blood accumulates and (2) the 
systole corresponding to the contraction and the emptying of the ventricles [88]. The maximal 
aortic pressure (120 mmHg) is reached during the systole [89] and the lowest arterial pressure 
(100 mmHg) during the diastole [90] (Figure 3). 
The tissue consists of atrial muscle, ventricular muscle, excitatory and conductive muscle 
fibers (Figure 3). A few anatomical and functional characteristics are different between 
humans and mice. For example, a mouse adult heart weighs around 150 mg, pumps 20.4 mL 
blood per minute beating 650 times at rest [91]. A human heart weighs around 275 g and beats 
on average 65 times per minute and 4 to 6 L per minute under resting conditions [92]. Due to 
the mouse body position, its heart displays mobility in the pericardial cavity and presents an 
ellipsoidal shape [93]. Inner, medium and outer epicardium constitute the cardiac layers. The 




mesothelium, circumferentially fibrous connective tissue with blood and lymphatic vessels 
forms the thin pericardium [94, 95]. Below the pericardium, the myocardium incorporates 
cardiomyocytes surrounded by a rich capillary network [95]. Finally in the inner side of the 
heart, the endocardium appears with an elevated number of vessels and with cardiomyocyte 
fibers oblique or parallel to the apical-basal axis [94].  
 
Figure 3: Mouse adult heart function. (A) Cardiac right and left ventricular pressure during 
systole and diastole, together with the aortic pressure and the corresponding volume of the 
left and right ventricle. (B) Adult mouse heart anatomy showing the different muscle 
pericardium (green), myocardium (red) and endocardium (yellow) and the blood flow direction 
with white arrows. rv: right ventricle; lv: left ventricle; ra: right atrium; la: left atrium; ao: aorta; 
vc: vena cava; pa: pulmonary artery; pv: pulmonary veins. 
The heart adjusts its contractile strength and frequency according to the body requirements. 
Mostly, neural, electrical, hormonal and mechanical signals are sensed affecting cardiac 
contraction strength and rate [96-98]. The cardiac rhythm is tightly regulated by the electrical 
activity of the heart. One of the unique characteristics of the heart is the cardiac pacemaker in 
the superior lateral wall of the right atria, the sinoatrial (SA) node. The SA node is composed 
of a cluster of specialized cardiomyocytes which have the unique property to spontaneously 
generate an electrical impulse [99]. 
The heart responds under different stimuli to pump enough blood to all the body tissues and 
organs. This cardiac plasticity allows cardiomyocytes to increase their width and length under 
physiological conditions leading to cardiac hypertrophy [100]. Physiological cardiac 
hypertrophy is caused by normal animal growth [101], pregnancy [102] and exercise [103, 
104], among others. Also, diverse growth hormones such as insulin or thyroid hormone, 
together with mechanical forcers can lead to cardiac hypertrophy [105]. This cardiac 




pressure [103, 105]. Morphologically, physiological hypertrophy leads to increased ventricular 
wall thickness together with 10-20% increase in the ventricular volume (eccentric 
hypertrophy). Under physiological conditions the hypertrophy is reversible and without 
cardiomyocyte death [105].  
There are diverse techniques to measure cardiac morphology and function, such as 
echocardiography, microCT, PET and MRI. However, due to the costs and accessibility 
echocardiography is one of the most used techniques [106].  
1.3.2. Cardiac diseases 
Cardiovascular disease is the leading cause of mortality worldwide in humans, accounting for 
31% of all deaths with 17.9 million people in 2016 according to the WHO 
(https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)). 
Cardiac diseases commonly result in heart failure (HF) constituting the leading reason of  
morbidity and mortality [107]. 
HF is typically characterized by systolic or diastolic dysfunction followed by low cardiac output 
[107].Left-sided HF is usually a precursor of right-sided HF, which is connected to a higher 
risk of sudden death [108]. Traditionally, left-sided HF can be classified based on reduced 
(HFrEF; EF < 50 %) or preserved (HFpEF; EF ≥ 50 %) left ventricular ejection fraction. HFrEF 
presents a ventricle unable to contract normally and is caused by several cardiac disorders as 
coronary artery disease and cardiomyopathies [109]. These cardiac diseases lead to 
cardiomyocyte apoptosis and high wall stress, decreasing the contraction capacity of the 
cardiomyocytes that cause eventually systolic failure. HFrEF presents a higher mortality rate 
than patients with HFpEF [110]. HFpEF shows diastolic dysfunction, resulting usually from 
chronic disease as hypertension, aging, obesity or renal dysfunction [109]. HFpEF is observed 
more frequently in women and older populations [111]. Patients with HFpEF show exercise 
intolerance, edema, dyspnea, pulmonary edema and pulmonary hypertension, all of the 
symptoms are related to increased fibrosis, decreased capillary content and cardiac 
hypertrophy [112]. 
As previously explained, hypertrophy can occur under physiological conditions. However, 
several factors including hypertension [113], myocardial infarction [114], gene mutations [115] 
and valve stenosis [116] can lead to pathological hypertrophy. At a morphological level, 




thickness with larger cardiomyocytes decreasing the ventricular inner chamber volume 
(concentric hypertrophy). Concentric hypertrophy is found in HF with normal left ventricular 
ejection fraction [117]. The concentric hypertrophy can lead to an eccentric hypertrophy 
comparable to physiological hypertrophy, but with a reduced contractile capacity and an 
increased cardiomyocyte length [105]. Eccentric hypertrophy is found in HF with decreased 
left ventricular ejection fraction [117]. Pathological hypertrophy is irreversible and associated 
with cardiomyocyte death, reduced capillary network [118] and fibrosis [119]. Overall, 
pathologic cardiac hypertrophy has a poor prognosis and generally leads to HFpEF [120], 
arrythmia [120], pulmonary edema and sudden death due to fibrillation [121]. 
Murine models represent one of the most relevant models to study cardiac human diseases 
[122]. For example, mouse models of HF are the most used animal models, mainly due to 
their genetic similarity with humans and the almost 85 % identical protein-coding regions [123]. 
Human cardiac diseases has been further understood and their treatment improved by 
mechanistic studies and candidate gene identification on genetically modified mice [124]. 
1.4. Energy metabolism in mice 
Mice are supplied with energy through a wide variety of metabolic pathways, depending on 
the available nutrients, energy requirements and others [125-127].  Energy metabolism can 
be distinguished based on the utilization of molecular oxygen, referred to as aerobic (in the 
presence of oxygen) or anaerobic (under the absence of oxygen) metabolism [125, 126]. To 
understand further the metabolism in humans, mice are commonly analyzed. This chapter 
focuses on mouse glucose metabolism and homeostasis, one of the major metabolic 
substrates alongside lipids, proteins and molecular oxygen. 
1.4.1. Glucose metabolism 
Monosaccharides are relevant components of the diet and can be divided between fructose, 
galactose and glucose [128]. After intestinal tract absorption and transport to the liver, fructose 
and galactose are mainly transform to glucose [129]. As a result, the glucose transported in 
the blood represents 95% of the circulating monosaccharides. One mechanism contributing 
to the circulating glucose content is the elevated amount of glucose phosphatase in liver cells 
that release glucose in the blood stream hydrolyzing  glucose-6-phosphate a product from the 
metabolism of fructose and galactose, also included in glucose metabolism  [130]. Blood 




of starvation [132]. In humans, blood glucose is around  6.5 mM [133] under non-fasting 
conditions and around 5 mM after 3 to 8 hours of starvation [133, 134]. Several factors other 
than nutrient intake affect the blood glucose levels, including the time of day, gender and age 
[134]. 
The maintenance of glucose homeostasis is regulated by diverse processes: glycogenesis 
(formation of glycogen from glucose), glycogenolysis (breakdown of glycogen into glucose), 
glycolysis (conversion of glucose into pyruvate) and gluconeogenesis (glucose formation from 
non-carbohydrate substrates) [129]. Glycogen is particularly important for many of these 
processes. Indeed, this large glucose polymer is mainly stored in liver and skeletal muscle, 
constituting up to 8% of the liver cell weight [135].  
Louis Pasteur first described glucose disruption via glycolysis in 1860 [136]. Glycolysis is the 
first step of glucose catabolism, breaking glucose into two pyruvic acid molecules [137]. 
Glycolysis produces energy in form of 2 molecules of ATP and without oxygen [138]. In the 
presence of oxygen, the catabolic process continues, and the pyruvic acids broken down into 
acetyl CoA that goes into the citric acid cycle into the mitochondrion. The citric acid cycle 
releases electrons from the breakdown of acetyl CoA to carbon dioxide [139]. These high-
energy electrons are used by the electron transport system that will produce more energy in 
the form of ATP [137]. Overall, for every molecule of glucose under the presence of oxygen 
more than 30 ATP molecules can be produced [137, 140].  
Glucose is transported via the cellular membrane by different glucose transporters, classified 
between sodium-glucose linked transporters (SGLTs) and facilitated diffusion glucose 
transporters (GLUT) [141, 142]. Immediately after entering the cell, glucose is phosphorylated 
by glucokinase in the liver and hexokinase in most of the other cells to initiate ATP production, 
facilitate enzyme binding and trap glucose in the cell by changing its charge [141]. Glucose 








1.4.2. Insulin-regulated metabolism 
Insulin is a 51 amino acid long anabolic hormone involved in the regulation of glucose [145]. 
Insulin is synthesized in the beta cells at the islets of Langerhans in the pancreas and cleared 
in the liver and kidney by the protease insulinase [146]. Its production is regulated by glucose 
but also affected by the concentration of amino acids, fatty acids, and keto acids in the plasma. 
As a result, insulin controls energy homeostasis [147]. 
Insulin is secreted into the blood, having a half-life of about 6 minutes [148]. Insulin interacts 
with two extracellular alpha subunits of the insulin receptors triggering the phosphorylation of 
two beta subunits. Intracellularly, tyrosine kinases are activated and phosphorylate several 
downstream signaling proteins including various insulin receptor substrates (IRS) [149]. The 
phosphorylation of IRS leads to binding of the lipid kinase PI3K that synthesizes the lipid PIP3 
in the plasma membrane, recruiting the kinase PDK that phosphorylates the kinase AKT on 
Thr308 [150, 151]. AKT is activated by its phosphorylation and phosphorylates in turn several 
protein substrates at Ser/Thr amino acids [152]. Targets of AKT include the transcription factor 
family FOXO that regulates glucose production and utilization, the GTPase activator protein 
TSC2 increases lipid and protein synthesis, the kinase GSK3 induces glycogen synthesis 
and the Rab GTPase activates the protein TBC1D4 that facilitates glucose uptake [150, 153]. 
Insulin signaling triggers diverse responses in different organs. In the liver, insulin signaling 
induce glycogen storage and decrease glucose output [154]. In the skeletal muscle and fat, 
insulin trigger glucose transport by translocating the glucose transporter GLUT4 to the 
membrane from intracellular vesicles [129, 149]. In the brain, insulin signaling leads to 
increased neural activity and downstream decreased hepatic glucose production, food intake 
and lipoprotein synthesis [150, 155]. 
One of the most studied diseases due to little or no insulin production or insulin resistance is 
diabetes where carbohydrate, protein and fat metabolism are abnormal [156]. There are two 
types of diabetes: type 1 or insulin-dependent diabetes with a lack of insulin secretion and 







1.5. The mTOR pathway 
Rapamycin was discovered in a soil sample collected on the island of Rapa Nui in 1964 [158], 
showing to have immunosuppressive [159], antitumor [160] and antifungal [161] properties. 
30 years later, the action mechanism of rapamycin showed the protein mechanistic (initially 
called mammalian) target of rapamycin (mTOR) [162, 163]. Since then, several studies 
uncovered the molecular structure, interactions and function of mTOR [164-167].mTOR is a 
serine/threonine protein kinase belonging to the PI3K-related kinase (PIKK) family [163]. 
mTOR plays a pleiotropic physiological role, overall controlling the balance between 
anabolism (production of macromolecules) and catabolism (breakdown of macromolecules) 
[168]. mTOR exists as the catalytic center in two different protein complexes (mTORC): 
mTORC1 and mTORC2. mTORC1 is formed by mTOR, Raptor, mLST8 (mammalian lethal 
with Sec13 protein 8), PRAS40 (proline rich Akt substrate 40 kDa) and DEPTOR (DEP domain 
containing mTOR interacting protein) [169-171]. Raptor is required for the cellular localization 
and substrate recruitment of mTORC1 [172]. mLST8 interacts with the catalytic domain of 
mTOR and is necessary to activate the kinase activity of mTOR [173]. PRAS40 interacts with 
Raptor and inhibits the kinase activity of mTOR [170, 171, 174-176]. DEPTOR inhibits directly 
mTOR activity during the inactive forms of mTORC1 [177{Peterson, 2009 #231]}. mTORC2 is 
formed by mTOR, Rictor, DEPTOR, mLST8 and the regulatory subunits mSin1 and Protor1/2 
[178-182]. Rictor is a kinase necessary to phosphorylate the downstream mTORC2 target 
AKT and is inhibited by DEPTOR [183]. mSin1 is necessary for the assembly of mTORC2 and 
the phosphorylation of AKT [178]. Protor-1/2 interacts with Rictor and it is only known that 
Protor-1 functions as an enhancer or adaptor of mTORC2 phosphorylation of the kinase SGK1 
(serum- and glucocorticoid-induced protein kinase 1) [180, 184]. Generally, mTORC1 is linked 
to the regulation of energy metabolism and cell growth, whereas mTORC2 regulates energy 
metabolism, cell cytoskeleton rearrangement, migration and apoptosis [185]. The main 
functions of mTOR can be generally grouped as follows (Figure 4): 
1. Anabolism: mTOR increases the synthesis of proteins, lipids and nucleotides via 
mTORC1 [172]. A strong trigger of mTOR is the nutrients that enhances growth and energy 
storage in mammals [185].   Starvation in turn inhibits mTOR [185]. Overall, there are several 
ways to stimulate the anabolic property of mTOR, including growth factors such as insulin, the 
signaling protein Wnt and the inflammatory cytokine TNF[186-188]. Inhibition of mTOR 
anabolism can be provoked by low ATP levels, hypoxia and tumor protein p53 regulation of 





a. mRNA translation: mTORC1 affects protein synthesis by phosphorylation of the p70 
S6 kinase 1 (S6K1) [192] and the translation initiation factor 4EBP. mTOR/Raptor 
phosphorylate S6K1 in its hydrophobic motif (Thr389), allowing the kinase PDK1 to 
interact with the phosphorylated S6K1 and to phosphorylate the S6K1 activation loop 
(Thr229). Phosphorylated S6K1 in Thr389 and Thr229 increases protein translation by 
phosphorylation of the ribosomal protein S6 [192, 193]. mTORC1-dependent 
phosphorylation of 4EBP impedes the binding of 4EBP with the translation initiation 
factor eiF4E, allowing eiF4E to position the ribosome to begin mRNA translation [194, 
195].  
b. Lipid synthesis: mTORC1-dependent phosphorylation of S6K1 also activates the sterol 
response element binding protein (SREBP) transcription factors that regulate fatty acid 
and cholesterol formation [196]. Furthermore, mTORC1 is able to phosphorylate the 
phosphatase lipin1, preventing its nuclear entry and the subsequent downregulation of 
SREBPs [197, 198].  
c. Nucleotide synthesis: following its activation by mTORC1, S6K1 further 
phosphorylates Ser1859 of carbamoyl-phosphate synthetase 2 aspartate 
transcarbamoylase dihydroorotase (CAD), increasing the de novo pyrimidine synthesis 
[199, 200]. mTORC1 also promotes the activation of the transcription factor ATF4, 
which enhances the expression of the dehydrogenase MTHFD2, increasing purine 
nucleotide production [201]. 
2. Catabolism: mTOR can inhibit autophagy, lysosome biogenesis and proteasome 
assembly via mTORC1. Additionally, mTORC1 and mTORC2 induce glycolysis [185]. 
Generally, food starvation and increased insulin levels in the blood stimulates the 
catabolic role of mTORC1 and mTORC2 [202]. The role of mTOR in catabolism includes: 
a. Autophagy: mTORC1 phosphorylates the kinase ULK1, preventing ULK1 activation via 
AMPK and subsequent autophagosome formation [203]. mTORC1 also inhibits 
transcription factors through phosphorylation that are involved in the regulation of 
proteins involved in the autophagy signaling process, as for example the transcription 
factor TFEB [204]. 
b. Lysosome biogenesis: mTORC1 phosphorylates and inhibits the transcription factor 
TFEB which is also involved in lysosomal biogenesis [191], besides participating in the 
transcriptional regulation of autophagy-regulating proteins. 
c. Proteasome assembly: On the one hand, inactivation of mTORC1 increases the 
proteasomal-dependent proteolysis via a general activation of the ubiquitin 
proteasome system [205] or via an increase of proteasomal chaperones inhibiting the 
kinase Erk5 [206]. On the other hand, hyperactivation of mTORC1 also enhances 




potential reason behind the enhanced proteasomal activity shown via inhibition and 
activation of mTORC1 could be a different regulation under acute inhibition and 
prolonged activation of mTORC1 [168]. Acute mTORC1 inhibition promotes proteolysis 
to obtain free amino acids, whereas prolonged mTORC1 activation leads to a 
compensatory increase in protein turnover to balance the increasing protein synthesis 
[168, 205-207]. 
d. Glycolysis: mTORC1 enhances the expression of the transcription factor HIF1, which 
regulates the transcription of several glycolytic genes, such as the phosphofructo 
kinase (Pfkp) leading to the stimulation of glycolysis [196]. mTORC2 phosphorylates 
AKT which induces the expression of the M2 isoform of pyruvate kinase (PKM2) that 
catalyzes the last reaction in the glycolytic pathway, promoting glycolysis [208]. 
 
Figure 4: mTORC1 and mTORC2 signaling pathways. mTORC1 (mechanistic target of 
rapamycin complex 1) and mTORC2 (mechanistic target of rapamycin complex 2) subunits 
and the mTOR domains are shown in the middle of the figure. The anabolic functions of 
mTORC1 are highlighted with a green background, catabolic functions of mTORC1 and 





A relevant regulation of mTOR in the metabolism is also through the regulation of insulin 
signaling [168]. Constitutive deletion of the mTOR inhibitor TSC2 in cells led to a biphasic 
regulation of cell mass [209]. In young mice with TSC2 Knock-out (KO) incells, 
pancreatic cell mass was increased combined with an enhanced insulin secretion and 
hypoglycemia [209]. In older mice, -cell number was decreased combined with  
hypoinsulinemia and hyperglycemia [209]. In obese rats, mTORC1 is hyperactivated by high 
fat diet, likely caused by increased amino acid availability and enhanced insulin production 
and secretion [210]. Hyperactivation of mTORC1 leads to increasing levels of activated 
S6K1/2, inhibiting the insulin/PI3K/Akt pathway and leading to insulin resistance [211]. Insulin 
resistance is also reached by direct inhibition of mTORC2, as for example shown with specific 
Rictor KO in liver, muscle or fat [212-215]. Overall, mTOR regulates insulin production as well 
as insulin regulates the mTOR signaling pathway. 
The inhibitor of mTOR, rapamycin, cannot be used to treat diabetes type 2 because it exerts 
opposite effects on the insulin-mediated regulation of metabolism by mTORC1 and 2 [216, 
217]. mTORC1 hyperactivation via genetic or triggered by nutrition leads to insulin resistance, 
which considered tamoxifen a potential treatment to improve glucose tolerance and treat type 
2 diabetes [217, 218]. However, inactivation of mTORC1 by deletion of Raptor in adipocytes 
in mice shows lipodystrophy with insulin intolerance, hepatomegaly and liver steatosis and 
loss of mTORC2 activity in adipocytes decreases Akt activity and leads to insulin resistance 
[212-216]. A more detailed understanding of the specific regulation of mTORC1 and mTORC2 
may help identifying possible treatments against type 2 diabetes [168]. 
Taken together of all the previous mentioned roles of mTOR, energy metabolism is a key 
target of the mTOR pathway. Other studies relate the mTOR pathway with pathological 
conditions particularly with cancer. Several proteins upstream  of mTOR are mutated in 
cancer, such as the kinases TSC1/2 [219] or the phosphatase PTEN [220], resulting in 
increased mTOR signaling and cell survival and proliferation [185]. Furthermore, mTOR 
inhibits the upstream pathway of the transcription factor NF-B, which is the major 
transcriptional regulator of the cellular inflammatory response [221]. Phosphorylated AKT has 
been shown to activate IKK that inhibits the inhibitor NF-B, IB, increasing NF-B activity 






1.5.1. mTOR pathway and cardiac abnormalities 
mTOR has been shown to induce striated muscle hypertrophy [224]. mTOR conditional 
deletion in skeletal muscle mice (Cre-mediated recombination in postmitotic myofibers) led to 
reduced body weight and muscle atrophy with premature death between 22 and 38 weeks of 
age [225]. Further studies with Raptor (part of mTORC1) and Rictor (part of mTORC2) skeletal 
muscle KO mice showed that mTORC1 plays a role in muscle hypertrophy and mTORC2 
shows a similar muscle than wild-type mice [226]. Inhibition of mTORC1 by deletion of Raptor 
increased autophagy, which in turn was the main regulator of the observed muscle 
hypertrophy [227]. 
In the cardiac muscle, mTOR has been linked to cardiomyocyte growth and homeostasis 
during both the embryonic and adult stage [228]. Heart specific mTOR KO embryos display 
decreased cardiomyocyte proliferation, increased apoptosis, a switch from fatty acids as main 
energy source to glucose oxidation and mitochondrial activity, dilation of the heart and 
impaired cardiac function [229-231]. Inducible heart specific Raptor KO mice display cardiac 
dilation and dysfunction due to increased cardiomyocyte apoptosis, mitochondrial activity and 
autophagy leading to mouse death after inducing the KO [230]. Stimulation of mTORC1 in vivo 
can be achieved by high levels of IGF-1, angiotensin-II and -adrenergic stimulation, ultimately 
leading to cardiac hypertrophy [232-234]. Furthermore, mTORC1 activity is increased in 
physiological cardiac hypertrophy due to exercise and in pathological hypertrophy by 
transverse aortic constriction (TAC) and hypertension [235]. mTORC2 specific cardiac 
function has only been study under stress condition so far and little is known about its 
physiological function. Cardiac Rictor KO in adult mice shows cardiac dilation, systolic 
dysfunction and wall thinning after induction of hypertrophy via TAC [236, 237]. 
1.6. The HIF pathway 
Hypoxia occurs, when the available oxygen levels for cells in organism drop below their energy 
demand [238]. Physiologically, hypoxia occurs for example during development, high altitude 
exposure or exercise [239, 240]. Hypoxia also occurs in various pathological conditions, such 
as muscle hypertrophy, HF, cancer, ischemia, stroke or in chronic inflammation [240-248]. 
To maintain metabolic homeostasis, diverse mechanisms are involved in the production of 
energy under hypoxia. During normoxia, ATP production occurs mainly through oxidative 




cellular energy [249]. Shortly after birth, changes in the energy metabolism of organs occur 
due to an increase in oxygen availability compared to the situation in utero [250]. For example 
in the heart, mitochondrial biogenesis increases and mitochondrial fusion decreases after birth 
combined with an increased ATP production [251]. Interestingly, mild hypoxia (10% oxygen) 
leads to cardiac hypertrophy in cardiomyocytes, inducing a switch to increased glycolysis [252, 
253]. 
Most organisms requires oxygen homeostasis to survive, hence, an oxygen sensing 
mechanism is required [254]. The best characterized cellular oxygen sensors are the prolyl-4-
hydroxylase domain 1-3 (PHD1-3) proteins and the asparagine hydroxylase factor inhibiting 
HIF (FIH), which use molecular oxygen (O2) together with 2-oxoglutarate (2-OG) as substrates 
and iron as well as a reducing agent as co-factors to regulate the HIF transcription factor by 
hydroxylation [255, 256].  HIF constitutes of heterodimers between one of the oxygen-sensitive 
HIF- subunits (HIF-1, HIF-2, HIF-3) and HIF-[257]. All of those subunits belong to the 
basic helix-loop-helix PER-ARNT-SIM (bHLH-PAS) family encoded by different genes [258, 
259]. Under normal oxygen levels, prolyl hydroxylated HIF- is recognized by the von Hippel-
Lindau (VHL) protein that facilitates the ubiquitination and proteasomal degradation of HIF 
[260]. Under hypoxic conditions, HIF-hydroxylation is decreased, stabilizing the protein and 
allowing its translocating to the nucleus of the cell where it forms an active transcription 
complex with HIFand the acetyltransferases p300/CBP (CREB-binding protein) as co-
activators leading to the enhanced transcription of many genes, including Epo [238]. The 
ability of cells to sense and adapt to oxygen level is highly relevant leading to the attribution 
of the 2019 Nobel Prize in Physiology or Medicine [261]. 
HIF has been linked to the development and diverse organ malformations. HIF-1 is 
ubiquitously expressed [262] and plays a vital role in vivo. KO of this gene in mice leads to 
embryonic lethality around E10.5 [263]. HIF1A (HIF-1) KO mouse embryos display vascular 
regression and malformations in the cephalic region with mesenchymal cell death [263, 264]. 
Whole-body HIF-2 deletion in mice leads to multi-organ defects including hepatic steatosis, 
skeletal myopathy and heart hypertrophy together with hypoglycemia, lactic acidosis and 
deficiency in red blood cells [265-267]. HIF-3 is only present in mammals [268], mainly 
expressed during late embryonic development and the early postnatal phase [269]. The 
relevant splice variant of HIF-3NEPAS under deletion in mice is associated with a 





1.6.1. The cellular oxygen sensor FIH 
FIH is ubiquitously expressed with highest expression levels in the skeletal muscle and 
salivary glands [270]. FIH catalyzes the hydroxylation of an asparagine in the C-terminal 
transactivation domain (CAD) of HIF, impeding p300/CBP coactivator recruitment [271, 272]. 
FIH is formed by two sheets of nine -strands and five -strands respectively. Eight of those 
strands constitute the central core dispersed through the structure [273]. FIH functions as 
homodimer, which is formed by helix-helix interactions located at the C-terminal end of each 
monomer [273]. 
Little is known about the regulation of FIH protein levels, Hif1an (the gene name of FIH) is not 
regulated transcriptionally by HIF [274]. At a transcriptional level there are only a few studies 
showing a transcriptional regulation of FIH. Active kinase PKC ζ in renal carcinoma cells is 
able to increase the binding between cut-like homeodomain protein (CDP/Cut) and the 
HIF1AN promoter region, inhibiting HIF1AN transcription [275]. Also, miR-455 targets HIF1AN 
increasing kinase AMPK activity and inducing browning of white adipose tissue and 
mitochondrial production in mice [276]. Ubiquitination of FIH can occur via the E3 ubiquitin 
ligase Siah-1 in normoxia, targeting FIH for proteasomal degradation [277]. This suggests that 
Siah-1-dependent regulation of FIH might play a role in the adaptation to hypoxia [277]. FIH 
is SUMOylated by SUMO2/3 particularly in hypoxia, but also in normoxia, followed by 
proteasomal degradation [278]. This process can be reversed by the SUMO specific peptidase 
3 (SENP3) [278]. 
Whole-body Hif1an KO mice display an energy metabolic phenotype levels [279].  The animals 
present with a decreased body weight, an increased metabolic rate (increased O2 
consumption and CO2 production), enhanced glucose and lipid homeostasis and pulmonary 
hyperventilation levels [279]. Under high fat diet, Hif1an KO mice are resistance to body weight 
gain and liver steatosis levels [279]. These metabolic differences seemed to be regulated at 
least in part by the brain levels [279]. Neuron-specific FIH deletion also led to a decreased 
body weight, enhanced metabolic rate, insulin sensitivity and protected against high fat diet-
induced body weight gain levels [279]. Hif1an KO mouse embryonic fibroblasts (MEFs) 
showed a suppressed AMPK activation and increased ATP levels [279]. More in-depth 
analysis demonstrated that FIH regulates a switch between oxidative phosphorylation in the 
mitochondria and glycolysis in the cytoplasm [270].  Hif1an KO cells increased mitochondrial 
activity in normoxia, glycolytic reserve and oxygen consumption [270]. Genome-wide 




plasma phospholipid fatty acid concentration [280, 281]. Hif1an was also associated with BMI, 
food conversion and muscle fat content in pigs [282, 283]. The connection between FIH and 
the metabolic phenotype shown under its deletion, suggest that might be another potential 
HIF-independent target of FIH leading to the metabolic changes. 
FIH has been shown to hydroxylate non-HIF dependent proteins, particularly ankyrin-repeat 
domain (ARD)-containing proteins[284], including the NF-B signaling pathway proteins IB 
and p105 [285, 286]. Other FIH substrates such as ASB4 are connected with the ubiquitination 
and degradation of substrate proteins [285, 287]. Therefore, several proteins outside the HIF 
pathway have been shown to be FIH substrates, but no known target was linked to the 
observed metabolic phenotype in Hif1an KO mice [285, 288]. Our group recently identify the 
deubiquitinase OTUB1 as a bona fide FIH substrate that is hydroxylated on Asn 22 [289, 290]. 
Loss of Asn22 hydroxylation increased the interaction of OTUB1 with different metabolic 
enzymes affecting OTUB1 substrate targeting and the cellular bioenergetic status [290]. 
Hence, OTUB1 is a target of FIH that might explain the HIF-independent metabolic changes 
in Hif1an KO mice [279, 290]. 
1.7. Protein ubiquitination 
Ubiquitination is a dynamic and widespread cellular post-translational protein modification that 
was first discovered in 1977 [291-293], gaining the recognition of the 2004 Nobel Prize in 
Chemistry [294]. Currently, it is known that among the 25,000 genes [295] about 5% are 
participants of the vast ubiquitin system [296]. 
Ubiquitination (Figure 5) occurs through an interplay of three different types of enzymes 
leading to the covalent attachment of the protein ubiquitin (consisting of 76 amino acids) to a 
substrate requiring the use of ATP in eukaryotes [297]. The contributing enzymes are 
classified as E1 ubiquitin-activating enzyme, E2 ubiquitin-conjugating enzyme and E3 
ubiquitin ligase [297]. E1 activates the C-terminus of ubiquitin attaching it to the sulphur of a 
cysteine residue in E1 [297]. The ubiquitin is then transferred to an E2.  E3 ligases can be 
differentiated into two different types in humans: HECT (Homologous to the E6-AP Carboxyl 
Terminus) and RING (Really Interesting New Gene) [298]. HECT E3 enzymes transfer 
ubiquitin to themselves first and afterwards to the substrate. RING E3 ligases directly transfer 




Ubiquitin is connected to a substrate protein via a covalent amide linkage formed between its 
the C-terminal Gly76 and an amino group on the side chain of a lysine residue of the substrate 
[299]. The attachment of the first ubiquitination is referred to as monoubiquitination if no further 
ubiquitin proteins are attached. Further ubiquitin attachment to the first connected ubiquitin 
leads to polyubiquitination. The following ubiquitin can bind to 7 different Lys (at positions 7, 
11, 27, 29, 33, 48, 63) or the N-terminal Met of ubiquitin [297, 300]. The different protein fate 
is determined depending on the ubiquitination amino acid residues and the type of ubiquitin 
chain. Between the different types of polyubiquitin, Lys63- and Lys48-linked ubiquitin chains 
are the most common ones. Lys63-linked ubiquitin chains plays a role in endocytosis, 
transport, DNA repair and ribosome function. Whereas Lys48-linked ubiquitin chains regulate 
proteolysis. Ubiquitin branches (ubiquitin chains attached within a linked ubiquitin chain to the 
protein substrate) can happen by diverse amino acid linkages increasing the complexity of the 
system [301-304].  
 
Figure 5: Protein ubiquitination. Two E1 ubiquitin--activating enzymes transfer a protein 
ubiquitin (Ub) to one out of 40 different E2 ubiquitin-conjugating enzymes. Subsequently, 
ubiquitin is covalently attached to a protein substrate with the help of an E3 ligase enzyme. If 
this process occurs once, it leads to monoubiquitination. Several consecutive ubiquitinations 
can lead to polyubiquitin chains with isopeptide bonds between lysine residues of Ub’s. 
Monoubiquitination and the diverse types of polyubiquitination have different functions. PPi: 
inorganic diphosphate. Image modified from [297]. 
Substrate ubiquitination is highly regulated. Phosphorylation is one of the most studied post-
translational regulations of ubiquitination [305, 306]. For example, glycogen synthase kinase 
3 phosphorylates the transcription factor MYC, facilitating its ubiquitination and proteasomal 
degradation [307, 308]. Another example is the phosphorylation of the androgen receptor by 
AKT followed by androgen receptor ubiquitination by the E3 ligase Mdm2 [309]. 




the serine/threonine kinase JNK1 phosphorylates the HECT E3 ligase Itch, enhancing its 
ligase activity [310]. Another case of post-translational modification of the ubiquitination is 
acetylation, consisting in the addition of an acetyl group to an ubiquitin protein. Acetylation of 
Lys6 and Lys48 has been shown to block ubiquitin chain formation via those amino acid 
residues [311]. 
Ubiquitination plays a significant role in diverse pathologies, such as in muscle-wasting 
disorders, where there is a loss of skeletal muscle mass caused by cancer, aging and 
metabolic abnormalities like diabetes [312]. In detail, E3 ligases Atrogin-1 and MuRF1 leads 
to the degradation of diverse proteins in the myofibrils leading to the disassembly of the muscle 
filament and breakdown the muscle [313, 314]. Also, the muscle specific E3 ligase MG53 is 
overexpressed under insulin resistance [315]. MG53 ubiquitinates the insulin receptor and 
IRS1, leading to its proteasomal degradation [315]. Other significant pathologies associated 
with abnormal ubiquitination are cardiac diseases. An example of cardiac pathologies is the 
E3 ligase TRIM63, where mutations are identified in patients with hypertrophy cardiomyopathy 
[316]. 
1.7.1. Protein deubiquitination 
The ubiquitination process can be reversed by deubiquitinases (DUBs) that cleave ubiquitin 
from the substrate. There are about 100 DUBs known in humans [317]. DUBs do not only 
remove ubiquitin chains, but also regulate the available pool of ubiquitin proteins for the 
ubiquitin pathway [318]. Besides, the modification of the ubiquitin chains can occur via the 
removal of ubiquitins in a chain modifying the architecture and length [318]. DUBs are 
classified into six protein families according to their structure and sequence similarity [319]: 
(1) Ubiquitin C-terminal hydrolases (UCHs). UCHs are cysteine proteases [297, 301]. The 
UCH protein family consists of four members: UCHL1 (isozyme L1), UCHL3 (isozyme L3), 
UCHL5 (isozyme L5) and BAP1 (breast cancer type 1 susceptibility protein associated 
protein 1) [319]. UCHL1 and UCHL3 include only a catalytic domain. UCHL5 contains 
also additional 100 amino acids that determine its binding to the proteasome at the subunit 
Rpn13 of the 19S regulatory particle of the 26S proteasome lid [320-322]. The last and 
larger component of this family is BAP1 with more than 500 amino acids in a C-terminal 
prolongation in addition to the catalytic domain [323, 324]. Members of the UCH family 
hydrolyze ubiquitin chains specifically from the C-terminal end [323, 324]. UCHs play a 




[325] and mutations in BAP1 constitute what is called BAP1-related tumor predisposition 
syndrome which includes lung, ovarian, pancreatic and breast cancer among others [326-
328]. 
(2) Ubiquitin-specific proteases (USPs). USPs are cysteine proteases that encompass the 
largest DUB family. Most of the USPs contain a catalytic triad consisting of Asp, His and 
Cys. Asp stabilizes His which deprotonates Cys in the presence of a ubiquitin chain, 
resulting in a nucleophilic attack on the isopeptide ubiquitin-substrate bond. USPs affect 
a variety of different processes, including proteasomal degradation, histone modification 
and cell signaling [329, 330]. 
(3) Ovarian tumor proteases (OTU). The OTU family comprises four sub-families of cysteine 
proteases [297, 301]: Otubains (OTUB1 and OTUB2), A20-like OTUs (A20, VCIP135, 
Cezanne), OTUD (OTUD1-6, ALG13 and HIN1L) and OTULIN (OTULIN, FAM105A) [297, 
301]. Within the subfamilies the catalytic domain dimensions differ. The smallest catalytic 
domain size is reported to be around 150 amino acids in OTUD enzymes. The largest 
catalytic domain contains around 350 amino acids in A20-like OTUs [331]. OTUs are 
involved in the regulation of NF-B signaling, protein degradation, DNA damage repair or 
angiogenesis [332-334]. 
(4) Josephins or MJDs. Josephins are cysteine proteases and four different members have 
so far been identified in humans [297, 301]. The DUB Ataxin-3 is the best characterized 
member [335]. A characteristic feature of the Josephins is that the catalytic triad shows 
allosteric impediment when ubiquitin is not present [336]. Josephins are linked to 
proteasomal degradation or autophagy among others [337]. Josephins are important in 
neural function, as for example Ataxin-1 modulates transcription important for the 
dopaminergic pathway [338-340]. 
(5) JAB1/MNP/MOV34 metalloenzymes (JAMMs). JAMMs are zinc metalloproteases [297, 
301], using two zinc molecules in their active sites as well as one water molecule in order 
to cleave the amide bonds in ubiquitin chains [341-344]. The most studied JAMM 
deubiquitinase is the proteasome regulatory particle lid subunit RPN11 that is essential 
for cell viability [345]. JAMMs play a role in DNA repair and proteasomal degradation [346, 
347]. 
(6) Monocyte chemotactic protein-induced protein (MCPIP): MCPIPs were first identified in 
2010 through the discovery of MCPIP1 [348]. Bioinformatic analyses indicate that the 
family is constituted of seven members [319]. This family has only been analyzed in detail 
regarding MCPIP1 which carries Cys and Asp in the active center of its catalytic domain. 
MCPIP1 regulates the macrophage inflammatory response by deubiquitinating the TNF 
receptor associated factors TRAF2, TRAF3 and TRAF6, resulting in negative regulation 




The deubiquitination of proteins is additionally regulated in a complex manner by post-
translational modifications of DUBs, including phosphorylation, hydroxylation or SUMOylation 
[349]. These post-translational modifications affect DUB stability, activity, location and/or 
interactions [350]. 
1.7.2. Deubiquitinases in vivo  
DUBs have mainly been studied in vivo regarding their role in cancer, but in the last years 
analyses started to focus on other fields, such as cardiac and metabolic diseases [351]. 
Hypertrophic and failing mouse hearts show increased UCHL1 level [352]. Cardiac UCHL1 
knockdown decreased cardiac hypertrophy induced by pressure overload [352]. Treatment 
with the UCHL1 inhibitor LDN-57444 ameliorated cardiac hypertrophy [352].  UCHL1 
stabilized epidermal growth factor receptor (EGFR), which is a positive regulator of cardiac 
enlargement by activating diverse downstream pathways including the PI3K/AKT pathway 
[352]. At the same time, the 19S proteasome-associated DUB inhibitor Auranofin ameliorates 
cardiac hypertrophy, resulting in the aggregation of IB and NF-B inactivation [353]. Usp20 
KO mice present with an impaired 1 adrenergic receptor-induced cardiac contractility and 
relaxation, but normal systolic function [354]. It is not well established whether there is a 
specific involvement of certain ubiquitin chains in the regulation of cardiac homeostasis. 
However, Lys63-linked ubiquitin chains are a potential target since they are highly linked to 
cardiac hypertrophy, mainly through their importance for the regulation of the NF-B pathway 
[355]. As an example, DUB cylindromatosis (CYLD) cleaves Lys63-linked ubiquitin chains 
from adaptor protein receptor-interacting protein 1 (RIP1) blocking NF-B signaling [356]. 
Several different DUBs were shown to regulate energy metabolism. CYLD suppresses non-
alcoholic steatohepatitis (NASH) in monkeys and mice [357]. The E3 ligase TRIM47 degrades 
CYLD upon interaction correlating with the increased NASH severity. In mice, an increase of 
hepatic CYLD levels reverses the progression of NASH in mice and of metabolic syndrome in 
monkeys [357]. In mice, hepatocyte Cyld overexpression inhibits insulin resistance, 
inflammation, fibrosis and lipid accumulation. On a molecular level, CYLD interacts and 
removes Lys63 of the TAK1 kinase, blocking downstream JNK-p38 cascades [357]. 
DUBs are also important for the regulation of inflammation. USP13 stabilizes the anti-
inflammatory single immunoglobin interleukin-1-related receptor IL-1R/Sigirr leading to 
suppression of pulmonary inflammation in mice [358].  Usp13 KO mice are sensitive to 




Otud4 KO mice display enhanced macrophage inflammatory signaling upon Toll-like receptor 
(TLR) stimulation. Mechanistically, OTUD4 is necessary for the Lys63 deubiquitination of 
MyD88, an important signaling protein associated to TLR. As a result, OTUD4 inhibits the 
activation of NF-B [359]. Interestingly, phosphorylated OTUD4 targets Lys63-linked ubiquitin 
chains, whereas unmodified OTUD4 hydrolyses Lys48-linked ubiquitin chains [359]. 
1.8. OTUB1 
In 2002, the DUB OTUB1 (ovarian tumor domain-containing ubiquitin aldehyde binding protein 
1) was discovered under the name HSPC263 as the first member of the OTU domain family 
[360]. Otub1 is located on chromosome 11q13.1 in Homo sapiens and on chromosome 19A 
in Mus musculus [361]. OTUB1 gained increasing interest by the research community over 
the last years due to its unique regulation of ubiquitin chains, its high ubiquitous expression 
and the modulation of a plethora of cellular processes [362-364]. In vivo, homozygous Otub1 
KO mice are perinatally lethal, but no further analysis demonstrate the reason behind the 
lethality or the detailed phenotype [365, 366]. Furthermore, cell type specific Otub1 deletion 
in mice has been further characterized showing anti-inflammatory and pro-inflammatory 
function [367, 368]. However, the physiological role of OTUB1 remains elusive. 
1.8.1. Structure, function and regulation of OTUB1 
The active site of OTUB1 is formed by the amino acid triad Asp88, Cys91 and His265 [369]. 
The active site with the catalytic Cys91 in its center is located at the interface of a -sheet lobe 
() and an -helical lobe (3-10) [370]. Isopeptide linkages of K48-linked polyubiquitin 
chains are hydrolyzed by nucleophilic attack through the Cys91, which is enabled by the 
proximity of the His265 to Cys91, lowering the Cys91 pKa [371]. OTUB1 contains a conserved 
OTU domain between residues 85 and 271 [372], that changes the conformation upon binding 
of free ubiquitin triggering the formation of an ubiquitin binding helix [373]. OTUB1 has a close 
family homologue, OTUB2. But both proteins differ in their structure and catalytic activity. The 
OTUB2 catalytic triad is formed by Asn226, Cys91 and His224 displaying a more permissive 
ubiquitin recognition in its canonical active site than OTUB1 [374, 375].  This is due to the lack 
of the N-terminal -helix of OTUB1, which restricts ubiquitin binding in a certain orientation 
[374, 375]. Besides, OTUB1 presents a unique structure  among the cysteine proteases in 
which the catalytic center is in a non-productive conformation [370]. OTUB2 shows a faster 




bonding distance between His224 and the Cys91 that facilitates the binding of the substrate 
[372].  
OTUB1 is one of the most highly expressed of all known DUBs [376]. Uniquely, OTUB1 has 
both catalytic and non-catalytic functions. Beside the catalytic cleavage of Lys48-linked 
ubiquitin chains, OTUB1 inhibits non-catalytically E2 conjugating enzymes, impeding Lys48-
linked and Lys63-linked ubiquitin chain formation [332, 370]. 
The catalytic activity of OTUB1 targets diverse proteins (Table 1). The canonical function was 
mainly studied in of the context of cancer progression and metastasis and OTUB1 was shown 
to stabilize the transcription factors FOXM1 and Snail [377-381]. Inflammation and the cellular 
response to viral infection are also regulated by OTUB1 by activation of the NF-B signaling 
pathway through deubiquitination of cIAP1, UBC13 and/or RIG-I [368, 382, 383]. Also, RhoA 
is deubiquitinated by OTUB1 rearranging the cytoskeleton and increasing the susceptibility to 
Yersinia infection [384]. In ischemia reperfusion injury, OTUB1 is nephroprotective 
deubiquitinating Lys48-linked YB-1 and increasing the levels of the anticoagulant 
nephroprotective aPC [366]. Furthermore, OTUB1 might aggravate neural diseases by 
deubiquitinating Tau and enhancing the formation of pathological Tau (AT8-positive Tau and 
oligomeric Tau forms) under an unkown mechanism [385]. Estrogen receptor alpha (ER) is 
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Increased susceptibility to 
Yersinia infection 
[384] 
YB-1 Lys48 n.d. Nephroprotection following IRI [366] 
Tau Lys48 






Decreased activity of placental 
alkaline phosphatase* 
[386] 
Table 1. Target proteins regulated by OTUB1 enzymatic activity. The color code used in 
the table indicates the regulation of diverse processes or diseases: grey, cancer; blue-gray, 
immune response; blue, viral and bacterial infection; orange, other diseases; yellow, others. 
EMT: epithelial-mesenchymal transition. IRI: ischemia reperfusion injury. n.d.: not determined. 
degr.: degradation.Ub: ubiquitin.* The study only showed the effect of the loss of OTUB1 
increasing the activity of placental alkaline phosphatase, no overexpression or recovery 




The non-catalytic activity of OTUB1 has been mainly connected to the regulation of the 
immune response (Table 2), targeting Nur77, p100, SOCS1 or AKT [367, 388-390]. OTUB1 
can bind to several different E2 enzymes, including UBCH5, UBE2E and UBC13 [365].  
Furthermore, OTUB1 stabilizes UBE2E1 (UBCH6) by suppressing its autoubiquitination [365]. 
Interestingly, free ubiquitin and charged ubiquitin E2 enzymes increase the affinity of OTUB1 
to E2 [332, 391, 392].  Free ubiquitin binds allosterically to the distal site of OTUB1 and induces 
the N-terminal ubiquitin-binding helix [332, 391, 392]. The donor ubiquitin of E2 enzymes 
interacts with the N-terminal ubiquitin-binding helix and provokes the inhibition of E2 enzymes 
[332, 391, 392]. Besides, OTUB1 prevents the interaction of E2 with E3 enzymes [393, 394].  
Interestingly, OTUB1 is monoubiquitinated by UBCH5, increasing the catalytic function of 
OTUB1 [393, 394]. Moreover, OTUB1 Lys48 cleavage activity is inhibited by the interaction 
with UBCH5B [391]. Due to the high sequence similarity between E2 enzymes, the inhibition 
of E2s by OTUB1 may occur via the same mechanism as demonstrated for UBCH5B [332]. 
Potentially any of the E2 enzymes with which OTUB1 has been shown to interact, as UBE2N, 
UBE2D, UBE2E [362]. Furthermore, OTUB1 interactome analysis shows an interaction with 
around 10 E2 enzymes [290]. Overall, a complex interplay between E2 enzymes and OTUB1 













RAS n.d. n.d. ERK signaling Enhanced lung cancer progression 
[395] 
Nur77 n.d. Lys48 TNFsignaling Inhibition of inflammation  [388] 
p100 n.d. Lys48 NF-B signaling Prevention of autoimmunity 
[389] 
SOCS1 n.d. Lys48 JAK2/STAT1 signaling 
Inhibition of CNS 
autoimmunity 
[367] 
AKT n.d. Lys63 AKT/IL-15R signaling 
Homeostasis of CD8+ T 
and NK cells 
[390] 
RIG-I UBCH5 Lys63 NF-B signaling 
IRF activation 
Enhanced response 
during IA virus infection 
[383] 
MDMX UBCH5 n.d. 






p53 UBCH5 Lys48 p53 signaling Increased DNA repair [397] 
pSMAD2/3 n.d. n.d. TGF- signaling Increased cellular migration 
[362] 
DEPTOR n.d. n.d. 
mTOR signaling Decreased cell 
proliferation, size and 
autophagy 
[398] 
RNF168 UBC13 Lys63 








Table 2. Target proteins regulated by OTUB1 non-canonical activity. The color code used 
in the table indicates the regulation of diverse processes or diseases: grey, cancer; blue-gray, 
immune response; blue, viral and bacterial infection; orange, other diseases; yellow, others. 
CNS: central nervous system. DSB: double strand brand. IA: influenza A. 
Apart from the canonical and non-canonical targets of OTUB1, there are other proteins for 
which the type of regulation by OTUB1 is unclear (Table 3). Although it was previously 
reported that OTUB1 cleaves, presumably, Lys48-linked polyubiquitin chains from RhoA 
reducing the proteasomal degradation of RhoA [384]. Also, OTUB1 stabilizes RhoA via p53 
expression increasing prostate cancer invasion [400]. Therefore, additional studies are 
required to identify OTUB1 regulation of RhoA. Furthermore, OTUB1 suppresses TRIM25 
ubiquitination increasing binding of ZAP (Zinc finger antiviral protein) to target mRNA, 
important process for antiviral activity [401]. Also, the interaction between PTEN (phosphatase 
and tensin homolog), RPA1 (replication protein A) and OTUB1 enables OTUB1 to 
deubiquitinate and stabilize RPA1, a protein that protects stalled replication forks and genomic 
stability [402]. In glomerulonephritis and pulmonary fibrosis, OTUB1 enhanced the 











repression of p53 
expression 




n.d. Inhibition of dendritic cell 
immune function 
Enhanced of phagocytic 
capacity of dendritic cells 
[404] 
TRAF6 n.d. Type I IFNs Inhibit virus-triggered type I IFN induction 
[405] 
TRAF3 n.d. Type I IFNs Inhibit virus-triggered type I IFN induction 
[405, 
406] 
TRAF3 Lys63 Type I IFNs Balance antiviral innate immunity 
[407] 
ZAP Lys63 n.d. Increased antiviral activity [408] 
Decorin n.d. Proteasomal degr. Promotes glomerulonephritides 
[401] 
FOXM1 n.d. 
Avoid proteasomal degr. 
Increased TBF by 
SMAD3/4 
Promotes pulmonary fibrosis [403] 
RPA1 n.d. n.d. Protects stalled replication forks and genomic stability 
[402] 
Table 3. Putative targets regulated by unkown OTUB1 activity. The color code used in 




immune response; blue, viral and bacterial infection; orange, other diseases; yellow, others. 
degr.: degradation. 
Post-translational modifications of ubiquitin or OTUB1 can affect the deubiquitinating activity 
of OTUB1. A post-translational modification that regulates OTUB1 is phosphorylation. 
Phosphorylation at Ser16 by casein kinase 2 increases OTUB1 nuclear localization [409]. As 
a result, OTUB1 is unable to inhibit chromatin ubiquitination in response to DNA damage in 
U2OS cells [409]. Also, phosphorylation of Ser65 activates OTUB1 Lys48 catalytic activity 
[410]. On the other hand, phosphorylation of Ser20 and Ser57 deactivates OTUB1 Lys48 
cleavage [410]. Our group previously showed that hydroxylation of OTUB1 Asn22 by FIH 
altered OTUB1 substrate targeting, particularly for proteins linked to the regulation of cellular 
energy metabolism [290]. OTUB1 can also be ubiquitinated by the E3 ligase E4B, leading to 
OTUB1 proteasomal degradation [411]. 
The mTOR pathway has also been shown to regulate OTUB1 in breast cancer cells and T 
cells [412-414].  ERK1/2 increases OTUB1 protein levels in breast cancer cells [414]. In 
lymphocytes, OTUB1 regulates the expression of gene related to anergy (GRAIL). Following 
the activation of CD4 T cells, Otub1 protein levels are increased, leading to the degradation 
of GRAIL enhancing cell proliferation [413]. Acute infection of CD4 T cells inhibits the mTOR 
pathway, which in turn decreases the expression of Otub1 maintaining GRAIL protein levels 
[415]. In T cells, upregulation of OTUB1 might be involved in delayed activation and 
proliferation of CD4+ and CD8+ cells compared to CD3+ T cells [416]. Furthermore, in T cells, 
inhibition of AKT and mTOR lead to a decreased OTUB1 expression [412, 413].  However, 
the underlying molecular mechanisms are unknown. OTUB1 protein levels are also affected 
by other pathways apart from the mTOR. As activated protein C increases OTUB1 expression 
under ischemia reperfusion injury [366]. 
1.8.2. Pathological role of OTUB1 
The physiological function of OTUB1 in vivo remains to be discovered. So far, it has been 
shown that following homozygous OTUB1 deletion mice die perinatally [365, 366]. During the 
recent years, the emphasis of OTUB1 studies in vivo was directed towards immunology and 
infection. In vivo (Table 4), OTUB1 deletion in T cells increased the activity of CD8+ T and NK 
cells enhancing anticancer immunity [390]. In B cells, OTUB1 deletion led to hyperplasia, 
activation of the NF-B pathway and lupus-like autoimmunity with high IL-6 production [389]. 
NF-B pathway activation together with increased MAPK signaling were also observed in mice 




to T.gondii infection and resistance to lipopolysaccharide sepsis treatment [280, 368]. In 
zebrafish, knock-down of OTUB1 led to capillary luminal narrowing and capillary detachment 
from the axial vessel, indicating vascular regression [382]. 
OTUB1 has also been linked to sclerosis and renal injury [366, 367]. In humans with multiple 
sclerosis and mouse with experimental autoimmune encephalomyelitis (EAE), OTUB1 levels 
were increased in astrocytes. Mice with OTUB deletion in astrocytes increased leukocyte 
accumulation, demyelination in the spinal cord and proinflammatory gene transcription 
developing more severe EAE [367]. These pathological symptoms are due to the inhibition of 
the JAK/STAT signaling pathway [367]. Further studies in brain research showed that OTUB1 
increases oligomeric Tau forms through its catalytic activity in vivo, which are linked to 
neurodegenerative disorders such as Alzheimer’s disease [377]. After intracerebral 
hemorrhage in rats, OTUB1 is upregulated in the neighboring neurons. This increase in 
OTUB1 coincided with an increase of apoptotic markers and in vitro studies with OTUB1 
downregulation of OTUB1 suggested an OTUB1 anti-apoptotic neuronal cell function [417]. 
In a genome-wide association study, Otub1 was associated with increased uric acid levels in 
patients with chronic kidney disease [418]. A Bayesian analysis of available transcriptomic 
and proteomic studies in renal collecting duct cells indicated that OTUB1 is the DUB with the 
highest impact on renal transport processes [419]. Under glomerulonephritis, OTUB1 was 
highly expressed in mesangial cells and decreased the renal disorder antagonizer decorin 
[401]. In vivo, OTUB1 levels were decreased following the inhibition of tubulointerstitial fibrosis 
in mice by the drug Mycophenolate Mofetil that  is commonly used as immunosuppressive for 
allograft rejection after transplant [420]. Otub1 heterozygous KO mice showed aggravated 
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Demyelination in the 
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Severe EAE [367] 
Heterozygous Whole-
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n.d. n.d. Aggravated IRI [366] 
Constitutive Whole-
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Table 4. Studies under OTUB1 deletion in vivo. The color code used in the table indicates 
diverse function: blue-gray, immune response; orange, disease; yellow, others. degr.: 
degradation. Ab: antibody 
Another important pathological role of OTUB1 was identified in cancer. OTUB1 interacts with 
Snail, localizing together in the nucleus and stabilizing Snail in esophageal squamous cell 
carcinoma [381]. As a result, epithelial mesenchymal transition increases and worsens cancer 
prognosis in vitro and in vivo in human glioma cells [381, 421]. In gastric adenocarcinoma, 
OTUB1 is highly expressed, which was linked to high tumor invasion and cell migration [422]. 
Upregulation of the non-coding OTUB1 isoform 2 was found in gastric cancer with poor 
prognosis with decreased survival rate and increased cell proliferation and invasion [423]. In 
ovarian cancer, OTUB1 interacts with FOXM1 provoking tumor progression, and OTUB1 
expression correlates also with poor prognosis [377]. In prostate cancer, OTUB1 induces 
tumorigenesis in vivo and cell invasion via RhoA activation in vitro [424]. In hepatocellular 
carcinoma patients, increased OTUB1 expression was suggested as an independent 
prognosis parameter. Following the downregulation of OTUB1 in hepatocarcinoma cancer 
cells, invasion, migration and proliferation was suppressed [425]. In colorectal cancer cells, 




inhibited by miR-542-3p treatment targeting OTUB1 [426]. Overall, OTUB1 has been related 
to bad cancer prognosis in many organs like the lung, ovaries, breast and stomach. 
Overall, OTUB1 is a DUB that is ubiquitously expressed in mice and humans. While most of 
OTUB1 studies were performed in vitro, the pathological role of the DUB in vivo has gained 
interest over the last years. Scrutinous characterization of the physiological role of OTUB1 in 
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2. Aims of the thesis 
The deubiquitinase OTUB1 plays an important role in the regulation of several processes 
in vitro and in vivo and has been linked to the development and/or progression of diverse 
pathologies. However, the physiological function of OTUB1 is unknown. Interestingly, we 
previously discovered that FIH hydroxylates OTUB1 on Asn22, regulating cellular energy 
metabolism. FIH deletion in mice leads to a metabolic phenotype, but the underlying 
molecular mechanisms are unclear. Understanding the molecular interaction of FIH and 
OTUB1 in detail as well as its relevance for physiology would enhance our knowledge 
about oxygen-dependent and ubiquitin-dependent regulations. In addition, both FIH and 
OTUB1 are considered as potential therapeutic targets in several different diseases. The 
characterization of the molecular and physiological interplay of FIH and OTUB1 may help 
identifying novel therapeutic options. 
The goal of this thesis was to analyze the molecular mechanism of the interaction between 
FIH and OTUB1 further as well as its potential physiologic relevance. To achieve this, the 
specific aims were: 
1) Analysis of the FIH-dependent regulation of OTUB1 in detail. 
2) Characterization of the physiological function of OTUB1 in mice. 
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3. Oxygen-dependent bond formation with FIH regulates the activity 




 FIH forms a (likely amide) bond with client proteins 
 Bond formation is highly hypoxia sensitive and occurs co-translationally 
 FIH forms a heterotrimer with the client protein OTUB1 (FIH2OTUB11) 
 Complex formation between OTUB1 and FIH regulates OTUB1 deubiquitinase 
activity 
 Bond formation by hydroxylases is an alternative mechanism for hypoxia adaptation 
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Protein:protein interactions are the basis of molecular communication and are usually of 
transient non-covalent nature, while covalent interactions other than ubiquitination are rare. 
For cellular adaptations, the cellular oxygen and peroxide sensor factor inhibiting HIF (FIH) 
confers oxygen and oxidant stress sensitivity to the hypoxia inducible factor (HIF) by 
asparagine hydroxylation. We investigated whether FIH contributes to hypoxia adaptation also 
through other mechanisms and identified a highly hypoxia sensitive, likely covalent, bond 
formation by FIH with several client proteins, including the deubiquitinase ovarian tumor 
domain containing ubiquitin aldehyde binding protein 1 (OTUB1). Biochemical analyses were 
consistent with a co-translational amide bond formation between FIH and OTUB1, occurring 
within mammalian and bacterial cells but not between separately purified proteins. Bond 
formation is catalysed by FIH and highly dependent on oxygen availability in the cellular 
microenvironment. Within cells, a heterotrimeric complex is formed, consisting of two FIH and 
one covalently linked OTUB1. Complexation of OTUB1 by FIH regulates OTUB1 
deubiquitinase activity. Our findings reveal an alternative mechanism for hypoxia adaptation 
with remarkably high oxygen sensitivity, mediated through covalent protein-protein 
interactions catalysed by an asparagine modifying dioxygenase. 
 
 
KEYWORDS: hydroxylase; HIF; hypoxia; oxygen sensor; deubiquitinase; ubiquitin system 
  




Cellular oxygen sensing is of vital importance for cells and tissues in order to adapt to hypoxic 
conditions when cellular oxygen demand exceeds its supply [1]. The best characterized 
cellular oxygen sensors are the prolyl-4-hydroxylase domain (PHD) proteins 1-3 and factor 
inhibiting HIF (FIH) [2]. PHDs hydroxylate two different prolines and FIH hydroxylates one 
asparagine residue of HIFα subunits [2]. Besides molecular oxygen, these enzymes requires 
Fe2+ and ascorbate or other reducing agents as co-factors and 2-oxoglutarate as co-substrate 
in order to reduce molecular oxygen and oxidize the substrate protein (hydroxylation) and 2-
oxoglutarate (conversion to succinate) [3, 4]. Proline-4-hydroxylation of HIFα leads to its 
proteasomal degradation whereas asparagine hydroxylation inhibits its interaction with the 
transcriptional co-activators p300 and CBP, attenuating HIF-dependent gene transactivation 
[2]. While in higher organisms the only known reaction of 2-oxoglutarate-dependent 
dioxygenases is hydroxylation [5], in lower organisms they also catalyse ring expansion, 
rearrangement, desaturation, halogenation and epoxidation [6]. 
Beside oxygen, FIH also senses peroxide [7]. Interestingly, FIH is more sensitive to 
H2O2 than the PHDs [7]. Peroxide reduces FIH enzymatic activity, leading to decreased HIF-
1 asparagine hydroxylation and higher transcriptional activity [7]. This indicates that FIH 
functionally integrates oxidant stress and hypoxia in cellular signalling. 
In vivo, FIH is essential for the regulation of energy metabolism [8, 9]. Amongst others, 
FIH deletion leads to an increased metabolic rate, increased glucose and lipid homeostasis 
and increased oxidative metabolism [8, 9]. The FIH-dependent regulation of energy 
metabolism is at least partly independent of HIF [8]. Therefore, a key question remaining is 
whether FIH regulates additional substrates outside of the HIF pathway that contribute to the 
observed phenotype. FIH has previously been shown to target proteins for hydroxylation other 
than HIFα, including ankyrin repeat domain (ARD)-containing proteins [10-15]. However, 
whether FIH-dependent hydroxylation of these proteins is functionally relevant for the 
regulation of energy metabolism is unclear [11, 16]. We recently demonstrated that FIH 
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interacts with the deubiquitinase (DUB) ovarian tumor domain containing ubiquitin aldehyde 
binding protein 1 (OTUB1) and hydroxylates it on asparagine 22 (N22), regulating cellular 
energy metabolism [17, 18]. 
OTUB1 is a ubiquitously expressed DUB with one of the highest expression levels of 
all DUBs [19, 20]. OTUB1 cleaves K48-ubiquitin chains through its canonical enzymatic 
activity, preventing proteasomal degradation of substrate proteins [21, 22]. In addition, OTUB1 
inhibits E2 ubiquitin-conjugating enzymes independent of its enzymatic activity, impeding 
ubiquitin chain formation [23-25]. OTUB1 enzymatic activity is regulated by complexation with 
E2 enzymes and free ubiquitin [26, 27]. A major characteristic of DUBs is their frequent 
occurrence in protein complexes, which controls DUB activity [28]. However, whether other 
proteins in addition to E2 enzymes and free ubiquitin affect OTUB1 activity by protein 
complexation is unknown. 
In this study, we further investigated the molecular interplay between FIH and OTUB1. 
We show evidence for an unexpected formation of a previously unknown strong, likely 
covalent, interaction between FIH and OTUB1. We demonstrate that this formation has 
functional consequences for OTUB1 deubiquitinase activity and is highly oxygen sensitive but 
relatively slow, indicating a role in chronic hypoxia adaptation. Interestingly, this type of FIH-
dependent bond formation is likely not restricted to the substrate OTUB1.  
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MATERIALS AND METHODS 
Cell culture and transient transfection 
Human HEK293 (embryonic kidney), MCF7 (breast adenocarcinoma) and Hep3B 
(hepatocellular carcinoma) cell lines were cultured in DMEM containing 4.5 g/l glucose, 
sodium pyruvate and L-glutamine (Sigma-Aldrich, St Louis, MO, USA), supplemented with 
10% heat-inactivated fetal bovine serum (Gibco by Life Technologies, Carlsbad, Ca, USA) 
and 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma-Aldrich). Transient transfection of 
siRNAs and plasmids was performed using lipofectamine 2000 reagent according to the 
manufacturer's instructions (Invitrogen, Carlsbad, CA, USA) or polyethylenimine (PEI; 
Polysciences Inc., Warrington, PA) as described previously [29]. 
 
Cell treatments 
Cycloheximide (CHX; Sigma-Aldrich) was dissolved in ethanol, desferrioxamine (DFX; Sigma-
Aldrich), (+)-sodium L-ascorbate (Sigma-Aldrich), 2-oxoglutarate (Sigma-Aldrich), diethyl 2-
oxoglutarate (DE-2OG; Sigma-Aldrich) and iron (II) sulfate (Sigma-Aldrich) in H2O, and 
dimethyloxalylglycine (DMOG; Frontier Scientific, Logan, UT, USA) and FG-4592 
(Roxadustat; Selleckchem, Houston, TX, USA) in dimethylsulfoxide (DMSO, Sigma-Aldrich). 
Hypoxic incubations were performed using the InvivO2 400 humidified cell culture workstation 
(Baker Ruskinn, Bridgend, South Wales, UK) operated at 0.2% O2 and 5% CO2 as described 
previously [29] or in humidified oxygen-regulated cell culture incubators (Binder GmbH, 
Tuttlingen, Germany) operated at 1% - 8% O2 and 5% CO2. If not otherwise indicated, 
"normoxia" refers to the standard oxygen concentration in the gas phase within a cell culture 
incubator at 500 m altitude (18.5% O2) and "hypoxia" to 0.2% O2 [30].  
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Plasmids and siRNAs 
The plasmid encoding human wildtype FIH-V5 was kindly provided by Dr. Eric Metzen 
(University of Duisburg-Essen, Essen, Germany). The plasmids encoding FIH H199A-V5 and 
MBP-FIH have previously been described [31]. The plasmid coding for human wildtype FLAG-
OTUB1 (containing two consecutive FLAG tags) [32] was a kind gift of Dr. Mu-Shui Dai 
(Oregon Health & Science University, Portland, OR, USA). The transfer vector pET3a and the 
polycistronic expression vector pST39 [33] were kind gifts from Prof. Song Tan (Pennsylvania 
State University, PA, USA). 
Nontargeting siRNA (siNT: 5'-gcuccggagaacuaccagaguauua-3') as well as siRNA targeting 
human FIH (siFIH: sequence F1, 5'-guugcgcaguuauagcuuctt-3') and the 3’UTR of human 
OTUB1 (siOTUB1: siRNA-4, 5'-gugguuguaaaugguccuatt-3') were purchased from Microsynth 
(Balgrach, Switzerland) according to previously reported sequences [10, 34]. 
 
Generation of OTUB1 mutants by site-directed mutagenesis 
The human FLAG-OTUB1 N22A mutant was previously described [18]. The human FLAG-
OTUB1 S16A, S18A, S16A/S18A, C23A, C23S, C91A, C91S point mutants were generated 
using the Quikchange II XL Site-Directed Mutagenesis kit (Agilent Technologies, Santa Clara, 
CA, USA) according to the manufacturer’s instructions and using the plasmid encoding 




Cells were lysed in 150 mM NaCl, 25 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1% NP-40, freshly 
supplemented with protease inhibitor cocktail (Sigma-Aldrich), 1 mM PMSF and 1 mM Na3VO4 
and 100 mM iodoacetamide where indicated. Protein concentrations of lysates were 
determined using the BCA assay (Thermo Fisher Scientific, Waltham, MA, USA). Equal 
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amounts of proteins were mixed with 5x loading dye (250 mM Tris-HCl pH 6.8, 30% glycerol, 
858 mM -mercaptoethanol, 10% SDS, 0.05% bromophenolblue), separated by SDS-PAGE, 
electro-transferred to nitrocellulose membranes and detected using anti-FIH antibody (Novus 
Biologicals, Littleton CO, USA; NBP1-30333), anti-V5 antibody (Invitrogen; R960-025), anti-
OTUB1 antibody (Cell Signaling Technology, Danvers, MA, USA; 3783), anti-FLAG antibody 
(Sigma-Aldrich; F3165), anti-ubiquitin antibody (clone P4D1; Cell Signaling Technology; 
3936), anti-HIF-1 antibody (BD Biosciences, San Jose, CA, USA; 610959), anti-HIF-2 
antibody (Bethyl Laboratories, Montgomery, TX, USA; A700-003), anti-GFP antibody (Roche 
Diagnostics, Rotkreuz, Switzerland; 11814460001), anti--actin antibody (Sigma-Aldrich; 
A5441), anti--tubulin antibody (Cell Signaling; 2144), anti-SMC1 antibody (Abcam, 
Cambridge, UK; 9262) and horseradish peroxidase-coupled secondary antibodies (Thermo 
Fisher Scientific; 31430, 31460). Bound antibodies were detected with SuperSignal enhanced 
chemiluminescence substrate (Thermo Fisher Scientific) and chemiluminescence was 
recorded using a CCD camera (LAS 4000 mini, Fujifilm, Tokyo, Japan). ImageQuant TL gel 
analysis software (GE Healthcare, Version 8.1) was used for quantification as previously 
described [35]. If not indicated otherwise, values were normalized to the respective loading 
control and the sum of the intensities of all samples of one signal of each experiment. 
 
Denaturing urea and blue native electrophoresis 
For urea electrophoresis, cells were harvested in 30 mM Tris-HCl (pH 8.5), 7 M urea, 2 M 
thiourea, 0.4% CHAPS, supplemented with protease inhibitor cocktail (Sigma-Aldrich) as 
described [36]. The protein concentration was determined by Bradford assay and equal protein 
amounts were separated by 8% urea gel electrophoresis according to the previous description 
[37, 38]. For blue native electrophoresis, cells were harvested in 20 mM Bis-Tris (pH 7.0), 500 
mM ε-aminocaproic acid, 10% glycerol, supplemented with 1 mM PMSF, 10 µg/ml aprotinin, 
10 µg/ml leupeptin and 1 mM Na3VO4, and lysed by dounce homogenisation. The protein 
concentration was determined by Bradford assay and equal protein amounts were separated 
 Publication I: Redox Biol. 2019 Sep; 26: 101265 
67 
 
by 15% blue native gel electrophoresis according to a previous description [39]. Following 
electrophoresis, proteins were transferred to nitrocellulose membranes and detected using 
antibodies as described above. 
 
Two-dimensional gel electrophoresis 
Cell lysates were prepared for native protein analysis and separated by blue native 
electrophoresis as described above. Single lanes were cut and separated in the second 
dimension by SDS-PAGE in 100 mM Tris-HCl (pH 6.8), 12% glycerol, 343 mM -
mercaptoethanol, 4% SDS, 0.02% bromophenolblue [40]. Following transfer to nitrocellulose 
membranes, proteins were detected using antibodies as described above. 
 
Bacterial expression and purification of His- and MBP-tagged recombinant proteins 
The plasmids encoding human pENTR4-OTUB1 WT/N22A were described previously [18] 
and utilized for generating pDEST17-OTUB1 WT/N22A (coding for His-OTUB1 WT/N22A) 
using the Gateway system according to the manufacturer’s description (Invitrogen). His-
OTUB1 WT/N22A was subcloned into the bacterial expression vector pET3a using pDEST17-
OTUB1 WT/N22A plasmids as templates. For cloning of MBP-tagged human FIH into pET3a, 
FIH WT/H199A was subcloned using pFIH WT/H199A-V5 as template, followed by subcloning 
of an N-terminal MBP tag using human pMBP-FIH as template. E.coli BL21(DE3)pLysS 
(Invitrogen) were transformed with the plasmids and expression of the respective proteins was 
induced by addition of 0.2 mM isopropyl-ß-D-thiogalactoside (IPTG) for up to 6 h at 30°C. For 
purification of His-tagged proteins, bacteria were resuspended in 20 mM Tris-HCl (pH 8.0), 
500 mM NaCl, 5 mM imidazole, and for purification of MBP-tagged proteins in 20 mM Tris-HCl 
(pH 8.0), 150 mM NaCl. Lysis buffers were supplemented with 1 mM PMSF and protease 
inhibitor cocktail (Sigma-Aldrich). Bacteria were lysed using a cell disruptor (TS Series Bench 
Top, Constant Systems Ltd., Northants, UK) in two cycles at 35 kPsi. Lysates were cleared by 
ultracentrifugation at 162,000 g, 4°C for 1 h and proteins were affinity purified with NiSO4-
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charged sepharose (HiTrap Chelating HP, GE Healthcare, Little Chalfot, UK) or dextrin 
sepharose (MBPTrap HP, GE Healthcare 28-918-780) columns using the Duo Flow system 
(Bio-Rad, Hercules, CA, USA). Protein concentrations were determined by Bradford assay. 
Dot blot, colloidal Coomassie staining [41] and OTUB1 and FIH immunoblotting were used to 
verify successful protein expression and purification.  
 
Bacterial expression and purification of the stable FIH-OTUB1 complex from a 
bicistronic expression vector 
Cloning of a bicistronic expression vector was performed as described [33]. Briefly, untagged 
human OTUB1 WT/N22A, FIH WT/H199A, His-OTUB1 WT/N22A and MBP-FIH WT/H199A 
were cloned into the transfer vector pET3a following PCR amplification. Untagged OTUB1 
WT/N22A or His-OTUB1 WT/N22A was subsequently subcloned into cassette 1 of pST39, 
followed by subcloning of untagged FIH WT/H199A or MBP-FIH WT/H199A into cassette 4. 
Bacteria lysates were prepared, the protein complex purified by sequential MBP- and Ni2+-
affinity purification and analyzed as described above.  
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Biochemical analyses of the purified stable FIH-OTUB1 complex 
Equal amounts of purified FIH-OTUB1 complex or albumin (fraction V, Carl Roth GmbH + Co. 
KG, Karlsruhe, Germany) were either exposed to 0.1 M NaOH, 10 mM NaOH, 10 mM HCl or 
1 M NH2OH at pH 7 or 10, or left untreated. Following incubation for 1 h at 37°C, samples 
were neutralized using corresponding amounts of NaOH or HCl and incubated for further 15 
min at 37°C and analyzed by SDS-PAGE as described above. 
 
Immunoprecipitation 
Immunoprecipitation was performed as previously described [17]. Briefly, for native conditions, 
cells were lysed with 150 mM NaCl, 20 mM Tris-HCl (pH 7.5), 1 mM MgCl2, 1% Triton X-100, 
supplemented with protease inhibitor cocktail (Sigma-Aldrich). For denaturing conditions, cells 
were scraped in PBS and centrifuged for 3 min at 200 g. The cell pellet was resuspended in 
the same lysis buffer but supplemented with 1% SDS and 0.75 U/µl benzonase (Sigma-
Aldrich), boiled for 10 min and the cellular solutes were cleared by centrifugation at 21,000 g 
and 4°C for 5 min. Cell lysates were incubated with anti-FLAG M2 antibody-coupled beads 
(Sigma-Aldrich) or anti-V5 agarose affinity gel (Sigma-Aldrich) at 4°C for 1 h. Agarose beads 
were washed twice with lysis buffer and twice with washing buffer (150 mM NaCl, 20 mM Tris-
HCl pH 7.5, 1 mM MgCl2). For analysis by MS, the beads were treated as described below. 
For analysis by immunoblotting, the beads were resuspended in non-reducing loading buffer 
(50 mM Tris-HCl pH 6.8, 6% glycerol, 2% SDS, 0.01% bromophenol blue) and boiled for 5 
min. 10 mM DTT was added to the supernatant and boiled for further 5 min. For endogenous 
FIH-specific immunoprecipitation, anti-FIH antibody or anti--actin control antibody was bound 
to protein G-sepharose (GE Healthcare) for 1 h at RT and incubated with non-denatured cell 
lysates over night at 4°C. Beads were washed and precipitated proteins were analyzed by 
immunoblotting. 
 
OTUB1 deubiquitinase (DUB) assay 
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Purified His-OTUB1 WT and MBP-His-heterodimer were quality controlled by SDS-PAGE and 
colloidal Coomassie staining. Enzymes at the indicated concentration were incubated with 600 
nM K48-tetraubiquitin (K48-Ub4; Boston Biochem, Cambrige, MS, USA) at 37°C in the 
presence or absence of 25 µM UBCH5B (Enzo Life Science, Inc., Farmingdale, NY, USA). 
K48-Ub4 alone was used as negative control. The reaction was stopped by addition of 5x 
loading dye and samples were incubated for 20 min at RT prior to immunoblot analysis. 
 
Mass spectrometry analysis of the FIH-OTUB1 HD 
For analysis of the stable FIH-OTUB1 complex, immunoprecipitated proteins from HEK293 
cells were separated by SDS-PAGE. Bands were cut from the Coomassie-stained gel, 
chopped into small pieces and washed twice with 100 mM NH4HCO3, 50% acetonitrile and 
once with acetonitrile. Digestion with 50 ng trypsin (sequencing grade; Promega, Madison, 
WI, USA) was performed in buffered conditions (10 mM Tris-HCl pH 8.2, 2 mM CaCl2) for 30 
min at 60°C in a microwave oven (Discover System, CEM Corporation, Matthews, NC, USA). 
The supernatant was collected and lyophilized in a SpeedVac (Thermo Fisher Scientific). For 
liquid chromatography-tandem MS (LC-MS/MS) analysis, the samples were dissolved in 20 µl 
0.1% formic acid and 3 µl were analyzed on a nanoAcquity ultra performance liquid 
chromatography (UPLC) column (Waters Corporation, Milford, MA, USA) connected to a Q 
Exactive mass spectrometer (Thermo Fisher Scientific) equipped with a Digital PicoView 
source (New Objective, Inc., Woburn, MA, USA). Peptides were trapped on a Symmetry C18 
trap column (5 µm, 180 µm x 20 mm, Waters Corporation) and separated on a BEH300 C18 
column (1.7 µm, 75 µm x 150 m, Waters Corporation) at a flow rate of 250 nl/min using a 
gradient from 1% solvent B (0.1% formic acid in acetonitrile)/99% solvent A (0.1% formic acid 
in water) to 40% solvent B/60% solvent A within 30 min. The mass spectrometer was set to 
data dependent analysis, precursor scan range 350 – 1,500 m/z, resolution 70,000, maximum 
injection time 100 ms, threshold 3e6. The fragment ion scan range was 200 – 2,000 m/z, 
resolution 35,000, maximum injection time 120 ms, threshold 1e5. Proteins were identified 
using the Mascot search engine (Matrix Science; Version 2.5.1.3.). Mascot was set up to 
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search the human SwissProt database assuming the digestion enzyme trypsin. Mascot was 
searched with a fragment ion mass tolerance of 0.030 Da and a parent ion tolerance of 10.0 
ppm. Oxidation of methionine was specified in Mascot as a variable modification. Scaffold 
(Proteome Software Inc., Version 4.8.6) was used to validate MS/MS based peptide and 
protein identifications. Peptide identifications were accepted if they achieved a false discovery 
rate (FDR) of less than 0.1% by the Scaffold Local FDR algorithm. Protein identifications were 
accepted if they achieved an FDR of less than 1.0% and contained at least 2 identified 
peptides. The number of peptides was determined by the number of spectra identifying 
specific peptide sequences for each protein. 
 
Mass spectrometry analysis of denatured and non-denatured FIH interactomes 
For analysis of the stable FIH interactome by label-free quantification (LFQ), human FIH-V5 
or tandem EGFP was expressed in HEK293 cells, and cells were lysed in native or denaturing 
conditions as described above. Following V5-specific IP, the beads were resuspended in 45 
µl digestion buffer (10 mM Tris-HCl pH 8.2, 2 mM CaCl2) and the proteins were on-bead 
digested using 5 µl of 100 ng/µl trypsin in 10 mM HCl (sequencing grade; Promega) in a 
microwave oven for 30 min at 5 W and 60°C. The supernatants were transferred into new 
tubes and the beads were additionally digested for 3 h at room temperature. The beads were 
washed with 100 µl TFA-buffer (0.1% TFA, 10 mM Tris, 2 mM CaCl2) and all supernatants 
were combined, lyophilized, resolubilized in 25 µl of 3% acetonitrile, 0.1% formic acid spiked 
with iRT peptides (Biognosys AG, Schlieren, CH), centrifuged at 20,000 g for 10 minutes and 
analyzed on a Q Exactive mass spectrometer coupled to a Nano Easy 1000 liquid 
chromatography system (Thermo Fisher Scientific). Solvent composition was 0.1% formic acid 
for channel A and 0.1% formic acid in acetonitrile for channel B. For each sample, 4 μl of 
peptides were loaded on a commercial Acclaim PepMap Trap Column (75 µm x 20 mm, 
Thermo Fisher Scientific) followed by a PepMap RSLC C18 Snail Column (75 μm × 500 mm; 
Thermo Fisher Scientific). The peptides were eluted at a flow rate of 300 nL/min by a gradient 
from 5 to 22% B in 79 min, 32% B in 11 min and 95% B in 10 min. Samples were acquired in 
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a randomized order. The mass spectrometer was operated in data-dependent mode (DDA), 
acquiring a full-scan MS spectra (300−1,700 m/z) at a resolution of 70,000 at 200 m/z after 
accumulation to a target value of 3,000,000, followed by higher-energy collision dissociation 
(HCD) fragmentation on the twelve most intense signals per cycle. HCD spectra were acquired 
at a resolution of 35,000 using a normalized collision energy of 25 and a maximum injection 
time of 120 ms. The automatic gain control (AGC) was set to 50,000 ions. Charge state 
screening was enabled and singly and unassigned charge states were rejected. Only 
precursors with intensity above 8,300 were selected for MS/MS (2% underfill ratio). Precursor 
masses previously selected for MS/MS measurement were excluded from further selection for 
30 s, and the exclusion window was set at 10 ppm. The samples were acquired using internal 
lock mass calibration on m/z 371.1010 and 445.1200. The acquired raw mass spectrometry 
MS data were processed by MaxQuant (Version 1.6.1) [42], followed by protein identification 
using the integrated Andromeda search engine [43]. Spectra were searched against a UniProt 
Homo Sapiens (taxonomy 9606) reference proteome (canonical version from 2016-12-09), 
concatenated to its reversed decoyed fasta database and common protein contaminants. 
Carbamidomethylation of cysteine was set as fixed, while methionine oxidation and N-terminal 
protein acetylation were set as variable modifications. MaxQuant Orbitrap default search 
settings were used. Enzyme specificity was set to trypsin/P. For Label-Free-Quantification, 
MaxQuant default settings were applied. In the MaxQuant experimental design template, the 
biological and biochemical replicates were grouped into non-adjacent fractions, to allow 
match-between-runs within but not between conditions. Each file was treated as a separate 
experiment to obtain individual quantitative values. Protein fold changes were computed 
based on intensity values reported in the proteinGroups.txt file. A set of functions implemented 
in the R package SRMService (http://github.com/protViz/SRMService [44]) was used to filter 
for proteins with 2 or more peptides, with quantification in at least 4 samples, and to normalize 
the data with a modified robust z-score transformation and to compute p-values using the t-
test with pooled variance. The MS proteomics data were handled using the local laboratory 
information management system (LIMS) [45]. FIH-specific interactors had an average LFQ 
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intensity of the four biological replicates of at least 2-fold over control (EGFP) and were 
statistically significantly different (p<0.05). The obtained lists of FIH-specific interactors were 
analyzed for overlaps using Excel (Microsoft). Functional annotation was performed via the 
PANTHER database (www.pantherdb.org). For comparison of relative intensities, individual 




The designed Primers for the site-directed mutagenesis of human OTUB1 were as follows 
(fwd, forward primer; rev, reverse primer): 
S16A - fwd: 5'-accttcggagtcggcgcccagcggctcc-3', rev: 5'-ggagccgctgggcgccgactccgaaggt-3'. 
S18A - fwd: 5'-gttaacaccttcggcgtcgctgcccagcg-3', rev: 5'-cgctgggcagcgacgccgaaggtgttaac-3'. 
S16/18A - fwd: 5'-ttaacaccttcggcgtcggcgcccagcggctcc-3', rev: 5'-
ggagccgctgggcgccgacgccgaaggtgttaa-3'. 
C23A - fwd: 5'-ttcatcataggccagagcgttaacaccttcggagtcgc-3', rev: 5'-
gcgactccgaaggtgttaacgctctggcctatgatgaa-3'. 
C23S fwd: 5'-cataggccagagagttaacaccttcggagtcg-3', rev: 5'-
cgactccgaaggtgttaactctctggcctatg-3'. 
C91A – fwd: 5'-gaaagcccgatagaaagcgttgccgtcaggcctg-3', rev: 5'-
caggcctgacggcaacgctttctatcgggctttc-3'. 
C91S – fwd: 5'-aaagcccgatagaaagagttgccgtcaggcc-3', rev: 5'-
ggcctgacggcaactctttctatcgggcttt-3'. 
 
Primers designed for the cloning of OTUB1 WT and N22A into pET3a - 
fwd: 5'-actgcatatggcggcggaggaacctcagga-3', rev: 5'-acgtggatccctatttgtagaggatatcgt-3'. 
 
Primers designed for the cloning of FIH WT and H199A into pET3a - 
fwd: 5'-acgtcatatggcggcgacagcggcgga-3', rev: 5'-acgtggatccctagttgtatcggcccttgatca-3'. 




Primers designed for the cloning of His-OTUB1 WT and N22A into pET3a - 
fwd 5'-acgtcatatgtcgtactaccatcaccatca-3', rev 5'-acgtagatctctatttgtagaggatatcgt-3'. 
 
Primers designed for the cloning of MBP into pET3a-FIH: 
fwd 5'-acgtcatatgaaaatcgaagaaggtaaact-3', rev 5'-actgcatatgggcgccctgaaaatacagg-3'. 
 
Statistical analysis 
For the analysis of the significance of difference between two data points, Student’s t-test was 
applied. For comparison of more than two data points, one-way or two-way ANOVA followed 
by Tukey post-test was applied. P values < 0.05 were considered statistically significant. 
  




The MS proteomics data have been deposited to the ProteomeXchange Consortium via the 
PRIDE [46] partner repository with the dataset identifier PXD011252.




FIH and OTUB1 form a covalently linked protein complex. 
Following our previous observations of FIH-dependent hydroxylation of OTUB1 on N22 [17, 
18], we here investigated the interplay between FIH and OTUB1 in more detail by 
immunoprecipitation (IP) of endogenous FIH. Intriguingly, we detected an unexpected signal 
in immunoblots with antibodies derived against FIH as well as OTUB1 (Fig 1A; marked with 
“X”). Protein X demonstrated a larger molecular weight than FIH or OTUB1 alone and its signal 
intensity was decreased following OTUB1 knockdown and abolished by iron chelation with 
desferrioxamine (DFX) (Fig 1A). Protein X was also detectable using antibodies against 
ectopically (plasmid-dependently) expressed tagged FIH and OTUB1 (Figs 1B and S1A). 
Protein X was subsequently investigated using ectopically expressed tagged OTUB1 and FIH 
to allow detailed analyses with complete control over the experimental conditions. Protein X 
signal intensity was proportional to OTUB1 protein levels, while mutation of the OTUB1 
hydroxylation site (N22A) abrogated it (Fig 1B). Mass spectrometry (MS) identified equimolar 
amounts of FIH and OTUB1 peptides in protein X (Fig S1B). Taken together, these results are 
consistent with a heterodimer (HD) consisting of FIH and OTUB1. Furthermore, the FIH-
OTUB1 HD was also detected in MCF7 (breast cancer) and Hep3B cells (liver cancer) (Figs 
S1C and S1D), indicating that HD formation is cell type independent. 
HD formation was resistant to denaturing SDS-PAGE, consistent with a possible 
covalent FIH-OTUB1 conjugation. This was further analyzed following the strategy of the 
original characterization of the covalent bond between ubiquitin (Ub) and substrate proteins 
[47]. The complex was resistant to chaotropic urea-PAGE (Fig 1C). The HD was also not 
disrupted by high concentrations of the reducing agents -mercaptoethanol (ME) (Figs 1A 
(lysates), 1D, 1E (lysates) and S1E), iodoacetamide (Fig 1B) and DTT (Figs 1A (IPs) and 1E 
(IPs)), excluding disulfide bonds as possible connection. For the further assessment of the 
nature of this conjugation, the HD was purified from bacteria. The purified complex was 
exposed to high (0.01 and 0.1 M NaOH) and low pH (10 mM HCl) as well as to 1 M 
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hydroxylamine (pH 7 and 10). NaOH treatment disrupts ester bonds and hydroxylamine 
disrupts thioester bonds at pH 7 and oxyester bonds at pH 10 [48, 49]. Amide bonds are 
resistant to these conditions [48, 49]. Low pH disrupts non-covalent bonds and esters. A 
specific disruption of the bond between FIH and OTUB1 in the HD should yield a decrease of 
HD levels with simultaneous increase in monomeric FIH and OTUB1. However, no increase 
in monomeric FIH or OTUB1 levels occurred when the HD decreased (Fig 1D). In addition, 
when the heterodimer was reduced, the BSA control was decreased to a comparable level as 
well (Figs 1D and S1F). This indicates that the observed decreases in the HD were due to 
general effects on protein stability and not due to specific disruption of the FIH-OTUB1 
conjugation. Hence, FIH and OTUB1 are covalently attached within the HD and this covalent 
linkage fulfils all biochemical criteria of an amide bond. 
OTUB1 N22A mutation abrogated HD formation (Fig 1B) as well as the non-covalent 
interaction between FIH and OTUB1 (Figs 1E, S2A and S2B). For a further investigation of 
the relevance of OTUB1 N22 for HD formation, additional mutations of OTUB1 were 
introduced within its FIH interaction region (S16, S18, C23) or catalytic domain (C91; leading 
to a catalytically inactive OTUB1 mutant [21]). Analysis via IP showed that C91 was 
dispensable, demonstrating that HD formation occurs independent of OTUB1 catalytic activity. 
The input as well as the FLAG-specific IPs showed that beside N22 also C23 mutation 
abrogated both the HD and the non-covalent FIH:OTUB1 interaction, while mutations of S16 
and/or S18 decreased the HD and the FIH:OTUB1 interaction by roughly 50% (Figs 1E, S2C 
and S2D). Overall, these results demonstrate that mutations of the OTUB1 hydroxylation site 
and of its FIH interaction site affect FIH-OTUB1 HD levels and that both are necessary for 
optimal interaction and HD formation. In addition, they indicate that the OTUB1 amino acid 
directly involved in the conjugation with FIH is either N22 or C23. 




Fig 1: Characterization of the FIH-OTUB1 conjugation. (A) Immunoblot analysis of 
endogenous FIH IP detected the unexpected protein signal (“X”), which was insensitive to 858 
mM -mercaptoethanol (ME) and 10 mM DTT. The same antibody was used for the FIH IP 
and subsequent FIH immunoblotting and the anti--actin antibody was derived from the same 
species as the anti-FIH antibody, leading to the detection of fragments of the IP antibodies 
(ab; highlighted by open arrows). Black arrows highlight specific signals of the indicated 
proteins. (B) The intensity of X detected by immunoblotting of cell lysates was proportional to 
FIH and wildtype OTUB1 (WT) levels, as seen with ectopic FLAG-OTUB1 expression, 
knockdown and ectopic mutant OTUB1 (N22A) expression. Protein signal X was insensitive 
to 100 mM iodoacetamide, the only agent present that disrupts disulfide bonds. (C) 
Investigation of the resistance of the FIH-OTUB1 HD interaction to a chaotropic agent by urea-
PAGE followed by immunoblotting. (D) Investigation of the effect of treatments disrupting 
thioesters and oxyesters using purified HD. The samples were analysed by Coomassie-
stained SDS-PAGE, which included boiling in the presence of 858 mM ME during sample 
preparation. (E) Residues of the FIH interaction site of OTUB1 were mutated and their 
relevance for HD formation investigated by ectopic expression of the mutated proteins and 
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anti-FLAG-IP. All samples were boiled in the presence of 858 mM ME or 10 mM DTT as 
indicated followed by immunoblot. exp, exposure; HD, heterodimer; M, monomer; ect, ectopic 
(plasmid-dependent) expression; end, endogenous protein. The data represent (A) two, (C, 
D, E (IPs)) three, (B) four or (E (lysates)) six independent experiments. 
 
FIH-dependent FIH-OTUB1 heterodimer formation is a hypoxia-regulated mechanism. 
While OTUB1 enzymatic activity was dispensable for HD formation, the OTUB1 hydroxylation 
site as well as the FIH interaction site were necessary. Therefore, we hypothesized that FIH 
catalyzes the formation of the putative covalent bond. In agreement with this hypothesis, 
hypoxia (0.2% O2), a 2-oxoglutarate (2-OG) competitor (dimethyloxalylglycine, DMOG) and 
the iron chelator DFX prevented HD formation (Fig 2A). The PHD-specific inhibitor FG-4592 
(roxadustat) [50] did not affect HD levels (Fig 2A). Accordingly, knockdown of endogenous 
FIH with parallel expression of a catalytically inactive FIH mutant (H199A) [31] completely 
abolished formation of the HD (Fig 2B). Overall, these results demonstrated that FIH 
enzymatic activity is required for covalent bond formation. A possibly limiting availability of FIH 
co-factors in cell culture affecting the FIH catalytic cycle could be excluded (Fig S2E). 
In order to investigate the sensitivity of HD formation to oxygen availability, 8 different 
oxygen levels were used in the range of 18.5% to 0.2% O2. HIF-1α and HIF-2α stabilization 
were determined as biological readout for the obtained level of hypoxia and for the comparison 
with the PHD sensitivity. We observed an unusually high hypoxia sensitivity with an EC50 of 
4.1% O2, which was even higher than the hypoxia sensitivity of the PHD-dependent HIF-1 
and HIF-2 stabilization with EC50 values of 2.15% and 3.5% O2, respectively (Figs 2C and 
2D). Of note, this is in stark contrast to the known hypoxia sensitivity for FIH-dependent HIF-
1 hydroxylation, which is below 1% O2 [51, 52]. 
Taken together, our results demonstrate that FIH catalyses HD formation with OTUB1, 
which is remarkably sensitive to changes in oxygen availability within the physiologically 
relevant range, suggesting a function in oxygen-dependent signalling. 




Fig 2: Hypoxia sensitivity of the FIH-dependent FIH-OTUB1 heterodimer formation. (A) 
Heterodimer (HD) formation was sensitive to hypoxia (Hx, 0.2% O2), DMOG and DFX, but not 
to the PHD-specific inhibitor FG-4592. (B) Immunoblotting of cell lysates with the indicated 
ectopic expressions. The H199A FIH mutant is catalytically inactive and was incapable of 
forming the HD. (C) Hypoxia sensitivity of HD formation in comparison with HIF-1 and HIF-
2 stabilization following 24 h of incubation at the indicated O2 levels. (D) Quantification of the 
experiment described in (C) and calculation of the oxygen sensitivity of HD formation and HIF-
1 and HIF-2 stabilization based on this quantification. Nx, normoxia; M, monomer. Data are 
shown as mean ± SEM from four independent experiments or are representative for (A, B) 
three or (C) four independent experiments. 
 
The FIH-OTUB1 heterodimer forms co-translationally and is extraordinarily stable. 
As next step, the stability of the HD was analyzed in cellulo. First, transiently transfected cells 
were allowed to form the HD for 24 h with subsequent inhibition of further HD formation by 
exposing these cells to 0.2% O2. The HD showed a pronounced stability with first significant 
decreases in HD levels after 24 h only (Figs 3A and S3A). 
For the investigation of the HD formation time, HEK293 cells were transfected with FIH 
and OTUB1 expressing plasmids for 5 h and subsequently incubated for 16 h in 0.2% O2 in 
order to inhibit FIH activity to express both FIH and OTUB1 without HD formation (Fig S3B). 
Media was replaced with normoxic media for instantaneous re-oxygenation and the time of 
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HD formation was analysed (Fig S3B). HD formation was unexpectedly slow with a half-
maximal level after 2.5 h, reaching a level comparable with normoxia after 8.7 h (Figs 3B and 
S3C; values calculated from Fig S3C). Re-oxygenation following hypoxia leads to active FIH 
within approximately 1 min [52], which can therefore not explain the slow HD formation. Hence, 
we assumed that a mechanism independent of FIH enzymatic activity was involved and 
investigated if HD formation occurred co-translationally using cycloheximide (CHX; Fig S3B). 
Simultaneous addition of CHX with the start of the re-oxygenation had no effect on the 
formation of the HD (Fig. 3C; Re-ox ctrl vs. Re-ox CHX). However, the simultaneous start of 
two different treatments such as CHX and re-oxygenation can make it difficult to interpret the 
result due to different kinetics involved. Therefore, we also included samples in which we pre-
treated the cells for 1 h with CHX prior to the start of re-oxygenation to allow for an efficient 
inhibition of translation at the time of re-oxygenation. In these samples, HD formation was 
markedly reduced after 6 h of re-oxygenation (Fig 3C; Re-ox ctrl vs. Re-ox CHX pre), indicating 
that translation might be important for HD formation. Interestingly, purified FIH and OTUB1 did 
not form the HD under cell-free conditions (data not shown). However, a bicistronic expression 
vector [33] for FIH and OTUB1 (Fig S3D), expressing both proteins in the same bacterium, 
resulted in HD formation which was dependent on the presence of the OTUB1 N22 
hydroxylation site and on active FIH (H199A abrogated HD formation) (Fig 3D). Co-inoculation 
of bacterial cultures that expressed either FIH or OTUB1 did not lead to detectable HD 
formation (Fig S3E). Taken together, these results strongly suggest that HD formation occurs 
co-translationally. 




Fig 3: Co-translational formation of the extraordinarily stable FIH-OTUB1 HD. (A) 
Following ectopic expression of the indicated proteins, the FIH-OTUB1 heterodimer (HD) was 
allowed to form for 24 h prior to the analysis of the HD stability in hypoxia when FIH is inhibited 
and no additional HD can be formed. (B) HD formation kinetics and (C) HD formation during 
translation inhibition by cycloheximide (CHX) according to the experimental setups described 
in Fig S3B. Re-Ox CHX, addition of CHX at the same time as re-oxygenation was started; Re-
Ox CHX pre, pre-incubation of cells with CHX for 1 h prior to the start of re-oxygenation. (D) 
Bicistronic expression of the indicated His-OTUB1-MBP-FIH in E.coli followed by immunoblot 
analysis. Time points indicate the time after induction of protein production by addition of 
isopropyl-ß-D-thiogalactoside (IPTG). Nx, normoxia; M, monomer. Data are representative for 
three independent experiments throughout. 
 
The FIH-OTUB1 HD is part of a native FIH:FIH-OTUB1 heterotrimer. 
The active form of FIH is a non-covalent FIH:FIH homodimer [53]. Therefore, we sought to 
investigate, if both FIH proteins of the homodimer form a covalent bond with OTUB1 and if HD 
formation interferes with the interaction of the FIH proteins within the FIH homodimer. 
Following native gel electrophoresis, ectopic FIH-V5 expression alone showed two bands in 
the immunoblot, which corresponded to monomeric FIH and homodimeric FIH, as 
homodimeric FIH was not detectable anymore after denaturation of the same sample (Fig 4A). 
With ectopic FIH-V5 and FLAG-OTUB1 co-expression, a complex was detectable that was 
composed of FIH and OTUB1 (detected with both antibodies) and moved slower in the electric 
field than the FIH homodimer (Fig 4A). Next, the composition of this complex was analyzed in 
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a second denaturing dimension following native gel electrophoresis. Alongside the HD, a 
further signal was observed in the anti-V5 immunoblot at the same molecular weight as the 
V5 signal obtained from FIH-V5 expression alone (Fig 4B). This revealed that the native 
complex contained an additional, non-covalently bound FIH protein. Non-covalently interacting 
(monomeric) OTUB1 was not detected within the complex (Fig. 4B). In summary, only 
covalently linked OTUB1 was present in the complex combined with a covalently linked FIH 
and a second, non-covalently interacting FIH. Hence, in cellulo a FIH:FIH-OTUB1 heterotrimer 
(HT) is formed. 
 
 
Fig 4: FIH:FIH-OTUB1 heterotrimer formation. Analysis of the composition of the 
covalently linked FIH-OTUB1 complex by (A) blue native-PAGE (first dimension, 1D) 
following ectopic expression in HEK293 cells and by (B) SDS-PAGE as second dimension 
(2D). *, FIH-OTUB1 heterodimer; x, FIH homodimer; y, FIH monomer; arrows 1-3, 
monomeric FIH originating from FIH monomers (1), FIH:FIH homodimers (2) or the FIH:FIH-
OTUB1 heterotrimer (3). Data are representative for three independent experiments 
throughout. 
 
Covalent complex formation with FIH regulates OTUB1 enzymatic activity. 
To assess possible functional consequences of HT formation for OTUB1 enzymatic activity 
(hydrolysis of K48-linked Ub chains), monomeric free OTUB1 and the native HT were purified 
from bacterial lysates (Figs S4A and S4B). To account for a small contamination of the HT by 
monomeric OTUB1, indicating that non-covalently bound OTUB1 was co-purified, molar 
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concentrations of the control (monomeric OTUB1) were matched with the contamination. 
Within the HT sample, there was a significant increase in cleavage of K48-Ub chains in 
comparison to monomeric OTUB1 following 5 min of incubation, as shown by significant 
decreases in Ub4 chains paralleled by significant increases in Ub3 chains (Figs 5A and 5B). 
This demonstrated a higher deubiquitinase activity within the HT sample over monomeric 
OTUB1, which could only be derived from the HT itself. Hence, OTUB1 enzymatic activity was 
maintained in the HT. Interestingly, at later time points this activity was decreased in 
comparison to monomeric OTUB1 (Figs 5A and 5B). 
Interaction of the OTUB1 N-terminus with uncharged E2s (such as UBCH5B) increases 
OTUB1 activity towards K48-ubiquitin chains by stabilizing the structure of an OTUB1 Ub-
binding site [26]. Because the OTUB1 N-terminus also contains the FIH interaction site, we 
investigated if the stimulating effect of UBCH5B on OTUB1 enzymatic activity was affected by 
HT formation. The activity of purified monomeric OTUB1 was strongly increased in the 
presence of UBCH5B, as demonstrated by a faster turnover of K48-linked Ub4 into smaller Ub 
chains when UBCH5B was present (Figs 5C, 5D and S4C). In contrast, HT-dependent 
cleavage of Ub4 chains was reduced in the presence of UBCH5B in comparison to HT alone, 
as shown by higher residual levels of Ub4 chains in samples containing both the HT and 
UBCH5B compared to samples containing the HT alone (Figs 5C, 5D and S4C). This 
demonstrated that UBCH5B had the opposite effect on OTUB1 activity when OTUB1 was 
bound by FIH (forming the HT) than on monomeric OTUB1. 
These results show that OTUB1 maintains its enzymatic activity within the 
heterotrimeric complex with FIH, but the important regulation of its activity by the E2 enzyme 
UBCH5B is inverted, demonstrating a functional effect of FIH:FIH-OTUB1 HT formation. 




Fig 5: UBCH5B-dependent regulation of OTUB1 DUB activity in the FIH:FIH-OTUB1 
heterotrimer. (A-D) Comparison of the OTUB1 enzymatic activity in purified monomeric 
OTUB1 and in the FIH:FIH-OTUB1 heterotrimer (HT) in (A, B) the absence or (C, D) presence 
of the E2 protein UBCH5B using (A, C) a DUB assay and (B, D) quantification. (D) The relative 
levels of Ub4 chains were quantified in each sample of the experiment described in (C). 
Quantified Ub4 chain amounts in the samples containing His-Otub1 alone were subtracted 
from the quantified Ub4 chain amounts in samples with His-OTUB1 + UBCH5B (clear bars). 
The same analysis was carried out for the His-MBP-HT: quantified amounts of Ub4 chains in 
samples with His-MBP-HT alone were subtracted from the quantified amounts in the samples 
containing His-MBP-HT + UBCH5B (grey bars). DUB, indicates the deubiquitinases OTUB1 
or HT, respectively. HD, heterodimer; M, monomer, Ubn, K48-linked ubiquitin chains with n 
number of Ub proteins; ns, not significant. Data are shown as mean + SEM from three 
independent experiments or are representative for three independent experiments. *, p<0.05; 
**, p<0.01; ***, p<0.001 by two-way ANOVA followed by Tukey post-test. 
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FIH forms denaturation resistant complexes with a specific subset of its interactome. 
During our analyses, we observed further higher molecular weight bands in addition to the HD 
that were also detected with an antibody against FIH (Fig S5A). Intriguingly, these bands 
disappeared when FIH activity was inhibited (Fig S5A). This indicated that FIH-dependent 
covalent bond formation was not restricted to OTUB1. For the investigation of such potential 
further covalent complexes formed by FIH, we utilized an assay previously described for the 
discrimination of covalent and non-covalent ubiquitin interactions [54]. In this assay, the FIH-
OTUB1 HD was pulled down under denaturing conditions without non-covalently interacting 
FIH (Fig 6A). When FIH-V5 was expressed alone, the same approach showed several high 
molecular weight complexes, of which some were maintained under denaturing conditions 
(“+SDS”) (Fig 6B). This further indicated that a subset of the FIH interactome forms covalent 
complexes with FIH similar to OTUB1. MS identified 71 proteins that interacted with FIH 
following native lysis (“- SDS”), while 375 proteins were observed following IP from denatured 
cell lysates (Fig 6C). The higher number of co-precipitants in the IP from denatured cell lysates 
was surprising, but denaturing lysis will lead to the extraction of more proteins, which could 
explain the difference in the number of detected proteins. Thirteen FIH interactors were 
present under denaturing as well as native conditions, including OTUB1 (Figs 6C, 6D and 
S5B). The interactomes covered a broad spectrum of different biological processes (Fig S5C). 
Among the 12 novel candidates for covalent complex formation, the previously described FIH 
interactors IB and CDK1 were present [13, 17]. These results demonstrate that FIH forms 
stable complexes with a subset of its interactome. 




Fig 6: Denaturing condition-resistant FIH interactome composition. (A) Following ectopic 
expression of the indicated proteins, HEK293 cells were lysed under native or denaturing 
(boiling in 1% SDS) conditions followed by anti-FLAG IP and immunoblot analysis. HD, 
heterodimer; M, monomer; ab, antibody. (B) Following ectopic expression of either FIH-V5 or 
tandem EGFP, HEK293 cells were lysed as described in (A) followed by anti-V5 IP and 
immunoblot analysis. exp, exposure. (C) Following the same sample preparation as in (B), the 
samples were analysed by MS. Venn diagram displaying the overlap between FIH interactors 
under native (-SDS) and denaturing (+SDS) conditions. (D) Rank order of the 13 proteins 
interacting with FIH under both conditions shown in (C), according to the relative label free 
quantification (LFQ) intensity following IP in the presence of SDS and normalized to FIH pull-
down. Data are shown as mean ± SEM. HD, heterodimer; M, monomer; ab, antibody; exp, 
exposure. Data are shown as mean ± SEM from (C, D) four biological replicates or are 
representative for (A) three or (B) one independent experiment. (B-D) Samples were 
processed in parallel and only differ in the analysis (immunoblot or MS).  




The formation of protein complexes is the basis for cellular processes and functions [55]. 
Hence, the understanding of protein complex formation is fundamental for our understanding 
of health and disease. Cellular oxygen sensing is vital for cells in order to be able to monitor 
oxygen availability in their local microenvironment and to adjust to changes accordingly [3]. In 
this study, we provide insights into a previously unknown cross-talk between FIH and OTUB1 
through amide bond formation catalysed by FIH, with unprecedented oxygen sensitivity and 
with functional relevance for OTUB1, regulating its K48-Ub chain cleavage activity. The 
covalent FIH-OTUB1 HD formation may represent an alternative molecular mechanism for the 
cellular adaptation to oxygen changes over longer time periods, linking oxygen sensing and 
deubiquitinase activity. Furthermore, we provided results indicating that FIH-dependent 
covalent bond formation is not exclusive for OTUB1. 
The covalent bond of the FIH-OTUB1 HD fulfils all biochemical criteria of an amide 
bond [47-49, 56, 57]. FIH enzymatic activity was necessary for HD formation and hence FIH 
appears to have amide synthase activity. This activity required the same co-factors and co-
substrates as FIH-dependent hydroxylation. But in contrast to amide bond formation in the 
ubiquitin system, FIH is not known to utilize ATP. Furthermore, the catalyzing protein (FIH) 
attaches itself instead of a third moiety, such as an ubiquitin or a hydroxyl group. Hence, the 
proposed FIH amide synthase activity on OTUB1 would be based on an unprecedented 
molecular mechanism. 
FIH can oxidize hydrophilic, hydrophobic, acidic, basic, polar and neutral amino acid 
side chains and FIH may catalyze the formation of β–oxo-histidine and dehydrohistidine [58-
60]. This demonstrates that FIH catalytic activity is highly promiscuous and that FIH may be 
capable of catalyzing more than asparagine hydroxylation. In our experiments, point mutations 
of OTUB1 indicated that N22 and C23 are necessary for HD formation. Cysteines such as 
C23 can form disulfide bonds or thioesters, but both types of covalent bonds were excluded 
by our analyses. N22 can be hydroxylated by FIH [18], demonstrating that N22 is accessible 
for FIH catalytic activity. Therefore, N22 is likely the OTUB1 amino acid that is involved in the 
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covalent bond formation. However, peptides corresponding to the suspected regions of FIH-
OTUB1 HD formation could not be detected by MS, which is likely due to the unknown 
molecular weight of these unique peptides, and excludes a direct examination of the nature of 
the FIH-OTUB1 bond. 
Interestingly, asparagine can non-enzymatically form succinimide intermediates, which 
lead to amide bond formations with lysine residues during aging [61]. Furthermore, in specific 
bacterial proteins asparagine can auto-catalytically form succinimide intermediates that lead 
to amide bond formation with lysyl residues, provided that an additional glutamate or aspartate 
is present within a hydrophobic pocket [62]. FIH contains an aspartate (D201; iron 
coordination) and a lysyl residue (K214; 2-OG coordination) within its active center [63, 64]. 
Unfortunately, the involvement of K214 in covalent bond formation cannot be assessed since 
the enzymatic activity of FIH is likely lost following K214 mutation. 
FIH-dependent asparagine hydroxylation of HIF still occurs at lower oxygen levels than 
PHD dependent prolyl hydroxylation [52, 65]. Here, we report an even higher oxygen 
sensitivity for FIH-mediated HD formation than for PHD-mediated HIFα destabilization. The 
half-maximal oxygen concentration (gas phase) for HD formation was determined as 4.1% O2, 
which is in stark contrast to the previously determined sensitivity for FIH-dependent HIFα 
hydroxylation, being below 1% O2 [51, 52]. Interestingly, the oxygen sensitivity of FIH-
dependent hydroxylation depends on the used substrate and its length [66, 67]. Therefore, it 
is likely that the here observed unprecedentedly high oxygen sensitivity of FIH is encoded 
within the interacting peptide of the specific substrate. 
Functionally, OTUB1 maintained enzymatic activity within the FIH:FIH-OTUB1 HT, 
while the regulation of its activity by UBCH5B was affected. OTUB1 enzymatic activity is 
regulated by E2 enzymes dependent on the presence of free mono-Ub and whether the E2 is 
charged with a covalently attached Ub. Mono-Ub in combination with Ub-charged E2 enzymes 
inhibits OTUB1 enzymatic activity due to interaction of the Ub of the charged E2 enzyme with 
an Ub binding site at the OTUB1 N-terminus and the interaction of the free mono-Ub with a 
second Ub binding site, preventing OTUB1 from binding its substrate (K48-linked Ub chains) 
 Publication I: Redox Biol. 2019 Sep; 26: 101265 
90 
 
[23, 26, 27]. Uncharged E2 enzymes in turn stimulate OTUB1 activity by stabilizing the 
structure of the N-terminal Ub-binding site that is disordered in the apoenzyme [21, 26, 27]. 
When we assessed if OTUB1 DUB activity was preserved within the HT (in the absence of 
UBCH5B), we observed an initial increase of OTUB1 activity at 5 min, which decreased in 
comparison to non-complexed OTUB1 at later time points, coinciding with an increased 
release of mono-Ub. An E2 was not present, but FIH might mimic the effect of a charged E2 
enzyme within the HT, as it also binds to the OTUB1 N-terminus. The stimulation of OTUB1 
activity by uncharged UBCH5B was inverted when OTUB1 was complexed by FIH. This effect 
was again comparable to the regulation of OTUB1 activity by a charged E2 enzyme, although 
this time in the absence of free Ub. Overall, it seems likely that the functional regulation of 
OTUB1 by covalently bound FIH:FIH is due to its localization and its resemblance to an 
interacting charged E2 enzyme. 
We observed that the formation of the FIH-OTUB1 heterodimer is slow (within the 
range of several hours) combined with slow degradation kinetics (up to 24 h). This is in stark 
contrast to the fast HIF-1α stabilization and degradation kinetics (seconds to minutes) [68]. 
The fast HIF-1α kinetic is crucial for its role as the main transcription factor for the cellular 
adaptation especially to acute changes in oxygen levels. The observed slow formation and 
degradation kinetics of the FIH-OTUB1 HD will make it insensitive to brief fluctuations of 
oxygen levels (minutes to possibly a few hours). Hence, the FIH-OTUB1 complex is likely not 
involved in acute but rather in chronic cellular adaptations to hypoxia, providing a further set 
point for cellular oxygen availability besides HIFα. 
Interestingly, the monomeric prolyl-3-hydroxylase 2-OG and Fe(II)-dependent 
oxygenase domain-containing protein 1 (OGFOD1) has been shown to form an OGFOD1 
activity-dependent SDS-PAGE resistant complex with its substrate ribosomal protein S23 
(RPS23) [69, 70]. However, the oxygen sensitivity of the complex formation, a possible 
functional consequence or the nature of the interaction remained unclear. Of note, a point 
mutation in RPS23 that impairs its hydroxylation and stable complex formation with OGFOD1 
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has recently been linked to ribosomopathy in humans [71], indicating that covalent HD 
formation of hydroxylases with their substrates may be involved in human diseases. 
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Fig S1. Cell-type independent covalent FIH-OTUB1 HD formation. (A) Ectopic expression 
of FLAG-OTUB1 in combination with FIH-V5 led to the detection of protein signal “X” at 72 
kDa with both anti-FLAG and anti-V5 antibodies. (B) MS analysis of protein X excised from a 
SDS-PAGE gel following IP from HEK293 cell lysates demonstrated that protein X contained 
both OTUB1 and FIH. (C, D) Detection of the heterodimer (HD) by immunoblotting in MCF7 
breast adenocarcinoma (C) and Hep3B liver carcinoma cell lysates (D) with the indicated 
plasmid-dependent expressions and knockdowns. (E) Immunoblot analysis of HEK293 lysates 
with the indicated ectopic expression in the presence or absence of 858 mM -
mercaptoethanol (ME) and boiling. (F) Quantification of the experiment described in Fig 1D. 
M, monomer; ab, antibody; nsp, non-specific. Data are shown as mean + SEM from (F) three 
independent experiments or are representative for (B) one or (A, C-F) three independent 
experiments. Statistical analysis by two-way ANOVA followed by Tukey post-test (ns, not 
significant).  




Fig S2. Formation of the FIH-OTUB1 HD depends on the OTUB1 hydroxylation site and 
FIH activity. (A) Immunoblotting following anti-FLAG IP of HEK293 lysates containing the 
indicated ectopic expressions. (B) Quantification of monomeric FIH (M) and of the FIH-OTUB1 
HD of the experiments shown in (A). (C, D) Quantification of the experiments shown in Fig 1E. 
(E) Immunoblot analysis of HEK293 cells following the addition of FIH co-factors/substrates 
or the iron chelator DFX. HD, heterodimer; M, monomer; ab, antibody. Data are shown as 
mean + SEM from (B, D) three or (C) six independent experiments or are representative of (A, 
E) three independent experiments. **, p<0.01; ***/###, p<0.001 by one-way ANOVA followed 
by Tukey post-test. *, statistically significant compared with HD WT; #, statistically significant 
compared with M WT.  




Fig S3. FIH-OTUB1 HD stability and formation kinetics. (A) Quantification of the 
experiment depicted in Fig 3A. (B) Illustration of the experimental procedures performed in 
Fig 3B and 3C. HEK293 cells were transiently co-transfected with FIH-V5 and FLAG-OTUB1 
WT, incubated in hypoxia (0.2% O2) for 24 h and instantaneously re-oxygenated in the 
presence or absence of 400 µM cycloheximide (CHX). (C) Quantification of the experiment 
depicted in Fig 3B. (D) Plasmid map of the bacterial bicistronic expression vector pST39-His-
OTUB1-MBP-FIH. T7 Ø10, T7 promotor; T7 term, T7 terminator; ε, translational enhancer; 
SD, Shine-Dalgarno sequence. (E) Immunoblot analysis of co-inoculated bacterial cultures 
expressing either OTUB1 or FIH. Bacteria were transformed with either OTUB1 or FIH 
expression plasmids, cultivated separately and then mixed in a 1:1 ratio followed by induction 
of the indicated protein expression. HD, heterodimer; M, monomer; exp., exposure. Data are 
shown as mean + SEM from three independent experiments or are representative for (E) two 
independent experiments.  




Fig S4. Quality control of purified FIH:FIH-OTUB1 HT and His-tagged OTUB1 for in vitro 
activity assays. (A) His-OTUB1-MBP-FIH:FIH-MBP heterotrimer (His-MBP-HT) was purified 
from E. coli by sequential MBP- and Ni2+-affinity purification and analyzed by SDS-PAGE and 
colloidal Coomassie staining. (B) His-OTUB1 was purified from E. coli by Ni2+-affinity 
purification and analyzed by SDS-PAGE and colloidal Coomassie staining. *, FIH-OTUB1 
heterodimer (predicted MW: 117.82 kDa); **, monomeric MBP-FIH originating from the native 
protein complex (predicted MW: 83.78 kDa); ***, monomeric His-OTUB1 (predicted MW: 34.04 
kDa). (C) Quantification of each single Ub chain of the experiment depicted in Fig. 5C. Data 
are shown as mean + SEM from three independent experiments. *, p<0.05; **, p<0.01; ***, 
p<0.001 by two-way ANOVA followed by Tukey post-test.  




Fig S5. FIH interactome under native and denaturing conditions. (A) Longer exposure of 
the FIH immunoblot shown in Fig 2A. (B) Protein abbreviations, full names and uniprot.org 
identifiers of proteins detected as FIH interactors under both lysis conditions. (C) Proteins 
shown in Fig 6C were analyzed and categorized for protein class using the Panther 
classification system (www.pantherdb.org). HD, heterodimer. Data were analyzed from (B, C) 
four biological replicates or are representative for (A) three independent experiments. 
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Deubiquitinases (DUBs) are key regulators of the ubiquitin system, which is an integral part of 
most cellular signalling pathways. The DUB OTUB1 is ubiquitously expressed with one of the 
highest cellular protein levels of all DUBs. However, the physiological function of OTUB1 is 
unknown. Here we show that constitutive Otub1 deletion in mice leads to perinatal lethality 
caused by asphyxiation. Adult mice with conditional whole-body Otub1 deletion (wbOtub1-/-) 
hyperventilated and were unable to adapt their respiratory pattern to hypoxia. wbOtub1-/- mice 
developed cardiac hypertrophy and left ventricular dysfunction. Moreover, wbOtub1-/- led to an 
increase in energy metabolism, including reduced body weight gain, accelerated energy 
expenditure and enhanced insulin sensitivity. Otub1 deletion elevated basal and stimulated 
AKT/mTOR signalling in cells and tissues, which likely caused the observed phenotypes. 
These results demonstrate that OTUB1 has an essential role in energy metabolism as well as 
for embryonic development, respiratory and cardiac function.  




The ubiquitin system plays an essential role in virtually all cellular signalling pathways and, 
hence, in cell and tissue homeostasis[72]. The ubiquitin system regulates cellular proteins by 
conjugation of ubiquitin proteins (Ub) via Ub-conjugating enzymes (E1s, E2s, E3s)[72]. Poly-
Ub chains can differ in the amino acid residue(s) used to inter-connect Ub proteins within the 
chains (either via the Ub N-terminal methionine or through seven different lysine residues), 
leading to distinct three-dimensional chain structures and different downstream effects[73]. 
K48-linked Ub chains are the most abundant Ub modification in cells, targeting modified 
proteins for proteasomal degradation[20]. K63-Ub chains are the second most abundant Ub-
chain type[20], serving as inducible scaffolds in multiple signalling pathways[74]. 
Deubiquitinases (DUBs) are negative regulators of the Ub system, removing or 
trimming Ub chains and regulating the available pool of free Ub[72, 73]. DUBs recently gained 
interest as therapeutic targets for various diseases[72]. However, the function and regulation 
of many DUBs is insufficiently understood. The DUB ovarian tumor (OTU) domain-containing 
ubiquitin aldehyde binding protein 1 (OTUB1) shows one of the highest cellular protein levels 
of all known approximately 100 DUBs[20, 72]. OTUB1 exhibits a unique combination of 
canonical and non-canonical functions. Canonically, OTUB1 specifically cleaves K48-ubiquitin 
chains, preventing proteasomal degradation of substrate proteins[22, 75]. In addition, OTUB1 
inhibits E2 enzymes independent of its enzymatic activity, impeding K48- and K63-linked 
ubiquitin chain formation[19, 24, 25, 76]. OTUB1 has been implicated in the regulation of 
various pathways and processes in vitro, ranging from pro-inflammatory signalling[77-79], to 
pro-fibrotic signalling[19], the DNA damage response[24], proliferation[80, 81] and 
apoptosis[77]. 
We previously showed that the cellular oxygen sensor factor inhibiting HIF (FIH) 
interacts with OTUB1[82-85] and hydroxylates it on asparagine 22[85], regulating cellular 
energy metabolism[85]. Furthermore, FIH and OTUB1 form a denaturation-resistant protein-
protein complex, regulating OTUB1 enzymatic activity[83]. 
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Constitutive whole-body deletion of Otub1 in mice is lethal during development[86, 87], 
but the induced developmental defects, the underlying cause(s) of the lethality and the 
involved molecular mechanism(s) are unknown. Some central nervous system (CNS) and 
immune cell-specific functions of OTUB1 were recently analysed in mice. In a mouse model 
of CNS autoimmunity, deletion of Otub1 in astrocytes increased neuroinflammation[87]. Otub1 
ablation in dendritic cells decreased the immune response to parasite infection and LPS 
stimulation[88]. Conditional deletion of Otub1 in B cells led to a hyperactive B cell state[89]. 
CD8+ T cells with Otub1 knockout (KO) revealed an increased sensitivity to IL-15[90]. Natural 
killer cells without Otub1 were hypersensitive to cytokine-dependent stimulation[90]. OTUB1 
recently gained interest as possible novel therapeutic target in cancer, because it was linked 
to the regulation of many cancer-associated pathways, such as p53, RhoA, AKT, mTOR, 
MAPK and FOXM1[90, 91]. Furthermore, increased OTUB1 levels were associated with 
increased tumor invasiveness and metastasis in different cancer types[91]. 
Overall, various links exist between OTUB1, cancer, inflammation and immunity, 
leading to an increasing interest in OTUB1 as pharmacologic target. However, the 
physiological function of OTUB1 is still unclear. Therefore, we aimed to characterize the 
physiological role of OTUB1 in mice to increase our understanding of its function in vivo and 
its value as pharmacologic target.  




Homozygous Otub1 deletion induces lethal developmental defects 
OTUB1 is ubiquitously expressed in humans and mice (Supplementary Fig. 1a-c). To elucidate 
OTUB1 function in vivo, we therefore characterized mice with constitutive whole-body 
heterozygous and homozygous Otub1 deletion (Fig. 1a). Homozygous Otub1 KO was lethal, 
while Otub1 haploinsufficient mice were viable (Fig. 1b,c). Absence of OTUB1 did not affect 
the sex ratio (Fig. 1b,c). Most Otub1-/- mice died perinatally, but there were still less Otub1-/- 
mice observed at E18.5 (births occurred on average at E19.5) than expected when assuming 
a Mendelian distribution (Fig. 1b,c). On a few occasions, remnants of absorptions were 
observed at E18.5, two of which could be identified as Otub1-/-, suggesting that a small number 
of Otub1-/- mice died during earlier developmental processes. While Otub1+/- embryos were 
comparable in size and weight to Wt mice, Otub1-/- embryos were significantly lighter and 
smaller than Otub1+/- mice (Fig. 1d,e). The ventricular wall diameter and the heart weight of 
Otub1-/- animals were increased (Fig. 1f,g). Other organs showed no gross histological 
abnormalities (Supplementary Fig. 1d) or weight differences (Supplementary Fig. 1e). 




Fig. 1: Gross developmental defects in Otub1-/- mice. a, Genotype of mice with 
heterozygous or homozygous Otub1 deletion (Otub1+/- or Otub1-/-). Image shows PCR results 
determining the genotype. En2SA, engrailed 2 gene splice acceptor; IRES, internal ribosome 
entry site; lacZ, β-galactosidase gene; pA, polyadenylation; FRT, flippase recognition target; 
loxP, locus of X (cross)-over in P1; Wt, wildtype; NTC, non-template control. b, Total numbers 
of observed mice and gender distribution within each genotype following Otub1+/- mating 
(E18.5 and P0). c, Relative distribution of genotypes and genders following Otub1+/- mating. 
The numbers in the graph indicate the total percentage of each genotype. d, Representative 
images of wildtype (Wt), Otub1+/- and Otub1-/- mice (P0). e, Body weight (BW) and body length 
relative to Wt littermates (E18.5; Otub1+/-, n = 94; Otub1-/-, n = 27) f, H&E staining of frontal 
heart sections (P0). Rv/Lv, right/left ventricle. g, Otub1+/- (n=27) and Otub1-/- (n = 14) heart 
weight corrected for BW and normalised to the corresponding Wt (n=15) littermates (E18.5). 
The dashed line indicates Wt littermates. Data are presented as mean ± SEM. ***, p<0.001 by 
two-tailed Student’s t-test. Exact P values: e, relative BW: <0.0001; relative body length: 
<0.0001; g, 0.0003.  
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Constitutive Otub1 deletion prevents respiration 
Although the lung of Otub1-/- mice showed no difference in weight and gross morphology, we 
observed gasping in Otub1-/- new-born pups (P0) and E18.5 embryos (excised by caesarean 
section). In contrast to Wt and Otub1+/- lungs, Otub1-/- lungs sank during a floating test, 
demonstrating that Otub1-/- animals were unable to inflate their lungs (Fig. 2a). Histological 
analyses of the lungs showed that the saccular air space was significantly decreased in Otub1-
/- mice (Fig. 2b). While glycogen is necessary for the production of surfactant 
phospholipids[92], we found no difference in glycogen stained by periodic acid-Schiff (PAS) 
(Fig. 2c). Also surfactant protein C (SPC) showed comparable levels by 
immunohistochemistry (IHC) between the genotypes (Fig. 2d) and transmission electron 
microscopy depicted a normal visual appearance of lamellar bodies in Otub1-/- embryos 
(Supplementary Fig. 1f). These results indicated a normal surfactant production in Otub1-/- 
embryos. IHC detection of CD31, a marker of vascular endothelial cells[93], showed a 
significant decrease for Otub1-/- lungs compared to Wt but not to Otub1+/- lungs (Fig. 2e). 
Otub1+/- embryos showed a (non-significant) decrease in CD31 lung staining compared to Wt 
without developing a lung phenotype (Fig. 2e) and the difference between Otub1+/- and Otub1-
/- embryos was rather small and also not significant (Fig. 2e). Therefore, it appeared 
implausible that the pulmonary vessel density was a major contributor to the Otub1-/- lung 
phenotype. 
OTUB1 has previously been shown to regulate apoptosis via e.g. increased cleaved 
caspase 3 (clCasp3) levels[77]. In E18.5 Otub1-/- lungs, clCasp3 levels were comparable to 
Wt lungs but significantly increased compared to Otub1+/- (Fig. 2f). The groups displayed a 
large variability in clCasp3 levels, but, importantly, the clCasp3 levels were overall very low 
(Fig. 2f). Hence, apoptosis was unlikely to contribute to the Otub1-/- lung phenotype. 
OTUB1 has also been reported to regulate proliferation[80, 81]. Analysis of 
proliferation by Ki67 IHC demonstrated that Otub1 deletion significantly enhanced proliferation 
in the developing lung compared to both Otub1+/- and Wt mice (Fig. 2g). In HEK293 cells, 
OTUB1 knockdown increased proliferation, and rescue by OTUB1 ectopic expression 
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decreased the proliferation back to levels comparable to control cells (Supplementary Fig. 1g). 
In summary, we suggest that Otub1 ablation decreased the saccular air space through 
increased cell proliferation, which led to the inability of Otub1-/- mice to inflate their lungs and 
caused the perinatal lethality.  




Fig. 2: Lung tissue and respiratory alterations in Otub1-/- mice. a, Floating test for P0 Wt, 
Otub1+/- and Otub1-/- lungs. Filled arrowheads indicate the surface, empty arrowheads indicate 
the lung. b-g, Histological analyses and quantification of E18.5 transversal lung sections by 
H&E (b), PAS (c), anti-surfactant C (SPC) antibody (d), anti-cluster of differentiation 31 (CD31) 
antibody (e), anti-cleaved caspase 3 (clCasp3) antibody (f) and anti-Ki67 antibody (g). 
Quantifications of the stainings in E18.5 Wt (n = 9-14), Otub1+/- (n = 14-25) and Otub1-/- (n = 
11-14) lung tissues were normalised to parenchymal (parench.) tissue area. pos., positive. 
Data are presented as mean ± SEM. *, p<0.05, **, p<0.01, ***, p<0.001 by two-tailed Student’s 
t-test. Exact P values: b, Wt versus Otub1-/-: <0.0001; Otub1+/- versus Otub1-/-: <0.0001; e, 




Conditional whole-body Otub1 deletion causes hyperventilation in adult mice 
To analyse the physiological relevance of OTUB1 in adult mice, we established a mouse strain 
with tamoxifen (Tx)-inducible whole-body Otub1 ablation (Fig. 3a). The deletion of Otub1 was 
highly efficient with some intra- and inter-organ variations (Fig. 3b and Supplementary Fig. 
2a). 
Because Otub1 deletion affected lung development, we analysed whether a deletion 
during adulthood impacted upon respiration and lung tissue. Under normal oxygen conditions 
(normoxia; 21% O2), the respiratory frequency was not significantly altered in Otub1 KO mice, 
but the tidal volume was increased relative to Tx-treated control mice and the minute volume 
was significantly higher in comparison to both controls (Fig. 3c), demonstrating that mice 
lacking Otub1 were hyperventilating. Following normoxia, the respiration of the same mice 
was determined in hypoxia (10% O2). Acute hypoxia increased tidal and minute volume in all 
groups (Fig. 3c, 10% O2, early), but Otub1 KO mice maintained an increased tidal and minute 
volume relative to both controls (Fig. 3c, 10% O2, early) whereas after 25-30 min in hypoxia 
(Fig. 3c, 10% O2, late), the control mice adapted and showed comparable respiration to 
normoxia (Fig. 3c). Otub1 KO mice did not adjust and maintained increased respiratory 
frequency, tidal volume and minute volume (Fig. 3c). These findings demonstrated that 
OTUB1 is integral for the regulation of respiration and the adaptation of respiration to hypoxia. 
The respiration of mice with constitutive Otub1 haploinsufficiency was not altered 
(Supplementary Fig. 2b), indicating that a partial loss of Otub1 can be compensated for. 
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Interestingly, the weight of lungs lacking Otub1 was significantly increased compared 
to controls (Fig. 3d). Lungs of Otub1+/- mice showed no weight difference (Supplementary Fig. 
2c). An increased number of proliferating and total cells was detected in adult Otub1 KO lungs 
(Fig. 3e), which was comparable to our findings in Otub1-/- E18.5 lungs (Fig. 2g). Hence, Otub1 
deletion induced proliferation in lung tissue independent of development. In summary, OTUB1 
is essential for lung tissue homeostasis, regulation of respiration and the adaptation of 
respiration to hypoxia.  
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Fig. 3 (see figure legend on p. 13). 
Fig. 3: Lung tissue and respiratory alterations in adult mice with induced whole-body 
Otub1 deletion. a, Otub1fl/fl mice were generated by crossing mice with the potential of 
conditional Otub1 deletion (pcOtub1+/-) with mice transgenic for Flippase (Flp). To obtain 
conditional whole-body Otub1 KO (wbOtub1-/-) mice, Otub1fl/fl mice were crossed with mice 
carrying one transgene of a CreERT2 expressed under the control of the ubiquitin C (UBC) 
promoter (UBC-CreERT2), followed by gavage of 200 g tamoxifen (Tx)/g BW during 5 
consecutive days. Images show PCR results determining the genotypes. PGK, 
phosphoglycerol kinase promoter; neo, neomycin resistance gene; Otub1fl/fl+Cre, Otub1fl/fl 
mice carrying one UBC-CreERT2 transgene; NTC, non-template control; Veh, vehicle; bp, base 
pairs. b, Quantification of OTUB1 mRNA (RT-qPCR) and protein (immunoblotting) in the 
indicated tissues (5 months after Otub1 deletion; 6.5 months old mice; n = 3). Numbers show 
the residual fraction of OTUB1. OTUB1 mRNA values were normalised to murine S12 mRNA 
levels. pgWAT, perigonadal white adipose tissue; iBAT, interscapular brown adipose tissue. 
c, Consecutive analysis of the respiration of unrestrained mice (2 month after Otub1 deletion; 
4 months old mice; Otub1fl/fl + Cre + Veh, n = 6; Otub1fl/fl - Cre + Tx, n = 7; Otub1fl/fl + Cre + 
Tx, n = 6) determined by barometric pressure plethysmography in normoxia (21% O2) and 
hypoxia (10% O2). Vt, tidal volume; VI, minute volume; early, first 5 min in hypoxia; late, 25-30 
min in hypoxia. d, Lung weight normalised to BW of the mice analysed in (C) (3.5 months after 
Otub1 deletion; 5.5 months old mice; Otub1fl/fl + Cre + Veh, n = 6; Otub1fl/fl - Cre + Tx, n = 8; 
Otub1fl/fl + Cre + Tx, n = 5). e, Immunohistology and quantification of Ki67 and total cell number 
in lung tissue (3.5 months after Otub1 deletion; 5.5 months old mice; n = 3). All data are 
presented as mean ± SEM. #/*, p<0.05; ##/**, p<0.01; ***, p<0.001 by two-tailed Student’s t-
test. #/##, compared to the corresponding measurements of the same mice in normoxia. Exact 
P values: b, mRNA - heart: 0.0057; liver: 0.0188; quadriceps: 0.0061; pgWAT: 0.0014; iBAT: 
0.0189; protein - lung: 0.0019; heart: 0.0057; liver: <0.0001; quadriceps: 0.0059; pgWAT: 
0.0028; iBAT: <0.0001; spleen: 0.0014; kidney: 0.0016; brain: 0.0004; c, frequency +Cre -Tx 
versus +Cre +Tx: 0.0254; frequency -Cre +Tx versus +Cre +Tx: 0.0169; Vt 21% O2 -Cre +Tx 
versus +Cre +Tx: 0.0273; Vt 10% O2 early +Cre -Tx versus +Cre +Tx: 0.0074; Vt 10% O2 early 
-Cre +Tx versus +Cre +Tx: 0.0046; Vt 21% O2 +Cre +Tx versus Vt 10% O2 early +Cre +Tx: 
0.0011; Vt 10% O2 late +Cre -Tx versus +Cre +Tx: 0.0062; Vt 10% O2 late -Cre +Tx versus 
+Cre +Tx: 0.0006; Vt 21% O2 +Cre +Tx versus Vt 10% O2 late +Cre +Tx: 0.0097; VI 21% O2 
+Cre -Tx versus +Cre +Tx: 0.0122; VI 21% O2 -Cre +Tx versus +Cre +Tx: 0.0164; VI 10% O2 
early -Cre +Tx versus +Cre +Tx: 0.0147; VI 21% O2 +Cre -Tx versus VI 10% O2 early +Cre -
Tx: 0.0213; VI 21% O2 +Cre +Tx versus VI 10% O2 early +Cre +Tx: 0.0263; VI 10% O2 late 
+Cre -Tx versus +Cre +Tx: 0.0055; VI 10% O2 late -Cre +Tx versus +Cre +Tx: 0.0029; d, +Cre 
-Tx versus +Cre +Tx: 0.0298; -Cre +Tx versus +Cre +Tx: 0.0412; e, Ki67 Veh versus Tx: 
0.0469; total cells Veh versus Tx: 0.0474. 
 
 
Mice lacking Otub1 develop cardiac hypertrophy and ventricular dysfunction 
Heart size and function were assessed in adult mice with induced Otub1 deletion using 
echocardiography (Fig. 4a), because of the previously observed cardiac phenotype in Otub1-
/- embryos (Fig. 1). Over time, Otub1 ablation increased the left ventricular mass (LVM) (Fig. 
4b). The isovolumic relaxation time (IVRT) was prolonged at one and four months following 
Otub1 deletion (Fig. 4c), indicating a diastolic dysfunction. The isovolumic contraction time 
(IVCT), an important part of the systole, was significantly increased four months after Otub1 
KO (Fig. 4d). The myocardial performance index (MPI)[94] was significantly raised at both 
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time points after Otub1 KO (Fig. 4e) and the E and A myocardial velocities ratio (E/A) was 
increased four months after Otub1 deletion (Fig. 4f), both further supporting a diastolic 
dysfunction. The ejection fraction and fractional shortening were significantly decreased four 
months after Otub1 KO (Fig. 4g and Supplementary Fig. 3a). But the extent of these regulation 
was relatively small and the ejection fraction remained on average above 50% (Fig. 4g), which 
is considered to be a preserved ejection fraction[95]. Other parameters showed no significant 
difference (Supplementary Fig. 3b-f), whereas tissue Doppler imaging (TDI) confirmed the 
observations for IVRT, IVCT and MPI (Supplementary Fig. 3g-i). Six months after Otub1 KO, 
the heart weight relative to tibia length showed a tendency to be increased (Fig. 4h). In an 
additional group of mice, the heart weight relative to tibia length was significantly increased in 
mice with Otub1 deletion (5.5 months after KO) compared to vehicle control (Supplementary 
Fig. 3j), overall supporting the observed increase in LVM. A cardiac failure did not develop 
following Otub1 KO in this group of mice at the analysed time point, because the wet versus 
dry lung weight - a read-out for lung congestion - was not changed (Fig. 4i). Constitutive 
haploinsufficiency of Otub1 did not affect cardiac tissue or function (Supplementary Fig. 3k-
aa), indicating that a partial loss of OTUB1 can be compensated for. 
We next analysed heart rate, systolic (SBP) and diastolic blood pressure (DBP) using 
a tail-cuff system. The heart rate of mice with Otub1 deletion was significantly decreased 1.5 
and 3.5 months after Otub1 KO (Fig. 4j). The DBP was unaltered 1.5 months after Otub1 KO 
and decreased 3.5 months after Otub1 KO compared to the Tx but not to the vehicle control 
(Fig. 4k). Of note, the Tx control group increased the DBP over time, whereas mice with Otub1 
KO maintained the DBP (Fig. 4k). This indicates that the difference between the Tx and the 
Otub1 KO group was not caused by Otub1 KO. A significant decrease of the SBP was 
observed 1.5 months after Otub1 KO compared to the Tx but not to the vehicle control (Fig. 
4l). 3.5 months after Otub1 KO there was no difference between the groups (Fig. 4l). An 
increased SBP or DBP could have contributed to the alterations in Otub1 KO hearts. But there 
were no indications for an increase in either SBP or DBP following Otub1 KO. Therefore, the 
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observed changes in ventricular wall size and cardiac function were likely due to intrinsic heart 
tissue alterations rather than an adaptive response to external stimuli. 
Ki67 levels were analysed in cardiac tissue to determine if proliferation contributed to 
the increased ventricular wall size. Only very little Ki67 positive cells were detected and there 
was no difference between the groups (Supplementary Fig. 3ab). FITC-WGA staining showed 
a cardiomyocyte hypertrophy in both ventricles (Fig. 4m), which likely led to the increased 
ventricular mass. 
In summary, our results demonstrated that conditional Otub1 KO leads to cardiac 
hypertrophy, left ventricular dysfunction and a decreased heart rate without affecting SBP and 
DBP. Hence, OTUB1 is an important regulator of cardiac homeostasis and function. 




Fig. 4: Cardiac function in adult mice with induced Otub1 KO. a, Representative M-mode 
scans of the left ventricle in short-axis view. b-g, Echocardiography of the left ventricular mass 
(LVM) (b), isovolumic relaxation time (IVRT) (c), isovolumic contraction time (IVCT) (d), 
myocardial performance index (MPI) (e), E and A myocardial velocities ratio (E/A) (f) and 
ejection fraction (g) at the indicated time points after Otub1 KO (3.5 and 6.5 months of age, 
Veh, n = 9-10; Tx, n = 7-9). h, Heart weight normalised to tibia length (n = 9) and I, wet to dry 
lung weight ratio (6 months after Otub1 deletion; 8.5 months old mice; Veh, n = 8; Tx, n = 9). 
j-l, Tail-cuff-dependent assessment of heart rate (j), diastolic blood pressure (DBP) (k) and 
systolic blood pressure (SBP) (l) at the indicated time points after Otub1 KO (3.5 and 5.5 
months of age; Otub1fl/fl + Cre + Veh, n = 5-6; Otub1fl/fl - Cre + Tx, n = 7-9; Otub1fl/fl + Cre + 
Tx, n = 5-6). m, FITC-WGA staining of heart tissue and quantification of transversal 
cardiomyocyte area (6 months after Otub1 KO; 8.5 months old mice; n = 3). Data are 
presented as mean ± SEM. *, p<0.05; **, p<0.01; ***, p<0.001 by two-tailed Student’s t-test. 
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Exact P values: b, 4 months KO: 0.0004; c, 1 month KO: <0.0001; 4 months KO: 0.0019; d, 4 
months KO: <0.0001; e, 1 month KO: 0.0082; 4 months KO: <0.0001; f, 4 months KO: 0.0249; 
g, 4 months KO: 0.0158; j, 1.5 months KO: +Cre -Tx versus +Cre +Tx: 0.0157; -Cre +Tx versus 
+Cre +Tx: 0.0089; 3.5 months KO: +Cre -Tx versus +Cre +Tx: 0.0015; -Cre +Tx versus +Cre 
+Tx: 0.0108; k, 3.5 months KO: +Cre -Tx versus -Cre +Tx: 0.0482; -Cre +Tx versus +Cre +Tx: 
0.0005; l, 1.5 months KO: -Cre +Tx versus +Cre +Tx: 0.0212; m, rv: 0.0246; lv: 0.0015. 
 
 
Otub1 deletion increases AKT/mTOR signalling 
MEFs were produced from Wt and Otub1-/- mice (Supplementary Fig. 4a) to analyse possible 
molecular mechanisms underlying the observed phenotypes. Total Ub chains, K48-linked and 
K63-linked Ub chains showed no difference in MEFs or heart tissue (Supplementary Fig. 4b,c). 
Therefore, Otub1 deletion had likely a more specific effect than altering general ubiquitin chain 
levels. 
OTUB1 was previously linked to the regulation of the phosphorylation of the 
serine/threonine kinase AKT following IL-15 stimulation of CD8+ T cells and NK cells[90] as 
well as to mammalian target of rapamycin (mTOR) activity in HeLa, HEK293T and H1299 
cells[96]. AKT/mTOR signalling plays a pivotal role in lung development[92, 97, 98], 
respiration[92, 99] and cardiac homeostasis[100, 101]. Therefore, we analysed whether 
OTUB1 affected the AKT/mTOR pathway in MEFs. Otub1 KO increased both AKT Thr308 and 
Ser473 phosphorylation under basal conditions (Fig. 5a). Following FCS and amino acid 
depletion, both AKT phosphorylations were also increased compared to Wt cells (Fig. 5a). 
After the re-addition of FCS (to stimulate AKT/mTOR signalling), both AKT phosphorylations 
were increased as well (Fig. 5a). This demonstrated that Otub1 deletion leads to increased 
AKT phosphorylation under both basal and stimulated conditions. To investigate mTOR 
activity, the phosphorylation status of the ribosomal protein S6 kinase (S6K) Thr389 was 
analysed, a direct target of mTOR complex 1 (mTORC1)[102]. Under baseline conditions, the 
phosphorylation of S6K Thr389 was comparable, but following stimulation, the 
phosphorylation of S6K was decreased in Otub1-/- MEFs relative to Wt (Fig. 5a), suggesting a 
decreased mTOR activity. OTUB1 has been reported to directly regulate DEPTOR protein 
stability[96], a negative regulator of mTORC1 and mTORC2[103]. Interestingly, in Otub1-/- 
MEFs DEPTOR levels were increased (Fig. 5b), which was inconsistent with a direct 
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regulation of the DEPTOR protein half-life by OTUB1, but consistent with the observed 
decrease in mTOR activity. Overall, these results demonstrated that Otub1 deletion affects 
the AKT/mTOR pathway in MEFs. 
Next, we analysed if Otub1 KO also led to a differential AKT/mTOR signalling in vivo. 
In E18.5 Otub1-/- lungs, AKT phosphorylation was not altered, but S6K phosphorylation and 
S6K total levels were increased compared to Wt mice (Fig. 5c). Interestingly, Otub1 
haploinsufficiency also led to an increase in phosphorylated S6K, but only in some of the 
tested animals (Fig. 5c), indicating a gene dosage-dependent effect. DEPTOR levels were 
decreased (Fig. 5c), which could explain the increase in phosphorylation of S6K and would be 
in line with a direct regulation of DEPTOR protein half-life by OTUB1. In summary, these 
results demonstrated that mTOR-dependent signalling was increased in OTUB1 deficient 
E18.5 lungs. 
In adult lungs with Otub1 KO, no difference in AKT phosphorylation was observed, but 
an increase in phosphorylated and total S6K levels (Fig. 5d) comparable to the results in E18.5 
lungs. DEPTOR levels showed a tendency to be increased (Fig. 5d). Because DEPTOR levels 
were differentially regulated between E18.5 and adult lungs with Otub1 KO, whereas 
phosphorylated and total S6K levels were affected in the same manner, DEPTOR may not 
play a major role in the observed effects in the lung. In adult Otub1 KO hearts, AKT 
phosphorylation was not altered, but S6K phosphorylation was increased and total S6K levels 
were decreased (Supplementary Fig. 4d). The observed alterations were not in complete 
agreement between the heart and the lung, indicating a tissue specific effect of Otub1. Overall, 
these findings demonstrate that Otub1 deletion leads to an increased activity of AKT/mTOR 
signalling in cells and tissues. 
The AKT/mTOR pathway is a major determinant of cellular metabolism [102, 104]. To 
analyse if the OTUB1-dependent effect on AKT/mTOR was functionally relevant, the 
metabolic energy status was compared between Wt and Otub1 KO MEFs. We observed a 
decrease in AMPK phosphorylation in Otub1-/- MEFs (Fig. 5e). Furthermore, ATP levels were 
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increased in the absence of Otub1 (Fig. 5f). These results were in agreement with an 
increased AKT activation in cells [105], indicating a functionally relevant regulation by OTUB1. 




Fig. 5: AKT/mTOR signalling in MEFs and mouse tissues with Otub1 deletion. a, 
Immunoblotting of the indicated (phospho)proteins (pAKT, pS6K) in Wt and Otub1 
homozygous KO (Otub1-/-) mouse embryonic fibroblasts (MEFs; n = 3) following the indicated 
(pre-)treatments (pre-treatment: 4 hours). b, DEPTOR protein levels in Wt and Otub1-/- MEFs 
(n = 3). c, Immunoblotting of the indicated (phospho)proteins in E18.5 mouse lung tissue 
lysates (n = 3). d, Immunoblotting of the indicated (phospho)proteins in lung tissue lysates 
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following 4 hours of starvation during the light cycle (5 months after Otub1 KO; 6.5 months old 
mice; n = 3). e, Immunoblotting of (phospho)AMPK in MEFs (n = 3). f, Intracellular ATP levels 
normalised to protein levels in MEFs (n = 4). Representative images are shown and all data 




Loss of Otub1 leads to a hypermetabolic state in vivo 
We hypothesised that a relevant regulation of cellular energy metabolism by OTUB1 would 
lead to a corresponding phenotype in vivo. Following five days of Tx treatment to ablate Otub1 
in adult mice, BW progression was monitored for 122 days. Mice with Otub1 gained around 
20 g in 127 days, while mice without Otub1 only gained around 11.5 g (Fig. 6a). The same 
mice showed a decreased fat/lean mass ratio 3 and 4.5 months after Otub1 KO (Fig. 6b). Both 
subcutaneous white adipose tissue (sWAT) and perigonadal (pgWAT) WAT were significantly 
decreased in mice lacking Otub1 (Fig. 6c). Interscapular brown adipose tissue (iBAT) was 
comparable between the groups (Fig. 6c). The liver weight was increased in mice with Otub1 
KO (Fig. 6c) without gross histological difference (Supplementary Fig. 5a). The quadriceps 
weight showed a tendency to be increased (Supplementary Fig. 5b). The brain weight was 
significantly increased, but the difference was rather small, while the weight of the spleen and 
kidneys was not altered (Supplementary Fig. 5b). Overall, these results showed weight 
changes in several organs that are important for energy metabolism in vivo. A reduced organ 
weight was only observed for WAT, suggesting that the reduced BW was due to a decreased 
WAT. 
Interestingly, despite a decreased BW gain, food and water intake showed a tendency 
to be increased in mice lacking Otub1 (Fig. 6d). In agreement with a higher intake, also the 
faeces weight and the urine volume were increased (Fig. 6d). The body temperature showed 
a tendency to be higher in mice lacking Otub1 (Fig. 6e). O2 consumption, CO2 production and 
energy expenditure were increased during the light cycle in Otub1 KO mice (Fig. 6f). The 
respiratory exchange ratio (RER) was not altered (Fig. 6f), indicating that the utilized nutrients 
for energy production were the same between the groups. In the dark cycle, comparable 
results were observed to the light cycle (Supplementary Fig. 5c). Overall, these results 
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demonstrated a hypermetabolic state in mice with Otub1 deletion, which was in agreement 
with an increased ATP production in MEFs (Fig. 5f). 
Mice with Otub1 KO showed a lower maximal exercise capacity than control mice 
(Supplementary Fig. 5d), but a similar lactate concentration despite a shorter running period 
(Supplementary Fig. 5e), demonstrating a comparable physical exhaustion. These results 
indicate that lactate was either produced at a higher rate or consumed at a lower rate following 
Otub1 ablation. 
Hypermetabolism can be caused by hyperthyroidism[106]. Plasma levels of thyroid-
stimulating hormone (TSH) are commonly used as primary read-out for thyroid 
dysfunction[106]. However, plasma TSH levels were not altered between the groups 
(Supplementary Fig. 5f), rendering a thyroid dysfunction unlikely as reason for the observed 
metabolic phenotype. 
In summary, Otub1 deletion in adult mice leads to a hypermetabolic state with reduced 
weight gain, decreased fat mass, increased nutrient and water intake combined with increased 
waste production as well as an increased energy expenditure and reduced exercise capacity. 
This metabolic phenotype was not caused by thyroid dysfunction. 
To further improve our understanding of the physiological role of OTUB1, 
haploinsufficient Otub1+/- mice were also analysed for a metabolic phenotype. Interestingly, 
the analysed group of Otub1+/- mice showed in most aspects the opposite regulation compared 
to mice with conditional Otub1 ablation. Otub1+/- mice had an increased BW and fat over lean 
mass ratio (Supplementary Fig. 6a-b). In the analysed group, excised sWAT, pgWAT and 
iBAT showed a tendency to be increased, whereas the liver weight was significantly decreased 
(Supplementary Fig. 6c). Food and water intake as well as faeces weight and urine volume 
showed a tendency to be decreased (Supplementary Fig. 6d). Indirect calorimetry 
demonstrated decreased O2 consumption, CO2 production and energy expenditure 
(Supplementary Fig. 6e,f). The RER was not significantly altered (Supplementary Fig. 6e,f). 
There was no histological difference observed in liver tissue (Supplementary Fig. 6g). In 
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summary, Otub1 haploinsufficiency in mice appears to lead to a hypometabolic state, but with 
a low penetrance. 
Maximal exercise capacity was decreased in the same Otub1+/- mice, with comparable 
lactate levels relative to control (Supplementary Fig. 6h), demonstrating a comparable 
physical exhaustion. This observation was similar to the results obtained in mice with induced 
Otub1 deletion despite an otherwise opposite regulation of energy metabolism. This indicates 
that the running time was not directly determined by the metabolic phenotype in these mice. 




Fig. 6: Energy metabolism in adult mice with induced Otub1 KO. a, Body weight gain after 
Otub1 KO during days 1-5 (n=5). b, Fat mass to lean mass ratio analysed by Echo-MRI in the 
mice shown in (a) at the indicated time after Otub1 KO (4.5 and 6 months of age; n = 5). c, 
Weight of indicated organs relative to BW (6 months after Otub1 KO; 8.5 months old mice; 
Veh, n = 10; Tx, n = 9). sWAT, subcutaneous WAT; pgWAT, perigonadal WAT; iBAT, 
interscapular brown AT. d, Food and water intake, faeces weight and urine volume over 72 
hours, collected in metabolic cages (4.5 months after Otub1 KO; 6 months old mice, n = 5). e, 
Rectal body temperature (2.5 months after Otub1 deletion; 5 months old mice; Veh, n = 6; Tx, 
n = 5). f, O2 consumption, CO2 production, energy expenditure (EE) and respiratory exchange 
ratio (RER) of 3 consecutive days during the light cycle (5 months after Otub1 deletion; 6.5 
months old mice; n = 5). All data are presented as mean ± SEM. *, p<0.05; **, p<0.01; ***, 
p<0.001 by two-way ANOVA with Bonferroni post-test (a) or two-tailed Student’s t-test (b-f). 
Exact P values: a, 85 days: 0.0230; 89 days: 0.0032; 92 days: 0.0084; 96 days: 0.0076; 99 
days: 0.0084; 103 days: 0.0026; 106 days: 0.0076; 110 days: 0.0023; 113 days: 0.0020; 117 
days: 0.0001; 120 days: <0.0001; 124 days: <0.0001; 127 days: <0.0001; b, 3 months after 
KO: 0.0342; 4.5 months after KO: 0.0146; c, sWAT: 0.0189; pgWAT: 0.0434; liver: 0.0191; d, 
0.0007; f, O2 consumption: 0.0291; CO2 production: 0.0071; EE: 0.0317. 
 
 
Otub1 deletion increases insulin-dependent signalling 
Next, we aimed to assess the underlying cause for the observed metabolic phenotype in adult 
mice with induced Otub1 KO. The AKT/mTOR pathway is activated by insulin and plays a key 
role in insulin-regulated metabolism[107]. In an intraperitoneal glucose tolerance test (IPGTT), 
Otub1 KO mice showed a faster glucose clearance than control mice (Fig. 7a). An 
intraperitoneal insulin tolerance test (IPITT) confirmed increased insulin sensitivity in mice with 
Otub1 deletion (Fig. 7b). Basal insulin levels (after 4 h of fasting) were decreased in Otub1 
KO mice (Fig. 7c). These results demonstrated increased insulin sensitivity in mice lacking 
Otub1. Haploinsufficient Otub1+/- mice (the same group that was analysed for the metabolic 
phenotype) showed a tendency towards decreased insulin sensitivity (Supplementary Fig. 7a-
c). 
Analysing AKT/mTOR signalling in the liver, no difference was observed in the 
phosphorylation of AKT or S6K under basal conditions (analysed 4 h after fasting; Fig. 7d). 
There was also no difference in AKT phosphorylation in heart and lung under basal conditions, 
and S6K phosphorylation was increased in both tissues (Fig. 5d and Supplementary Fig. 4d). 
But the same mice had decreased basal insulin levels (Fig. 7c). Therefore, a maintained or 
increased AKT/mTOR signalling in the presence of decreased basal insulin levels indicated 
an enhanced sensitivity of AKT/mTOR signalling to insulin-dependent stimulation when Otub1 
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was deleted. Consequently, we next analysed the response of AKT/mTOR signalling to insulin 
stimulation in vivo. 15 minutes after insulin injection, the phosphorylation of AKT on Ser473 
was increased in livers with Otub1 KO (Fig. 7e). The effect on AKT Thr308 was less clear (Fig. 
7e). The phosphorylation of S6K was not altered, but total levels of S6K showed a tendency 
to be decreased in both basal as well as stimulated conditions (Fig. 7d,e), indicating that 
additional regulation may have occurred. In the hearts of the same animals, phosphorylation 
of AKT Ser473 was also at least in some animals increased in response to insulin stimulation, 
which could also be observed for the phosphorylation of S6K (Supplementary Fig. 7d). 
The phosphorylation of ERK1/2, another insulin target[108], was not altered in the liver 
under basal conditions (Fig. 7d). In response to insulin stimulation, ERK1/2 phosphorylation 
was increased in livers with Otub1 KO (Fig. 7e), indicating that the OTUB1-dependent 
regulation of insulin signalling was either not confined to AKT/mTOR or occurred upstream of 
the bifurcation point of both signalling cascades. The phosphorylation of ERK1/2 showed a 
tendency to be decreased in hearts with Otub1 KO following insulin stimulation, again 
supporting a tissue-specific effect of Otub1 KO on cellular signalling pathways (Supplementary 
Fig. 7d). In summary, Otub1 deletion led to increased insulin sensitivity under basal and 
stimulated conditions, which likely contributed to the hypermetabolic state. 
  




Figure 7. Insulin sensitivity of adult mice with induced Otub1 KO. a, Intraperitoneal 
glucose tolerance test (IPGTT; 2 mg glucose/g BW; Veh, n = 4; Tx, n = 5) and b, IP insulin 
tolerance test (IPITT; 0.75 mU insulin/g BW; 4 months after Otub1 KO; 5.5 months old mice; 
n=5). c, Plasma insulin levels in the mice shown in a and b (5 months after Otub1 KO; 6.5 
months old mice; n = 5) following 4 hours of starvation during the light cycle. d, Immunoblotting 
of liver lysates from the mice in (c) (n = 3). e, Immunoblotting of liver lysates from mice (10 
days after Otub1 KO; 2 months old mice; n = 3) starved overnight (16 h) followed by IP insulin 
application (0.75 mU insulin/g BW) 15 min prior to tissue harvest. *, p<0.05; **, p<0.01; ***, 
p<0.001 by two-way ANOVA with Bonferroni post-test (a, b) or two-tailed Mann-Whitney t-test 
(c). Exact P values: a, 15 min: 0.0131; 30 min: <0.0001; 45 min: 0.0003; b, 30 min: 0.0056; c, 
0.0159.  




We provide in vivo evidence that the DUB OTUB1 is essential for embryonic development, 
respiration, lung and heart tissue homeostasis, cardiac function and energy metabolism. 
Previous investigations of OTUB1 in mice focussed on the relevance of OTUB1 for specific 
immune cells and/or a cell type-specific role of OTUB1 during inflammation[87-90]. Our 
analyses of mice with whole-body Otub1 deletion indicate that the general physiological 
function of OTUB1 differs from its specific role in immune cells and during inflammation. 
 We propose that the failure of Otub1-/- mice to inflate their lungs is caused by the 
observed increased proliferation and decreased saccular air space, which may augment the 
lung tissue resistance against mechanical stretch. In adult mice, OTUB1 is important for the 
control of the oxygen-dependent regulation of respiration. Therefore, OTUB1 may play a key 
role in oxygen sensing by the carotid body, the main sensor of arterial oxygenation regulating 
lung function[109]. Future investigations should assess if Otub1 deletion specifically in the 
carotid body contributes to the perinatal lethality. 
 Cells derived from mice lacking Otub1 showed increased ATP levels and a decreased 
AMPK phosphorylation, which corresponds with our previous observation that OTUB1 
overexpression elevates AMPK phosphorylation[85]. Otub1-/- embryos were lighter and 
smaller than their littermates, which may at least in part be caused by an altered energy 
metabolism. In adult mice, our results show that OTUB1 defines a set-point for whole-body 
glucose metabolism, with Otub1 deletion leading to increased glucose utilization and a 
hypermetabolic state. 
Lack of Otub1 generally enhanced AKT/mTOR signalling in MEF cells and in all 
investigated organs, although the detailed underlying mechanisms somewhat differed. The 
variability may be explained by the presence of different stimuli of the AKT/mTOR signalling 
pathway which is not exclusively regulated by insulin[102, 104]. AKT/mTOR signalling affects 
cellular ATP levels and AMPK phosphorylation[105], controls body weight and size during 
development[101], and plays a key role in lung development[97, 98]. Increased AKT/mTOR 
signalling causes death by respiratory failure following caesarean section at E18.5[92]. In adult 
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mice, increased AKT/mTOR signalling leads to decreased body weight and fat mass, 
increased oxygen consumption, improved glucose clearance and insulin sensitivity as well as 
decreased serum insulin levels[110, 111]. In the heart, enhanced AKT/mTOR signalling leads 
to cardiac hypertrophy[100, 101]. Inhibition of AKT and ERK1/2 signalling decreased the 
response of the carotid body to hypoxia[99]. Of note, OTUB1 directly regulates the 
phosphorylation of AKT in CD8+ T and NK cells following IL-15 stimulation and Otub1 deletion 
led to increased phosphorylation of AKT and S6K in these cell types[90]. OTUB1 furthermore 
regulates DEPTOR, a negative regulator of mTORC1 and 2[96]. Therefore, we conclude that 
OTUB1 is a negative regulator of AKT/mTOR signalling and that an increased AKT/mTOR 
signalling underlies at least in part the observed phenotypes in mice with Otub1 deletion. 
 While Otub1 haploinsufficiency neither affected embryonic development nor 
respiratory or cardiac function, at least some animals showed changes in energy metabolism, 
indicating that tissues important for the regulation of energy metabolism have a higher 
sensitivity to a partial loss of Otub1 than the lung or the heart. The observed decrease in 
energy metabolism in Otub1 hypomorphs is in contrast to the hypermetabolic state in mice 
with a (nearly) complete loss of Otub1 and demonstrates an unexpected gene dosage-
response curve of OTUB1. A similar gene dosage-response curve has previously been 
described for a negative regulator of PI3K/AKT/mTOR signalling, the phosphatase and tensin 
homolog located on chromosome 10 (PTEN). The partial loss of PTEN leads to spontaneous 
tumor development in mice, but a complete PTEN deletion can obstruct tumor growth[112]. 
Because the metabolic phenotype showed a low penetration in Otub1+/- mice, OTUB1-
dependent regulation of energy metabolism may not only depend on OTUB1 protein levels 
but likely also on additional mechanisms. Previously, it was shown for another regulator of 
AKT/mTOR signalling, the IQ motif containing GTPase activating protein 1 (IQGAP1), that its 
effect on AKT/mTOR is governed by the input of different stimuli. IQGAP1 can increase or 
decrease AKT/mTOR activity and downstream insulin synthesis as well as secretion, 
depending on the available amount of nutrients in concert with EGF-dependent 
signalling[113]. For OTUB1, it was shown that its interaction with DEPTOR is partially 
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dependent on amino acid availability[96]. We showed that O2 availability can regulate OTUB1 
interactions and enzymatic activity[83, 85]. The OTUB1-dependent effect on AKT/mTOR 
signalling may hence integrate different stimuli depending on the OTUB1 protein levels. 
We previously reported that the oxygen sensor FIH regulates cellular energy 
metabolism through hydroxylation of OTUB1[85]. Mice lacking the gene encoding FIH (Hif1an) 
present with a decreased body weight gain, a decreased fat mass, increased insulin 
sensitivity, increased food and water intake as well as increased O2 consumption, CO2 
production and energy expenditure, while maintaining the RER[114]. Furthermore, Hif1an 
deletion led to hyperventilation[114]. While not lethal, these phenotypes of Hif1an KO mice 
are otherwise identical with our observations in Otub1 KO mice, supporting our hypothesis 
that FIH is an important regulator of OTUB1[83, 85]. 
In summary, OTUB1 has multiple physiological roles, ranging from its essential 
function during embryonic development to the control of respiratory and cardiac function as 
well as general energy metabolism. These results highlight the physiological relevance of this 
DUB and indicate that pharmacologic targeting of OTUB1 – as for example suggested for 
cancer treatment[91] - may not be without severe side effects. Furthermore, our findings may 
help identifying previously unknown causes of developmental, respiratory and heart diseases 
as well as metabolic disorders.  





Mice with heterozygous Otub1 deletion (Otub1+/-, strain C57BL/6N-Otub1tm1b(EUCOMM)Hmgu/H) 
were purchased from the EUCOMM consortium (http://www.mousephenotype.org; via the 
EMMA repository, https://www.infrafrontier.eu/) [115] and bred to generate Otub1-/- mice (Fig. 
1a). Mouse Contract Services were provided by the Mary Lyon Centre at MRC Harwell 
(http://www.har.mrc.ac.uk; UK). Wildtype mice (Wt; C57BL/6N, Charles River, MA, USA) were 
used for maintenance breeding with Otub1+/- mice. Mice with induced whole-body Otub1 
(wbOtub1-/-) deletion were generated by crossing heterozygous mice with potential of 
conditional Otub1 deletion (pcOtub1+/-; strain Otub1tm1a(EUCOMM)Hmgu/lcsORl; purchased from the 
EUCOMM consortium via the EMMA repository and provided by the Institut Clinique de la 
Souris, ICS, Illkirch, France) with Flp deleter mice (129S4/svJaeSor-
Gt(Rosa)26Sortm1(FLP1)Dym), leading to the removal of the inserted lacZ gene and neomycin 
cassette and resulting in mice with floxed Otub1 exons 2 and 3 (Otub1fl/fl; Fig. 3a). Otub1fl/fl 
mice were crossed with mice carrying one copy of a CreERT2 transgene under the control of 
the ubiquitin C promoter (UBC-CreERT2; strain B6.Cg-Ndor1Tg(UBC-cre/ERT2)1Ejb/2J; purchased from 
The Jackson Laboratory; https://www.jax.org/strain/008085). For the induction of Otub1 
deletion, Otub1fl/fl x UBC-CreERT2 (Otub1fl/fl+Cre) mice were treated with 200 g of tamoxifen/g 
BW (Sigma-Aldrich, St. Louis, MO, USA). Mice were maintained at a constant ambient 
temperature (21±1°C) with 12 hours light/dark cycles, standard chow diet (Provimi Kliba, 
Gossau, Switzerland) and water available ad libitum under optimal hygienic conditions (OHC), 
unless indicated otherwise. Both genders were used for the investigations of developmental 
phenotypes, in adult mice female mice were analysed. All animal experiments were approved 
by the veterinary office of the canton Zurich, Switzerland. 
 
Cell culture 
MDA-MB468 (breast cancer), HepG2 and Hep3B (hepatocarcinoma), Caco-2 (colon 
carcinoma) as well as HEK293 (immortalized kidney) cells were cultured in DMEM (Sigma-
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Aldrich) containing 4.5 mM sodium pyruvate, glucose and L-glutamine (Sigma-Aldrich), 
supplemented with 10% heat-inactivated fetal calf serum (FCS; Gibco by Life Technologies, 
Carlsbad, Ca, USA), 100 g/ml streptomycin (S) and 100 U/ml penicillin (P; Sigma-Aldrich). 
SUM149PT (breast cancer) cells were cultured in 50% DMEM and 50% RPMI (Sigma-Aldrich) 
supplemented with 10%FCS and 100 g/ml S and 100 U/ml P. AB8/13 cells (kidney) were 
cultured in RPMI supplemented with 10% FCS, 50 IU/ml P, 50 μg/ml S, supplemented with 5 
μg/ml insulin, 5 μg/ml transferrin and 5 ng/ml sodium selenite (Roche, Mannheim, Germany). 
AB8/13 cells were propagated at 33°C and differentiated for 10-14 days at 37°C. Kelly 
(neuroblastoma) cells were cultured in RPMI, 10% FCS, 100 g/ml S and 100 U/ml P. If not 
otherwise indicated, cells were maintained under standard conditions (humidified atmosphere 
at 37ºC with 18.5% O2 and 5% CO2). Wt and Otub1 KO mouse embryonic fibroblasts (MEFs) 
were obtained at day 12.5 of gestation. MEFs were cultured in DMEM containing 10% FCS, 
1% GlutaMAX (Gibco), 200 M 2-mercaptoethanol (Gibco), 100 g/ml S and 100 U/ml P and 
maintained at 5% O2. For transient transfection of cells, Lipofectamine 2000 reagent 
(Invitrogen) or polyethylenimine (PEI; Polysciences, Warrington) was used as described 
previously[116]. For FCS and/or amino acid deprivation, MEFs were kept in RPMI 1640 
medium containing glucose but no FCS or amino acids for 4 hours. To reintroduce FCS, the 
media was exchanged with RPMI 1640 containing 10% FCS and the cells were harvested at 
the indicated time points. 
 
Protein extraction and determination of protein concentration 
Protein extraction was performed with lysis buffer containing 150 mM NaCl, 1 mM EDTA, 25 
mM Tris-HCl pH 8.0, 1% NP-40, 1 mM Na3VO4, 1 mM PMSF and 1 mM NaF. For cell lysis, 
protease inhibitor cocktail (Sigma-Aldrich) was added to the lysis buffer. For tissue lysis, 1 
g/ml aprotinin, 1 g/ml leupeptin and 1 g/ml pepstatin A were included in the lysis buffer, 
and tissue samples were homogenised using a polytron homogenizer (VWR International, 
Amsterdam, Netherlands). For the analysis of insulin-dependent signaling in vivo, mice were 
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intraperitoneally injected with 0.75 U/kg insulin, following an overnight fasting period. Organs 
were harvested 15 minutes after injection and proteins were extracted. For the analysis of 
polyubiquitin chains, the deubiquitinase inhibitor[117] N-ethylmaleimide (50 mM; Sigma-
Aldrich) was added to the lysis buffer. Protein concentrations were determined by the BCA 
assay (Thermo Fisher Scientific, Waltham, MS, USA). 
 
RNA analyses 
RNA was extracted from tissues using the guanidine thiocyanate-acid phenol-chloroform 
method as previously described[118]. The RNA was converted to cDNA by reverse 
transcription of 2 g of total RNA using AffinityScript transcriptase (Agilent, Santa Clara, CA, 
USA). The cDNA was analysed using the SYBR Green qPCR reagent kit (Kapa Biosystems, 
London, UK) in a MX3000P light cycler (Agilent). Transcript levels were normalised to mouse 
ribosomal protein S12 mRNA levels. OTUB1 RNA-sequencing data from human organs were 
extracted from a previous analysis[119]. 
 
ATP assay 
Intracellular ATP levels were measured with the CellTiter‐Glo 2.0 Assay according to the 
manufacturer's description (Promega, Madison, WI, USA). Cells were lysed with Passive Lysis 
Buffer (Promega) and diluted 1:100 in cell culture media. Samples were mixed with equal 
amounts of CellTiter‐Glo 2.0 reagent for 2 minutes on an orbital shaker followed by additional 
10 minutes of incubation at room temperature. Luminescence was determined in a microplate 
luminometer (Berthold Technologies, Bad Wildbach, Germany) and normalized to protein 
concentration determined by the Bradford method[120]. 
 
Cell proliferation analysis 
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Stably transfected HEK293 cells (shControl, shRNA targeting OTUB1 or shRNA targeting 
OTUB1 + Flag-OTUB1)[34, 85] were seeded and counted every 24 hours with the Vi-Cell XR 
cell counter (Beckham, Indianapolis, IN, USA). 
 
Plasmids and siRNAs 
The plasmid encoding human FLAG-OTUB1 was generously provided by Dr. Mu-Shui Dai 
(Oregon Health & Science University, Portland, OR, USA)[121]. Nontargeting siRNA (siNT, 5’-
GCUCCGGAGAACUACCAGAGUAUUATT-3’) and siRNA targeting the 3’UTR of hOTUB1 
(siOTUB1, 5’-GUGGUUGUAAAUGGUCCUATT-3’) were previously described[83, 121] and 
were purchased from Microsynth (Balgach, Switzerland). 
 
Immunoblot analysis 
Equal protein amounts were separated by SDS-PAGE, transferred to nitrocellulose or 
polyvinylidene difluoride membranes and detected using anti-FIH (Novus Biologicals, Littleton, 
CO, USA; npb1-3033), anti-OTUB1 (Cell Signaling, Danvers, MA, USA; 3783), anti-DEPTOR 
(Novus Biologicals; nbp1-49674), anti-p70 S6 kinase (Cell Signaling; CST9202), anti-
phospho-p70 S6 kinase (Cell Signaling; 9234), anti-Akt (pan; Cell Signalling; 2920), anti-
phospho-Akt (Ser473; Cell Signaling; 4060), anti-phospho-Akt (Thr308; Cell Signalling; 2965), 
anti-p44/42 MAPK (Erk1/2; Cell Signaling, 4695), anti-phospho-p44/42 MAPK (Erk1/2; 
Thr202/Tyr204; Cell Signaling; 4376), anti-AMPK (Cell Signaling; 2603), anti-phospho-AMPK 
(Thr172; Cell Signaling; 2535), anti-poly-ubiquitin (clone P4D1; Cell Signaling; 3936), anti-
Lys48-linked poly-ubiquitin chains (Millipore, Darmstadt, Germany; 05-1307), anti-Lys-63-
linked poly-ubiquitin chains (Millipore; 05-1308), anti--actin (Sigma-Aldrich; A5441), anti--
tubulin (Cell Signaling; 2144), anti-SMC1 antibodies (Abcam, Cambridge, UK; 9262) and 
horseradish peroxidase (HRP)-coupled secondary antibodies (Thermo Fisher Scientific; 
31430, 31460). Chemiluminescence detection was performed with Supersignal West Dura 
(Thermo Fisher Scientific) and recorded with a CCD camera (LAS-4000; GE Healthcare, 
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Chalfont, St. Giles, UK) as previously described[116]. Quantification was perfomed with 
ImageQuant TL gel analysis software (GE Healthcare, Version 8.1). 
 
Lung inflation test 
The trachea of P0 mice was tied shut, the lung was excised and its floatability was tested in 
PBS. Inflated lungs float, non-inflated lungs sink. 
 
Tissue staining 
Organs were fixed in 4% formaldehyde for 24 hours (Sigma-Aldrich). The sections were 
deparaffinised with xylene and rehydrated with decreasing concentrations of ethanol in water. 
Tissue sections (3-5 m thick) were stained with haematoxylin and eosin (H&E), periodic acid-
schiff (PAS), fluorescein isothiocyanate-coupled wheat germ agglutinin (FITC-WGA; Sigma-
Aldrich) or subjected to immunohistochemistry (IHC) for cleaved caspase 3 (Asp175; Cell 
Signaling; 9664), SP-C (Santa Cruz Biotechnology, Dallas, TX, USA; sc-13979), Ki67 
(Ventana Medical Systems, Tucson, AZ, USA; 790-4286) or CD31 (Santa Cruz Biotechnology; 
sc-1506R). Discovery XT research instrument (Ventana Medical Systems) was used for the 
detection of cleaved caspase 3 and Ki67. An autostainer (Dako) was employed for SP-C and 
CD31. All antibody blocking steps were performed with H2O2 (Dako) and REAL Antibody 
Diluent (Dako). Conditioning 1 pre-treatment (Cell conditioning 1 (CC1), Ventana Medical 
Systems) was used for the antigen retrieval for subsequent analysis with the Discovery XT 
systems and antigen retrieval with EDTA buffer (pH 9) was used for the Dako autostainer. For 
IHC signal detection, HRP-coupled secondary antibodies were used (Ventana Medical 
Systems; 760-4311; Jackson ImmunoResearch; 711-065-152) together with DAB substrate 
buffer (Dako, Glostrup, Denmark; K3468). Quantification was performed with ImageJ 1.53a 
(NIH, MD, USA)[122, 123]. Lipidosis and extramedullary hematopoiesis (EMH) analyses were 
performed by a certified mouse pathologist in a blinded manner using PAS-stained livers (0, 
no abnormality; 1, minimal abnormality; 2, mild abnormality; 3, moderate abnormality; 4, 
severe abnormality; 5, very severe abnormality). 




Transmission electron microscopy (TEM) 
Tissue samples of the cranial right lung lobe were fixed for 24 hours in 2.5% glutaraldehyde 
in 0.2 M sodium phosphate buffer (pH 7.3) for TEM examination in the TEM Unit (Institute of 
Veterinary Pathology, Laboratory for Animal Model Pathology, University of Zurich). Briefly, 
specimens were washed in sodium phosphate buffer and fixed in 1% osmium tetroxide in 
phosphate buffer/distilled water for 60 min. Tissues were dehydrated in ascending 
concentrations of ethanol, followed by propylene oxide. Specimens were subsequently 
infiltrated with 50% resin (Epoxy embedding medium, Sigma Aldrich, Germany) and incubated 
overnight. The tissues were then incubated in polyethylene embedding capsules filled with 
100% resin for 3 days. Semi-thin sections (1 m) were prepared using an ultramicrotome 
(Reichert-Jung Ultracut, Munich, Germany) with a diamond knife (Diatome, Biel, Switzerland), 
stained with toluidine blue and areas of interest for the preparation of ultrathin sections were 
chosen under the light microscope. Ultrathin sections (90 nm) were prepared with a diamond 
knife, mounted on copper grids, stained with uranyl acetate and Reynold’s lead citrate and 
examined with a transmission electron microscope (Philips CM10, FEI, Thermo Fisher 
Scientific) operating with a Gatan Orius Sc1000 digital camera (Digital Micrograph, Gatan, 
Pleasanton, CA, USA). 
 
Blood pressure measurement 
Heart rate, systolic and diastolic blood pressure were measured with a tail‐cuff system 
(Visitech Systems, Apex, NC, USA) in restrained mice. Mice were acclimatised during 5 days 
prior to the beginning of the experiment. For each mouse, 20 consecutive measurements were 
analysed. The experiment was performed between 2 and 4 hours after the beginning of the 
light cycle at 37°C. 
 
Maximal acute exercise capacity 
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Mice were run on a Simplex II metabolic rodent treadmill (Columbus Instruments, Columbus, 
OH, USA). Following 1 hour of acclimatization on the previous day, each mouse was placed 
in a closed individual treadmill lane during 15 minutes without exercise. The exercise was 
started at 6 m/min at 0° inclination and the intensity was increased every minute by 1 m/minute 
and every two minutes by 5° inclination, until reaching 20° inclination. The mice were 
stimulated to run until exhaustion by a mild electric shock (1 mA, pulse 200 ms, 1 Hz) 
experienced on a shock grid at the bottom of the running belt. Complete exhaustion of a mouse 
was reached when the mouse spent more than 3 consecutive seconds on the shock grid or 
jumped more than 3 times on the shock grid without reengaging the treadmill. Prior to and 
immediately after the experiment, blood samples were taken and analysed for lactate levels 
using the StatStrip Xpress Lactate Meter (Nova Biomedical, Waltham, MA, USA). 
 
Intraperitoneal glucose tolerance test (IPGTT) 
After fasting for 16 hours over night, 2 mg of glucose/g BW (20% w/v; Braun, Hessen, 
Germany) were intraperitoneally injected into the mice. Blood samples from the tip of the tail 
were analysed after the indicated time points using a StatStrip Xpress Glucose Meter (Nova 
Biomedical). 
 
Intraperitoneal insulin tolerance test (IPITT) 
Following fasting for 16 hours over night, mice were intraperitoneally injected with 0.75 IU/kg 
BW (Lilly Humalog, Indianapolis, IN, USA). Blood glucose levels were measured in blood from 




Basal insulin levels were determined in plasma taken from mice starved for 4 hours during the 
light cycle using an anti-insulin enzyme-linked immunosorbent assay (ELISA) following the 
manufacturer’s description (Mercodia, Uppsala, Sweden). Thyroid-stimulating hormone (TSH) 
 Manuscript I: submitted 
140 
 
plasma values were analysed with an anti-TSH ELISA following the manufacturer’s description 
(Cloud-clone Corporation, Katy, TX, USA). Absorbance was determined with a microplate 
reader (Infinite 200 Pro, Tecan, Maennedorf, Switzerland). 
 
Body composition analysis 
An EchoMRI whole body composition analyser was used to analyse lean and fat mass non-




Basal respiration as well as the adaptation of respiration to hypoxia were assessed in 
unrestrained conscious mice using a whole-body plethysmograph and BioSystem XA software 
(Buxco Research Systems, Wilmington, NC, USA). Each mouse was placed in a 1 dm3 
chamber and allowed to adapt for 1 hour. Respiratory parameters were analysed over a 5 
minute interval at 21% O2 and during the first 5 min after reaching 10% O2 (referred to as 
“early”). In addition, the respiration was assessed after 25-30 min at 10% O2 (referred to as 
“late”). To exclude measurements of non-basal respiration, data was not taken into account if 
at least 3 consecutive respiratory frequencies showed a variability of above 70 breaths/min 
and/or a total frequency of 400 breaths/min or above. 
 
Indirect calorimetry 
Animals were single housed in acrylic glass airtight metabolic cages attached to an open 
calorimetry system (TSE Systems, Bad Homburg, Germany). Food and water were provided 
ad libitum. O2 consumption and CO2 production were measured during 3 days and the average 
was calculated. Energy expenditure (EE) was calculated according to the Weir equation and 
normalised to the corresponding lean mass + 0.2 times the fat mass, as determined by body 
composition analysis by EchoMRI[124, 125]. 
 




Mouse echocardiography including tissue Doppler imaging (TDI) was performed under 
isofluorane anesthesia with a high resolution Micro-Ultrasound System (Vevo 3100, 
Visualsonics, Toronto, ON, Canada) as previously described[94]. The myocardial 
performance index (MPI) was calculated as: MPI = (isovolumetric contraction time [IVCT] + 
isovolumetric relaxation time [IVRT])/aortic ejection time (AET)[94]. 
 
Food/water intake, urine/faeces production 
Mice were single housed in metabolic cages with grid surfaces (Techniplast, Schwerzenbach, 
Switzerland) and food, water, urine, faeces and BW were monitored every 24 hours for 72 
hours. Urine was collected under light mineral oil (Sigma-Aldrich) to avoid evaporation. 
 
Genotyping primers 
Otub1+/- and Otub1-/-: 
Otub1-5arm-WTF:  5'-TAGATGCTACACAGTGCTTTTAGA-3' 
Otub1-Ctrl-WTR:  5'-TTAGAGATCAGCTCTGGAAATATAG-3' 
5mut-R1: 5'-GAACTTCGGAATAGGAACTTCG-3' 
pcOtub1 KO+/-: 
Kr_3209:  5'-CCAACAGCTTCCCCACAACGG-3' 
Ef_5272: 5'-TCCACCCCTTCATCCTGCTTTCT-3' 
Otub1fl/fl: 
Ef_5272:  5'-TCCACCCCTTCATCCTGCTTTCT-3' 
Er_5277:  5'-CAGACCAGAGCAGGATTAAGAAGCCTA-3' 
UBC-CreERT2: 
UBCre 25285:  5'-GACGTCACCCGTTCTGTTG-3' 
UBCre-oIMR7338: 5'-CTAGGCCACAGAATTGAAAGATCT-3' 
UBCre-oIMR7339: 5'-GTAGGTGGAAATTCTAGCATC-3' 






L3r_ 5274: 5'-TCTACCCATCCCAACACCAGCAAG-3' 
loxP: 
Primer 1307 forw: 5'-GGCAGAAGCACGCTTATCG-3' 






For the statistical analysis between two different data points, two-tailed Student’s t-test or 
Mann-Whitney test were applied as indicated. Comparison of more than two data points 
included One-Way ANOVA followed by Tukey post-test analysis or Two-Way ANOVA followed 
by Bonferroni post-test as indicated. 
 
Data availability 
All main data of this study are included in the main part of the manuscript or supplementary 
information. All underlying raw data will be available on https://datadryad.org/ upon 
acceptance of this article and the accession code will be inserted in this paragraph prior to 
publication.  
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Supplementary Figure 1. OTUB1 tissue expression levels and developmental effects of 
Otub1 deletion. a, Human OTUB1 RNA-sequencing analysis of the indicated organs [119]. 
b, Immunoblot analysis of OTUB1 protein levels in the indicated human cancer cell lines. α-
Tubulin served as loading and blotting control. c, Immunoblotting of OTUB1 in murine Wt 
tissues. Ponceau S staining of the membrane served as loading and blotting control. BAT, 
brown adipose tissue; WAT, white adipose tissue. d, H&E staining of sagittal sections of Wt, 
Otub1+/- and Otub1-/- mice (E18.5). e, Otub1+/- (n=27) and Otub1-/- (n=14) liver and lung weight 
corrected for BW and normalised to the corresponding Wt littermates (E18.5). The dashed line 
indicates Wt littermates. f, Transmission electron microscopy of lung tissue from Wt and 
Otub1-/- mice (E18.5). lb, lamellar body; m, mitochondrium; n, nucleus. g, Cell proliferation 
analysis of HEK293 cells stably co-transfected with shRNA targeting OTUB1 (shOTUB1) 
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together with an empty vector (control), or shOTUB1 together with an expression construct for 
FLAG-OTUB1, or an shRNA without target (shCtrl) together with the empty control vector 
(n=3). Representative pictures of three independent experiments are displayed. All data are 
shown as mean ± SEM. *, p < 0.05 by Student’s t-test. Exact P values: g, 3 days shCtrl + 
Control versus shOTUB1 + Control: 0.0267; 4 days shCtrl + Control versus shOTUB1 + 
Control: 0.0402. 
  




Supplementary Figure 2. Efficiency of induced Otub1 KO and lung function analysis in 
Otub1+/- mice. a, OTUB1 protein levels were analysed by immunoblotting 5 months after the 
induction of Otub1 deletion. pgWAT, perigonadal white adipose tissue; iBAT, interscapular 
brown adipose tissue. b, Consecutive analysis of the lung function of unrestrained Wt (n = 5-
8) Otub1+/- mice (6 months old mice; n = 7-8) determined by barometric pressure 
plethysmography in normoxia (21% O2) and hypoxia (10% O2). Vt, tidal volume; VI, minute 
volume; early, first 5 min in hypoxia. c, Lung weight normalised to BW of Wt (n=10) and 
Otub1+/- (n=9) mice (10 months old). Representative pictures of three independent 
experiments are displayed. All data are shown as mean ± SEM. #, p < 0.05; ##, p < 0.01 by 
Student’s t-test compared to the corresponding analysis of the same mice in normoxia. Exact 
P values: b, Vt 10% O2 early Wt versus Vt 21% O2 Wt: 0.0015; Vt 10% O2 early Otub1+/- versus 
Vt 21% O2 Otub1+/-: 0.0295; VI 10% O2 early Otub1+/- versus VI 21% O2 Otub1+/-: 0.0037. 
  




Supplementary Figure 3. Cardiac function in mice with Otub1 KO. a-i, Echocardiography 
of the fractional shortening (a), left ventricular end diastolic diameter (LVEDD) (b), left 
ventricular end systolic diameter (LVESD) (c), left ventricular end diastolic volume (LVEDV) 
(d), left ventricular end systolic volume (LVESV) (e), aortic ejection time (AET) (f), isovolumic 
contraction time determined by tissue Doppler imaging (IVCTTDI) (g), isovolumic relaxation 
time determined by tissue Doppler imaging (IVRTTDI) (h) and the myocardial performance 
index determined by tissue Doppler imaging (MPITDI) (i) at the indicated time points after Otub1 
KO (3.5 and 6.5 months of age; Veh, n = 9-10; Tx, n = 8-9). j, Heart weight normalised to tibia 
length (3.5 months after Otub1 KO; Otub1fl/fl + Cre + Veh, n = 6; Otub1fl/fl - Cre + Tx, n = 8; 
Otub1fl/fl + Cre + Tx, n = 5). k-y, Echocardiography of the left ventricular mass (LVM) (k), IVRT 
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(l), isovolumic contraction time (IVCT) (m), myocardial performance index (MPI) (n), E and A 
myocardial velocities ratio (E/A) (o), ejection fraction (p), LVEDD (q), LVESD (r), LVEDV (s), 
LVESV (t), fractional shortening (u), AET (v), IVCTTDI (w), IVRTTDI (x) and MPITDI (y) in the 
indicated mice (10 months old; Wt, n = 9-10; Otub1+/-, n = 9). z, Heart weight normalised to 
tibia length and aa, wet over dry lung ratio in Wt (n=10) and Otub1+/- (n=9) mice (10 months 
old). ab, Immunohistochemistry of transversal heart sections with anti-Ki67 antibody and 
subsequent quantification (3.5 months after Otub1 deletion, 5.5 months of age; n=3). All data 
are shown as mean ± SEM. *, p < 0.05 by Student’s t-test. Exact P values: a, 4 months KO: 
0.0164; g, 4 months KO: 0.0023; h, 1 month KO: 0.0073; 4 months KO: <0.0001; i, 1 month 
KO: 0.0345; 4 months KO: <0.0001; j, +Cre -Tx versus +Cre +Tx: 0.0486.  




Supplementary Figure 4. Protein levels in mouse embryonic fibroblasts and hearts with 
homozygous Otub1 deletion. a,b, Immunoblotting of the indicated proteins in Wt and Otub1-
/- MEFs (n = 3). K63-Ub, K63-linked ubiquitin chains; K48-Ub, K48-linked Ub chains. c,d, 
Immunoblotting of the indicated proteins in heart tissue from mice with the indicated genotype 
and treatment 3.5 (c) or 6 (d) months after Otub1 deletion (n = 3).  




Supplementary Figure 5. Energy metabolism in mice with induced Otub1 ablation. a, 
Representative PAS staining of transversal liver slices with scored lipidosis levels and 
extramedullary hematopoiesis (EMH) assessed 5 months after Otub1 deletion (5 months after 
Otub1 deletion; 6.5 months old mice, n=3). b, Weight of the indicated tissues normalised to 
BW (5 months after Otub1 deletion; 6.5 months old mice, n=5). c, Averaged O2 consumption, 
CO2 production, energy expenditure (EE) and respiratory exchange ratio (RER) of 3 
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consecutive days during the night cycle (5 months after Otub1 deletion; 6.5 months old mice; 
n=5). d, Total running time during a maximal exercise capacity analysis (3 months after Otub1 
deletion; 4.5 months old mice; Otub1fl/fl + Cre + Veh, n = 6; Otub1fl/fl - Cre + Tx, n = 8; Otub1fl/fl 
+ Cre + Tx, n = 5). e, Blood lactate analyses prior to and following the maximal exercise shown 
in (d). f, Thyroid-stimulating hormone (TSH) plasma levels (5 months after Otub1 deletion; 6.5 
months old mice; n=5). *, p < 0.05; **, p<0.01; ***, p<0.001 by Student’s t-test. Exact P values: 
b, brain weight: 0.0460; d, +Cre -Tx versus +Cre +Tx: 0.0033; -Cre +Tx versus +Cre +Tx: 
0.0005; e, +Cre -Tx: 0.0006; -Cre +Tx: <0.0001; +Cre +Tx: 0.0102.  




Supplementary Figure 6. Energy metabolism in adult Otub1+/- mice. a, Age-dependent 
weight development of Otub1+/- mice (n=8) b, Fat mass to lean mass ratio analysed by Echo-
MRI in the same mice as shown in (a). c, Organ weight relative to BW in the same mice as 
shown in (a, b) (12 months of age; n = 7). d, Averaged food and water intake, faeces weight 
and urine volume over 72 hours, collected in metabolic cages (9.5 months of age; Wt, n = 5-
8; Otub1+/-, n = 8). e, O2 consumption, CO2 production, energy expenditure (EE) and 
respiratory exchange ratio (RER) of three consecutive days during the dark and f, light cycle 
(11.5 month old mice; Wt, n = 6; Otub1+/-, n = 8). g, Representative PAS staining of transversal 
liver slices with scored lipidosis levels and extramedullary hematopoiesis (EMH) assessed in 
4 month old mice (n=3). h, Total running time and blood lactate measurements before and 
after maximal exercise capacity analyses (7 month old mice; n = 8). All analyses were 
performed with the same group of mice. *, p < 0.05; **, p<0.01; ***, p<0.001 by Student’s t-
test. Exact P values: a, 0.032; b, 5 months: 0.0181; 7 months: 0.0295; 9 months: 0.0465; c, 
liver weight: 0.0283; e, CO2 production: 0.0322; EE: 0.0216; f, O2 consumption: 0.0237; CO2 
production: 0.0046; EE: 0.0172; h, running time: 0.0018; blood lactate: Wt: <0.0001; Otub1+/-
: 0.0005. 




Supplementary Figure 7. Insulin sensitivity in mice with Otub1 KO. a, Intraperitoneal 
glucose tolerance test (IPGTT; 2 mg glucose/g BW) and b, intraperitoneal insulin tolerance 
test (IPITT; 0.75 mU insulin/g BW) in 7 month-old mice (n = 7-8). c, Plasma insulin levels 
determined in 7 month-old mice (n = 8). d, Immunoblotting of heart lysates from mice (10 days 
after Otub1 KO; 2 months old) starved overnight (16 h) followed by insulin IP application (0.75 
mU insulin/g BW) 15 min prior to tissue harvest (Veh, n = 3; Tx, n = 4). *, p < 0.05 by two-way 
ANOVA with Bonferroni post-test (a,b) or Student’s t-test (c). Exact P values: c, 0.0105. 
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5. Conclusions and future perspectives 
Protein ubiquitination plays a crucial role in a plethora of physiological processes, such as cell 
apoptosis, cell metabolism and inflammation [127]. DUBs negatively regulate ubiquitination 
and are currently investigated as possible novel therapeutic targets. This possible role of the 
DUBs is especially due to their role as regulators in cancer, chronic inflammation or 
autoimmune disorders [128]. However, further understanding of the function and regulation of 
DUBs is necessary to understand their mechanism of action. One of the most highly expressed 
DUBs in cells is OTUB1 [20, 72]. Remarkably, OTUB1 possesses both catalytic and non-
catalytic activities. Through its catalytic activity, OTUB1 cleaves Lys48-linked polyubiquitin 
chains [22, 129]. Non-catalytically, OTUB1 inhibits the formation of Lys48- and Lys63-linked 
polyubiquitin chains by the inhibition of E2 ubiquitin-conjugating enzymes [19, 24, 25, 130]. 
OTUB1 participates in diverse cellular processes including fibrosis [19], inflammation [77-79], 
DNA repair [24], apoptosis [77] and proliferation [80]. We previously showed that OTUB1 is 
also the substrate of the oxygen-sensing factor FIH, which hydroxylates OTUB1 Asn 22, 
regulating cellular energy metabolism [85]. 
We provided detailed insights into the molecular interplay between FIH and OTUB1. We 
showed that FIH and OTUB1 likely interact through a covalent bond catalyzed by FIH, forming 
a heterodimer. Following the heterodimer formation, the catalytic cleavage of Lys48-linked 
ubiquitin chains by OTUB1 was maintained and regulated by the E2 enzyme UBCH5B [83]. 
Additionally, we showed a metabolic phenotype in mice with Otub1 deletion, which was 
comparable to the published phenotype of Hif1an KO mice [9, 114]. To know if the downstream 
mTOR/AKT activation under OTUB1 deletion in mice is also observed under deletion of FIH, 
the mTOR/AKT pathway could be studied under FIH deletion in mice. Currently, it is known 
that overexpressed FIH in cells decreases the levels of AKT and GSK phosphorylation [131, 
132] with silencing of FIH having the opposite effect [131]. Furthermore, it would be interesting 
to study if the FIH-dependent hydroxylation of OTUB1 and/or the FIH-OTUB1 heterodimer 
occur in vivo and if the FIH-dependent regulation of OTUB1 is linked to the observed metabolic 
phenotype in both mouse models. Distinct mouse organs could be tested for the presence of 
the heterodimer via co-IP against FIH and OTUB1. The likelihood to detect the heterodimer is 
the bigger in tissues with the highest FIH and OTUB1 expression levels, which are the brain, 
skeletal muscle and kidney [114, 133]. Under a double inducible knock-out for OTUB1 and FIH 
in mice, the presence of the heterodimer could also be studied in distinct organs. Unfortunately, 
an antibody detecting asparagine hydroxylated proteins is not available. If such an antibody 
could be developed, the inter- and intra-organ localization of OTUB1 Asn22 hydroxylation 
could be detected in mice to give insights into the most important organs for FIH-dependent 
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OTUB1 regulation. To clearly determine the physiological relevance of the FIH-dependent 
regulation of OTUB1 in vivo, a transgenic mouse strain carrying OTUB1 with a mutated Asn22 
to Ala would be needed. We showed that OTUB1 Asn22 is necessary for both OTUB1 
hydroxylation by FIH as well as the FIH-OTUB1 heterodimer formation in vitro and that 
Asn22Ala mutation abrogates both. Hence, if FIH solely regulates energy metabolism through 
OTUB1 Asn22, mice with OTUB1 Asn22Ala mutation should display the same phenotype as 
Hif1an KO mice (Figure 1).  
 
 
Figure 1: Summary of OTUB1 and FIH-dependent physiological functions. FIH and OTUB 
form a heterodimer with two FIH proteins likely covalently bound to one OTUB1 protein (top). 
FIH deletion leads to increased ATP levels in cells. In mice, deletion of FIH led to decreased 
body weight and fat mass, increased energy expenditure and increased glucose clearance 
(bottom left). Our results from mice with Otub1 deletion suggest that OTUB1 is an inhibitor of 
the AKT/mTOR pathway. Following the deletion of OTUB1, we observed an increased 
proliferation and ATP production in cells. OTUB1 deletions also led to a perinatal lethality due 
to asphyxiation and lung malformation, to cardiac hypertrophy and to a decreased body weight 
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and size. Following induction of OTUB1 knock-out, adult mice show a decreased body weight 
and fat as well as an increased energy expenditure and glucose clearance, hyperventilation, 
lung malformation, cardiac hypertrophy, and ventricular dysfunction (bottom right). 
 
In vivo, we found that perinatal lethality observed in homozygous Otub1 KO mice was due to 
asphyxiation with a decreased airway space and increased cell proliferation. Furthermore, the 
animals showed a cardiac hypertrophy and a decreased body weight and length. The analyses 
of the embryonic lungs were performed at E18.5, just before the mice are born. Homozygous 
Otub1 KO mice at E18.5 showed an increased cell proliferation; however, the type of cell(s) 
was not identified. Hence, to analyze which type(s) of cells were proliferating in Otub1 KO 
mice, co-staining analysis of the proliferation marker with different cell type markers could be 
performed. These results could help to understand the effect of OTUB1 in the lung in more 
detail. Surfactant protein C levels and lamellar body morphology were similar in homozygous 
Otub1 KO mice compared with Wt mice at E18.5. Nonetheless, an embryonic time point study 
could be used to understand OTUB1 levels, pulmonary histopathology, developmental gene 
expression and early lethality throughout the different embryonic stages. This development 
studies could determine the specific time during which OTUB1 is most relevant for lung 
development.  
A cardiac phenotype was also observed in induced adult Otub1 KO mice with cardiac 
hypertrophy, decreased heart rate, impaired systolic and diastolic function. To analyze the 
cause of the observed decrease in heart rate, electrocardiography (ECG) could be performed. 
ECG will further help to understand the transmission of the electric signal in the heart of 
induced adult Otub1 KO mice and will identify whether the cells transmitting the electric impulse 
along the heart were damaged or not and a potential different input from the central nervous 
system. The increased left ventricular mass and impaired systolic function of the heart could 
be explained by an impaired mTOR pathway signaling. At a protein level in the heart, 
phosphorylated S6K was increased and in MEFs phosphorylated AMPK was decreased. 
Phosphorylated AMPK has been shown to inhibit the activity of mTORC1. Additionally, 
mTORC1 inhibits autophagy avoiding the development of cardiac hypertrophy [134]. 
Therefore, decreased phosphorylated AMPK could increase mTORC1 activity inhibiting 
autophagy and as a result leading to the observed cardiac hypertrophy. At an experimental 
level, this could be analyzed by deletion and overexpression of OTUB1 in cardiomyocytes and 
in Otub1 KO mouse hearts. In the cardiomyocytes and hearts, pAMPK/AMPK levels could be 
studied since we previously observed the decrease in pAMPK in MEFs but did not investigate 
the heart. Furthermore, autophagy could be measured by investigating the autophagosome 
markers LC3B-II/LC3B-I ratio, Atg4 protease and beclin-1 protein levels [135]. To further 
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characterize the cardiac hypertrophy, the expression of different pro-hypertrophic genes may 
be analyzed, such as Hey2 and TGF-β [136, 137]. Furthermore, the investigation of lung and 
heart specific Otub1 KO mice would determine whether the lung malformation alone is 
responsible for the embryonic death and/or the organ malformations in the embryos and adults 
are completely independent. 
Regarding the metabolic phenotype, induced adult Otub1 KO mice displayed decreased insulin 
levels but similar glucose basal levels as well an enhanced glucose clearance under glucose 
challenge. These glucose/insulin signaling differences might be due to an increased number 
or activity of the insulin receptors that activates downstream IRS proteins and the Akt signaling 
pathway. To study the insulin receptor signaling, total amount of insulin receptors and IRS 
activation could be assessed. To further understand the reason of the reduced insulin plasma 
amount under deletion of OTUB1 in mice, the direct study of insulin production via b-cells from 
the pancreas could be analyzed. The mTOR pathway participates in fatty acid oxidation and 
glycolysis pathways. We observed a decreased body weight with an increased food intake 
under deletion of OTUB1 as well as increased liver weight. Further analysis of the glycolytic 
enzymes might give insights into whether glycolysis is altered or regulated by OTUB1/mTOR 
signaling. 
Additionally, the study of specific KO mice could provide insight in the specific relevance of 
OTUB1 at an organ level as well as understand the molecular mechanism behind. For 
example, heart inducible KO mice could be studied by cardiomyocyte-specific OTUB1 deletion 
could use by alpha-myosin heavy chain promoter directing the expression of a tamoxifen 
inducible Cre recombinase to cardiac myocytes (MHC-MerCreMer) [138]. Also, liver-specific 
KO mice could be studied by Cre recombinase under the control of albumin promoter (Alb-
Cre) [139].  Furthermore, overexpression of OTUB1 levels in vivo would be interesting to 
assess whether the observed phenotype will be reversed, compensated, or maintained, 
information that could also determine the most relevant function of OTUB1 in vivo. To optimize 
time and costs, a previous study on overexpression of OTUB1 in organ specific cell lines could 
provide information that could be further analyzed in vivo. 
Furthermore, OTUB1 is highly expressed in the brain and in our studies, Otub1 KO mice 
showed increased brain weight normalized to total body weight. Because of an impaired neural 
regulation, the metabolic and cardiac phenotype may also be explained. Also, brain FIH KO 
mice phenocopies partly whole-body FIH KO mice, showing decreased body weight, increased 
oxygen consumption and increased insulin sensitivity [114]. Therefore, the study of OTUB1 
function in the brain could provide information whether OTUB1 is the substrate of FIH leading 
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to the metabolic phenotype. For example, food intake and body weight are regulated by the 
hypothalamus via insulin, leptin and ghrelin [140, 141]. We found that insulin levels in Otub1 
KO are decreased with similar TSH hormone levels, which does not support a direct effect of 
the hypothalamus. However, alterations in ghrelin level by an impaired hypothalamic regulation 
can produce differences in insulin levels [142]. Hence, the assessment of ghrelin and leptin 
levels could help to determine if the brain function leads to metabolic changes in Otub1 KO 
mice. 
To understand the molecular mechanism behind the observed differences, the overall cellular 
ubiquitin chain levels were studied in the presence and absence of OTUB1. MEFs and organs 
from adult knock-out mice showed no differences in the total ubiquitin levels, Lys48- and 
Lys63-linked ubiquitin chains. In the future, it would be interesting to analyze if following 
proteasomal inhibition with MG-132 ubiquitin chain levels change in the absence of OTUB1. 
OTUB1 is raising interest in cancer and immune research, due to its major role in cancer 
development and progression as well as in the regulation of immune cells. In our research, we 
not only identify and analyze the interaction among OTUB1 and FIH at a cellular level, but we 
also characterized the phenotype of OTUB1 deletion in vivo. The functional consequence of 
the stable FIH-OTUB1 complex has not yet been studied, but a potential field of study would 
be the regulation of energy metabolism in vitro and in vivo. Besides the metabolic phenotype, 
OTUB1 has a pleiotropic role in vivo, including the regulation of embryonic development, 
cardiac and pulmonary functions. The phenotypes observed under the deletion of OTUB1 
could be explained by OTUB1 regulation of the AKT/mTOR pathway. OTUB1 is a potential 
pharmacologic target where the side effects should be carefully considered. Our analyses 
indicate that non-targeted inhibition of OTUB1 may lead to severe side effects. Overall, our 
results show that further understanding in the molecular and physiological interplay of FIH and 
OTUB1 may help targeting novel therapeutic treatments.  
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